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ABSTRACT

MECHANISTIC INSIGHTS INTO COPPER-INDUCED REGRESSION
OF HEART HYPERTROPHY
Katherine Bourcy
July 26, 2011

Previous studies have shown that copper (Cu) supplementation at physiologically
relevant levels reverses cardiac myocyte hypertrophy induced by phenylephrine (PE), and
that this effect was VEGF-dependent. Yet, the amount of VEGF in the media was
unchanged. However, we observed that Cu caused an increase in the ratio of VEGFR1:VEGFR-2 as well as an increase in PKG-1 activity. PKG-1 activity is associated with
the regression of cardiac myocyte hypertrophy. The present study was undertaken to test
the hypothesis that VEGFR-1 is associated with PKG-1 and their association is involved
in Cu induced regression of cardiomyocyte hypertrophy. Human cardiac myocytes
(HCM) in cultures were exposed to phenylephrine (PE) at a final concentration of 100
flM for 48 hours to induce cell hypertrophy. Copper sulfate at a final concentration of 5
flM was added to the hypertrophic HCM cultures for 24 hours with the concomitant
presence of PE to reverse the hypertrophy. Both hypertrophic and hypertrophic-reversed
HCM cells underwent immunoprecipitation using anti-VEGFR-1 antibody or anti-PKG-1
antibody. The immune complex underwent gel-electrophoresis separation and Western
blotting and LC-MSIMS analysis. Proteomic analysis identified Vimentin in the immune
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complexes that immunoprecipitated with VEGFR-l and PKG-l. This study thus
demonstrates that the association between VEGFR-l with PKG-l is mediated by
Vimentin, and that Vimentin plays a critical role in copper regression of cardiac myocyte
hypertrophy.
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I. INTRODUCTION

Heart disease is the leading cause of death in the United States, killing more than
927,000 people every year. While it does not receive as much attention as cancer,
cardiovascular disease claims more lives than all cancers combined, fewer than 560,000
deaths 1. With these statistics come with a tremendous cost to society in the form of
health care costs, as health care spending is projected to reach $4.7 trillion dollars by the
year 2020 2• Additionally, this also comes with personal costs as well, as this disease is so
prevalent it is highly unlikely anyone will go through life and somehow not be affected
by heart disease.
The heart is the first organ to develop during embryogenesis 3 . Throughout the
lifetime of the organism, there will be many changes in stress and demand on the heart,
and in some circumstances the heart will undergo growth, or hypertrophy. There are two
kinds of hypertrophy: physiological and pathological 4 • Physiological hypertrophy is both
normal and reversible5 . In response to an increased workload and stress, the heart muscle
(myocardium) will become thicker to preserve normal heart function. This can occur in
athletes, for example, who train intensively. However, once the stimulus is removed, the
heart will eventually go back to its normal size. In contrast, pathological hypertrophy is
neither normal nor it is considered reversible. In the case of pathological hypertrophy,
the stimulus is often some type of injury to the heart, such as a myocardial infarction.
The heart undergoes an adaptive response and becomes enlarged in an attempt to
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preserve function. However, pathological hypertrophy is an important milestone in the
progression to heart failure, and once developed cannot be reversed 6 . Moreover, the
prognosis for those with heart failure is often worse than those with cancer? While there
are current therapies for heart failure, such as beta-blockers, angiotensin converting
enzyme (ACE) inhibitors, diuretics and digoxin, these can, in some cases, buy the patient
some time but will not stop or reverse the progression to heart failure. Other options such
as heart transplantation are often prohibitive in nature for no other reason than the cost.
The past two decades have brought better understanding and improved approaches to
treating cardiac hypertrophy and heart failure. As it turns out, while it was previously
thought that pathological hypertrophy was irreversible, there are data suggesting that it
may, in fact, be reversible.
Copper is a critical micronutrient and is essential for life 8 . Roughly twenty
enzymes within the human body contain copper, and of those, ten require copper to
function. Additionally, because these enzymes are found within most tissues, the effects
of copper deficiency are systemic and widespread9 • Copper is essential for the
development of healthy bones 10, skin 11, and blood vessels 12. The cardiovascular system
is especially sensitive to copper levels 13. The strongest evidence for this can be found by
the extreme consequences of copper deficiency mainly manifesting as damage to the
heart and blood vessels

l4

.

It is interesting to note that while the recent health benefits of

red wine are often touted as being due to resveratrol, red wine is made with the skins of
the grape intact; copper-based fungicides are often used on wine grapes thereby making
red wine a good source of copper. For centuries, copper has been used to treat a wider
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variety of maladies. As it turns out, it may also be useful in healing an injured, and
maybe even a failing heart.
Previous studies have shown that copper (Cu) supplementation at physiologically
relevant levels can reverse cardiac myocyte hypertrophy induced by phenylephrine (PE),
and that this phenomenon was VEGF-dependent. This observation recaptures the in vivo
observation that Cu supplementation can reverse cardiac hypertrophy induced by pressure
overload in a mouse model, and this effect is also VEGF-dependent 15 • However, there
are fundamental differences between in vivo observations and those observed in cardiac
myocytes grown in cultures. Coronary angiogenesis clearly plays a critical role in the
regression of cardiac hypertrophy, however there are no blood vessels in cell cultures,
which indicates VEGF has a direct effect on cardiac myocytes in the regression of cell
hypertrophy.
Because the amount of VEGF in the media was unchanged, we looked to VEGF
receptors. We observed that Cu caused an increase in the ratio ofVEGFR-l:VEGFR-2
as well as an increase in PKG-l activity, which is associated with the regression of
cardiac myocyte hypertrophy. The present study was undertaken to test the hypothesis
that VEGFR -1 is associated with PKG-l and their association is involved in Cu induced
regression of cardiomyocyte hypertrophy.
When the phenomenon of the regression of cardiac hypertrophy was first
observed, it was observed in vivo in a mouse model, then in rat cardiac myocytes. We
used human cardiac myocytes. Because there are differences between human and rat
cells, we first established a phenotype. Indeed, Cu supplementation also reversed cardiac
myocyte hypertrophy induced by PE in human cardiac myocytes.
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Human cardiac myocytes (HCM) in cultures were exposed to phenylephrine (PE)
at a final concentration of 100 /lM for 48 hours to induce cell hypertrophy. Copper
sulfate at a final concentration of 5 /lM was added to the hypertrophic HCM cultures for
24 hours with the concomitant presence of PE to reverse the hypertrophy. Both
hypertrophic and hypertrophic-reversed HCM cells underwent immunoprecipitation
using anti-VEGFR-l antibody or anti-PKG-l antibody. The immune complex underwent
gel-electrophoresis separation and Western blotting and LC-MSIMS analysis.
Initially, we had hypothesized that VEGFR-l and PKG-l were directly linked,
and this is, in part, how cardiac myocyte hypertrophy is reversed. But we found that the
link was not direct, but indirect. Functional proteomic analysis identified Vimentin in the
immune complex likely involves VEGFR-l and PKG-l. This study thus demonstrates
that the association between VEGFR-l with PKG-l is mediated by Vimentin, and that
Vimentin plays a critical role in copper regression of cardiac myocyte hypertrophy.
While initially thought to be nothing more than a 'decoy' receptor, these data
suggest that VEGFR-l plays a critical role in the regulation of cardiac myocyte size. And
once thought to be nothing more than an intermediate filament that helped provide
scaffolding for the cell, this study suggests Vimentin, a known Cu-binding protein, may
playa critical role in signaling pathways in cardiac myocytes, perhaps acting as a
molecular switch, shutting down hypertrophic pathways, while allowing regression
signaling to prevail and thus reversing the size of hypertrophic cardiac myocytes.
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1-1. THE HEART & HEART FAILURE

The heart is a pump that rivals any man-made machine. Before the day is done,
the heart will beat over 100,000 times, propelling blood throughout the pulmonary
and systemic circulation, supplying the body with life-supporting oxygen and
nutrients. During the average lifetime, the human heart will beat roughly 2.5 billion
times, without cessation. It is the first organ to develop during embryogenesis, and
all subsequent events throughout the life of the organism are dependent upon its
function.
In its most simplistic view, the heart can be organized into three layers: the

endocardium, the innermost layer of tissue that lines the chambers of the heart; the
myocardium, the middle, muscular layer of the heart; and the epicardium, which is
composed of the connective tissue surrounding the heart. Most of the heart is
composed of non-muscle cells that constitute more than 2/3 of the total populations of
the cardiac cells. However, the contractile muscle cells, which are known as
myocytes or cardiac myocytes, are less than 1/3 of the total populations of the cardiac
cells, but account for nearly 75% of cardiac volume. The rest of the heart is
composed of pacemaker and conducting tissue, which are involved in the initiation
and conduction of electrical impulses to the ventricles; blood vessels and extracellular
space.
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Cardiac myocytes consist of mainly contractile proteins. Z lines are found at the
ends of the myocyte. From the Z line, thin actin filaments stretch inward and form
cross-links with the much larger and thicker myosin filaments. Myosin filaments,
which typically resemble golf clubs lying on their side, extend from the center of the
myofibril toward the Z line but do not touch them. Titan elastic molecules indirectly
link myosin fibers to the Z line. The release of calcium ions initiates muscle
contraction. The heads of the myosin fibers flex and move actin fibers such that the Z
lines move towards one another.
The concentration of intracellular calcium ions is regulated in a series of
interconnecting events. The sarcolemma, or external cell membrane contains calcium
channels. With the arrival of each action potential and wave of electrical excitation,
these channels open, allowing a small amount of calcium to enter the cell. Electrical
impulses make their way into the cardiac myocyte by way of invaginations called T
tubules, which are in close proximity to the sarcoplasmic reticulum, which stores
calcium ions. A conformational change in the ryanodine receptor triggers the release
of more calcium from the sarcoplasmic reticulum, a process called calcium-induced
calcium release. Contractions are triggered by an increase in internal cytosolic
calcium.
Just as the release of calcium initiates contraction, relaxation of contractile
proteins occurs when calcium is uptaken into the longitudinal component of the
sarcoplasmic reticulum. While the increase in calcium concentrations acts upon the
sarcoplasmic reticulum, it also triggers the phosphorylation of the regulatory protein
phospholamban, which in turn activates ATP-dependent calcium uptake pumps of the
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sarcoplasmic reticulum. Phorphorylated phospholamban blocks the inhibition of the
calcium pump of the sarcoplasmic reticulum. Calcium is removed and relaxation
occurs.
The heart is a dynamic organ; its component muscle is capable of growing and
adapting to changing workloads. The contraction of the myocardium plays a critical
role in regulating the circulatory system by ejecting blood from the left ventricle; the
tone of the peripheral arterioles provides most of the resistance that the heart must
work against. In order to adapt to changes in workload, or arterial tone, the heart will
undergo remodeling. The main players in this remodeling are cardiac myocytes.
Enlargement of the heart is attributed to enlargement of individual cardiac myocytes
In certain circumstances, such as pregnancy or increased aerobic activity, the

heart will undergo physiological hypertrophy. This type of hypertrophy is normal,
reversible, and associated with normal or enhanced cardiac functionality.
Conversely, in response to disease-induced stimuli, such as pressure overload or
myocardial infarction, congenital malformations, myocarditis, or diabetic
cardiomyopathy, pathological hypertrophy may result. These stimuli damage the
heart. In an attempt to compensate for the damage, the heart increases the pump
function along with an irreversible enlargement of the size, or undergoes pathological
hypertrophy. Pathological hypertrophy ultimately leads to cardiac dilation and loss of
contractility. It is associated with an upregulation of fetal genes, cardiac dysfunction,
decreased contractile function and increased mortality. It is an early milestone in the
clinical progression to heart failure and in many cases, sudden cardiac death l6 . Once
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a patient develops pathological hypertrophy, it cannot be reversed and the progression
to heart failure becomes inevitable 17 .
At the most basic understanding, heart failure is when the heart can no longer·
deliver the necessary nutrients and oxygen to peripheral tissues in the body. In the
Western world, adult cardiac disease, most frequently in the form of heart failure,
kills more people than all cancers combined 18 . Patients with heart failure fall under
two major categories: systolic heart failure or diastolic heart failure, and the
distinction is whether the dominant functional problems result from decreased
contractility (systolic failure) or decreased relaxation (diastolic failure). Nearly a
third of patients with evidential heart failure have preserved ejection fractions, and
their symptoms are either largely or entirely stem from diastolic dysfunction 19. This
negative lusitropic state is attributed to structural changes in the heart such as fibrosis,
hypertrophy and infiltrative processes. Additionally, subcellular aberrations in
repolarization-relaxation coupling are often present in many cases 20 ,21.
Heart failure

ca~

involve the right, left or both ventricles of the heart, most often

both ventricles. The right ventricle of the heart pumps blood to the lungs where blood
is reoxygenated. The left ventricle of the heart pumps oxygen-rich blood and
nutrients to the rest of the body. Right ventricle heart failure often follows long-term
high blood pressure in the pulmonary arteries, or pulmonary hypertension, causing a
strain on the right side of the heart. In the event of right ventricle heart failure, the
heart cannot pump enough blood to the lungs. Left ventricle heart failure can be
caused by coronary artery disease as well as many other factors, and similarly with
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left ventricle heart failure, the heart cannot pump enough blood to the peripheral
tissue.
Heart failure is the most expensive cardiovascular disorder in the United States
with annual expenditures estimated to be in excess of $29.6 billion22 .23 . It is a leading
cause of death in the u.S. 24 and is quickly becoming more prevalent globally25. By
the year 2020, it is projected that deaths from cardiovascular disease will exceed
those from infectious and parasitic diseases for the first time throughout the world
with the exception of sub-Saharan Africa 26 .27 . While there are current treatments
available for heart failure ranging from pharmacological intervention to heart
transplantation, they all carry inherent risks and hefty price tags. Medications used to
treat heart failure may exacerbate the condition. Additionally, medications used to
treat heart maladies other than heart failure, such as antiarrhythmics and calcium
28
channel blockers, may induce heart failure . Currently, no treatment is available that
can reverse hypertrophy, thereby halting the progression to heart failure.
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1-2. ELKMENT #29: CUPRUM
Cup rum or what is more commonly known as copper is a transition metal. It is

used as an electrical conductor, as well as in the construction of metal alloys such as
bronze and brass. While Hippocrates was known for prescribing copper compounds
to treat disease 29 as well as to prevent pregnancy30 the use of copper compounds such
as copper carbonate, copper oxide, copper sulfate and copper chloride predates the
ancient Egyptians. In fact, the use of copper as a medicinal agent can be traced as far
back as Aztec civilization where it was used to treat sore throats. Throughout history,
copper compounds have been used to treat a wide variety of diseases; Ancient
Egyptians used copper for the sterilization of drinking water as well as the treatment
of wounds; the Romans recorded numerous medicinal uses for copper; in Persia and
India it was used to treat maladies from boils to venereal ulcers 31 .
After iron and zinc, copper is the third most common trace element in the human
body. Copper is an important micronutrient for man and it is essential for life. The
most compelling evidence for this can be found by the severe consequences of copper
deficiency mainly manifesting as damage to the heart and blood vessels. At least
twenty enzymes within the human body contain copper, and of those ten are
dependent upon copper to function. Additionally, because these enzymes are found
within most tissue, the effects of copper deficiency are systemic and widespread.
Low copper levels can result in numerous pathological states including, but not
limited to: poor neuronal myelination, reduced aortic elasticity, impaired immune
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responses, decreased motor function, blood vessel abnormalities and cardiac
hypertroph y32,33,34.
The cardiovascular system is especially vulnerable to alterations in copper status.
The essentiality of copper in the cardiovascular system has been demonstrated in
numerous clinical and experimental studies35 ,36,37,38,39,40,41,42,43,44. Because copper
facilitates the absorption and utilization of iron, it follows that copper deficiency is
also associated with anemia, decreasing the amount of oxygen that is delivered to
tissue45 ,46. Furthermore, copper deficiency decreases clotting capabilities after injury,
increasing the amount of blood lost47 . And once clots are formed, their ability to
dissolve is also impaired. Copper deficient blood vessels are inherently leaky, and
exacerbate swelling.
Yet the strongest evidence for the importance of copper to the cardiovascular
system has been observed in laboratory mouse model with pre-established
hypertrophic cardiomyopathy induced by ascending aortic constriction. Copper
supplementation alone reversed cardiac hypertrophy and this recovery occurred
despite sustained pressure overload48 . This suggests that copper supplementation
prevents heart failure by reversing cardiac hypertrophy. Upon further investigation, it
was discovered that cytochrome c oxidase recovery is essential to this coppersupplementation-induced recovery, and is also validated by other studies which
demonstrated that copper deficiency reduced the hearts ability to utilize energy and
contribute to reduced coronary function 49 , 50, 51, 52 .
As a transition metal, it also plays an important role as a cofactor in a wide variety
of biological reduction and oxidation (redox) reactions. However, some suggest that
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this also contributes to its potential for toxicity. In cases of copper overload, copper
may cause oxidative damage to cells in a Fenton-type redox reaction. However, it is
interesting to note that there is no free copper within the ce1l53 , and it is tightly
controlled.
Copper metabolism was of little interest to researchers until the 1920s after the
discovery that copper was required for the formation of hemoglobin in rats 54.
Subsequent studies in the 1930s and 40s were done in humans amounted to studies in
the ADME (Absorption, Distribution, Metabolism and Excretion) of copper55 ,56,57,58.
Much of the debate regarding the metabolic fate of copper in the 1930s and 40s are
not much different than the debates that occur today, and the same can be said for
minimum dietary copper requirements; amounts vary from 0.63 mg/d to 2.65 mg/d.
The current RDI for copper is 0.9 mg per day59. Though, it goes without saying that
the study of whole body copper metabolism in humans is inherently difficult. Tissues
available for analysis are few, and this alone greatly limits what can be learned. The
few tissues which can be sampled, for example skin and the liver, are only available
through invasive means and even then, concentrations of copper in tissue can only
give limited information. Also, it is impossible to determine which copper was
already in the body, and which copper came from a meal without the use of isotopic
tracers.
Copper is obtained by the body from the diet 60 and drinking water from copper
piping. It is absorbed through the duodenum and intestinal mucosa and transported to
the liver through the portal vein. The liver is the most important organ for copper
homeostasis and is primarily responsible for removal of excess copper from the body.
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In the liver, it was thought that copper is incorporated into ceruloplasmin and released
into the bloodstream as Cu-ceruloplasmin, and is taken up by various tissues within
the body. However studies have demonstrated that ceruloplasmin is not essential for·
copper transport to extrahepatic tissue as aceruloplasminemia did not exhibit signs of
organ system copper deficiency61. Copper is also released into the blood from the
intestine in the form of Cu-albumin, Cu-histidine, Cu-transcuprein, as well as other
unidentified complexes. Most dietary copper is excreted into the gastrointestinal tract
and lost in the bile. After combining with the small amount of copper that is excreted
from intestinal and pancreatic fluids and intestinal cells, it is eliminated from the
body. Copper concentrations are highest in the liver, followed by the brain, kidney
and heart. As the amount of copper intake increases, so does absorption, however a
higher percentage is absorbed when intake is low. Studies suggest the primary factor
to influence copper absorption is the amount of available copper.
Whole-body copper metabolism can vary depending on conditions, such as
pregnancy, and disease states. Metabolic defects, such as Wilson disease or Menkes
syndrome are two frequently encountered copper malmetabolism disease conditions.
Wilson disease is a rare, autosomal recessive disorder affecting normal copper
metabolism. Typically, excess copper is excreted in the bile, but with this disease,
mutations in the putative copper transporting P-type ATPase, ATP7B cause copper to
build up in the liver. Over time, the liver is damaged and copper is released directly
into the bloodstream causing damage to the kidneys, brain and eyes. Symptoms can
appear as early as 4 years old, but onset can also be as late as 40 years of age. A
rusty, brown ring around the cornea of the eye is the most characteristic sign of the
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disease. On the other extreme is Menkes syndrome. This syndrome is caused by a
defect in the ATP7 A gene, which manifests as a mutation in the MNK protein, a Ptype ATPase. This results in copper defiCiency as copper distribution and transport
into the cells are inadequate. Consequently, the brain and other parts of the body do
not get enough copper. Symptoms include structural abnormalities in the hair
(Menekes syndrome is also known as "kinky hair syndrome" as it results in brittle,
kinky hair), abnormal bone structure and severe neurological impairment. Most
Menkes patients die in early childhood. Both of these disorders illustrate how critical
copper metabolism and balance is within the body, and the need for strict homeostatic
control of copper.
The exact mechanism by which copper is taken into cells, and its journey within
the cell is not completely understood, yet there is still much that is known. Under
normal conditions, copper is thought to be transported into intestinal cells through the
high affinity copper transporter, CTRI and bound to cytosolic copper chaperones.
COX17 and SCOl/I1 are believed to act as chaperones, delivering copper to the
mitochondria and facilitating the incorporation of copper into cytochrome c oxidase.
Cu-ATPases ATP7A and ATP7B receive copper from ATOX1, transporting copper
into the lumen of the secretory pathway of the trans Golgi network, as well as
removing excess copper from the cell. CCS (copper chaperon for superoxide
dismutase), as the name implies, delivers copper to cytosolic CU,Zn superoxide
dismutase 1 (SOD1).
Due to the regulation of body copper stores, indices of copper (save under
extreme conditions) are resistant to change62 . Even after dietary intake of copper
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went from 0.8 to 7.5 mg/d, traditional indexes of copper status, such as
ceruloplasmin, plasma copper, erythrocyte superoxide dismutase and urinary copper
excretion were not significantly different63 . However, recent studies have
demonstrated that there is no reliable biomarker for copper. Neither cuproenzymes
nor plasma copper reflect copper status 64,65,66. While traditionally, ceruloplasmin has
been used as a biomarker for copper status, it is subject to season changes 67 , and is
also age-dependent

68

•

The only known exact indicator of copper status is copper

content in the liver, which is not readily measured69 . Alternatively, a recent
promising candidate as a biomarker for copper status is CCS. In a rat feeding study,
it was shown to increase in a dose-response manner as copper intake decreased in
erythrocytes and liver70 . Furthermore, there was a concomitant decrease in SOD!
levels, and the authors of the study have suggested using the CCS:SODI ratio as an
indices of copper deficiency. Thus far, it seems to be the most promising candidate
of not only a measure of copper deficiency, but excess as well.
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1-3. VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND ITS
RECEPTORS

Vascular Endothelial Growth Factor (VEGF) is a robust mitogen for endothelial
cells derived from lymphatics, arteries and veins, although it does not elicit a consistent
and appreciable mitogenic response in any other types of cells 71 ,n,73,74,75,76,77. Because of
its ability to induce vascular leakage in guinea pig skin, VEGF is also known as Vascular
Permeability Factor (VPF)78,79. Additional effects of VEGF include the stimulation of
hexose transport in the vascular endothelium8o , promote the expression of VCAM
(Vascular Cell Adhesion Molecule-I), ICAM (Intracellular Adhesion Molecule-I) and Eselectin, all of which are adhesion molecules, via NF-KS with PI3K
(phosphotidylinositol-3 kinase )-mediated suppression, in endothelial cells 81 ,82 and may
regulate or promote monocyte chemotaxis 83 . In vitro studies have shown VEGF induces
vasodilation in a dose-dependent manner and can produce hypotension, tachycardia and
decreased cardiac output when injected intravenously in rats 84. However in vitro studies
have shown VEGF does not affect contractility in isolated rat hearts 85 . It is important to
note, though that these hemodynamic effects are not limited to VEGF whereas other
angiogenic factors can also induce hypotension and nitric oxide-mediated vasodilation 86 .
There are several VEGF isoforms, each arising as a result of alternative splicing,
VEGFI21, 145, 165, 183, 189 and 206. They are characterized by the presence of eight
conserved cysteine residues and a cystine knot residue 87 . Native VEGF is a heparinbinding, basic, homodimeric glycoprotein88 . VEGFI65, the other major isoform, shares
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the same properties. VEGF165 appears to be the most abundant and potent isoform in
man, acting as an angiogenic cytokine regulating vascular permeability,89 followed by

°.

VEGF121 and 1899

VEGF is induced by hypoxia and cytokines, such as TNF-a, ILl, 6

and 8, and oncostatin M91. Despite numerous isoforms, VEGF can be easily categorized
by the biological property of their ability to bind heparin and heparin-sulfate. VEGF121
is the most soluble, weakly acidic and does not bind heparin or the extra cellular matrix
(ECM)92,93, however, VEGF189 and 206 are more basic, bind heparin and are completely
sequestered to the ECM94 . VEGF165 does bind heparin, and roughly 50-70% is bound to
the cell surface and the ECM. Both VEGF145 and 165 induce angiogenesis in vivo,
however VEGF145 is mainly expressed in cells derived from reproductive organs, as is
VEGF206. These findings suggest there are two different mechanisms by which VEGF
may become available to endothelial cells: by protease activation following cleavage of
the larger isoforms, or freely diffusible proteins (VEGF121, VEGFI65). When
comparing VEGF165 to VEGF121 or VEGFIlO, a 50-fold reduction in potency was
observed in an endothelial cell growth assa/5 . These results allude to VEGF exerting
structural and functional heterogeneity in order to yield a controlled biological response.
The biological consequences of VEGF are mediated by two receptors, VEGFR-l
(also known as FIt-I) and VEGFR-2 (also known as Flk-l/KDR), both of which are
receptor tyrosine kinases (RTK) and are how VEGF induces biological responses 96 •
VEGFR-3 is a member of RTK family, but it does not bind VEGF instead binding its
homologues, VEGFC and VEGFD 97 . In mice lacking VEGFR-2, the development of
hematopoietic and endothelial cells is impaired 98 , It was observed in Flt-l null mice
overgrowth of endothelial cells and blood vessel disorganization99 , While our
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understanding of these receptors is incomplete, the distinct phenotypes of VEGFR -1 and
VEGFR-2 knockout mice suggest these receptors have differing biological functions. It
then follows that the downstream signaling transduction pathways are also different and
have considerably different signaling properties 100. VEGFR-1 and 2 are similar in
structure with an extracellular domain that is comprised of seven immunoglobulin-like
domains, one transmembrane region and a consensus tyrosine kinase sequence that is
split by a kinase-insert domain lO l,l02. Both receptors bind VEGF with a very high
affinity. VEGFR-1 has the highest affinity for rhVEGF165, with a Kd of 10-20 pM 103 •
VEGFR-2 binds VEGF with a slightly lower affinity, with a Kd of 75-125 pM 104•
For almost thirty years, it has been known that eu stimulates angiogenesis in the
avascular cornea of rabbits 105. This has been demonstrated in subsequent studies in both
experimental and clinical settings lO6 . Another study showed that eu stimulates VEGF
synthesis in human keratinocytes lO7 . The exact mechanism by which eu regulates VEGF
expression is unknown. It is known, however, that HIF-1a is a required transcription
factor for VEGF I08 ,109, ergo oxygen tension plays a critical role in VEGF regulation.
During normoxia conditions HIF-1a undergoes hydroxylation at a proline residue by
prolyl hydroxylase (PHD), which requires oxygen, iron and 2-oxoglutarate to
function" 0,"1,1l2,13. This increases (and is also required for) HIF-la binding to von
Hippel-Lindau (VHL) tumor suppressor protein, thereby targeting HIF-1a for
proteasomal degradation" 4 . However, under hypoxic conditions, PHD cannot function.
HIF-1a is neither hydroxylated nor targeted for degradation; it accumulates in the cells
and its activity increases ll5 . Studies in the lab have demonstrated that eu
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supplementation reverses cardiac hypertrophy in part by Cu chaperone for superoxide
dismutase-1(CCS)-mediated HIF-1a activation ofVEGF 116 .
Our preliminary studies have demonstrated the requirement of VEGF for the
reversal of cardiac hypertrophy in primary culture of neonatal rat cardiomyocytes.
Because these cells are treated with VEGF in culture without the presence of blood
vessels, the effect of VEGF is independent of angiogenesis. Additionally, a recent study
showed that chronic activation of PKG-1 prevents and reverses cardiac hypertrophy in
hearts exposed to sustained pressure overload l17 . Upon further investigation into the
mechanism, it was discovered that this effect was also mediated by the upregulation of
VEGF.
While investigating the potential mechanisms by which Cu reverses cardiac
hypertrophy, we observed Cu deficiency suppressed and Cu repletion restored VEGF
expression in the heart 1l8 . The heart is designed such that every cell is in contact with a
blood vessel, supplying the cardiomyocyte with a constant flow of oxygen and nutrients.
Consequently, coronary angiogenesis is critical. And a delicate balance between cardiac
growth and angiogenesis must be maintained. During the acute phase of cardiac
hypertrophy, angiogenesis is increased. However, if angiogenesis is reduced, the heart
undergoes pathological remodeling. Further, if cardiac growth and angiogenesis are not
coordinated, the transition to heart failure occurs 119. This disruption suppresses VEGF.
It is also interesting to note that blocking VEGF promotes and VEGF administration

delays the transition to heart failure in pressure overloaded mouse models 120,121. In our
preliminary studies, we observed that Cu supplementation enhanced VEGF expression,
reversed hypertrophic cardiomyopathy and restored angiogenesis despite pressure
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overload in mouse models with AAC-induced cardiac hypertrophy and dysfunction.
Together, this suggests that Cu is involved in the regulation of VEGF expression in the
heart.
VEGF is critical in Cu induced reversal of cardiac hypertrophy. It also plays a
role in and is required for the cell growth that leads to cardiac hypertrophy. This suggests
that VEGF plays a dual role in controlling the physiological function of cardiomyocytes.
Under stress conditions, it is required for cell growth, but also decreases the size of
hypertrophied cardiomyocytes. While the importance of VEGF-induced angiogenesis
has been demonstrated for the amelioration of ischemic myocardium 122,123, VEGF alone
is not a good strategy for the reversal of cardiac hypertrophy l24. VEGF, which is also
known as vascular permeability factor, can induce vascular leakage 125 ,126, and in cases of
mitochondrial dysfunction, the addition of VEGF culminates in the creation of leaky
vessels 127. However, an independent and direct effect ofVEGF that is independent of
angiogenesis on cardiomyocytes should playa crucial role in the retrogression of
hypertrophic cardiomyopathy.
The main focus of this dissertation is the identification and characterization of
VEGFR mediated signaling pathways involved in the reduction of hypertrophied
cardiomyocyte cell size and thus, reversal of cardiac hypertrophy. In order to gain a
comprehensive understanding of these signaling pathways, VEGFR associated pathways
of normal cardiomyocytes were compared to that of hypertrophied cardiomyocytes. We
observed that Cu-induced regression of heart hypertrophy is VEGF-dependent. Yet, the
amount of VEGF in cultures did not change. VEGF mediates its effects through its
receptors. It was later determined that Cu causes a change in the ratio of VEGFR-
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l:VEGFR-2 and hypothesized that this leads to a switch in signaling pathways from
growth to the regression of cell hypertrophy. Additionally, siRNA targeting VEGFR-2,
which elevated the ratio of VEGFR -1: VEGFR -2 differentiated but also reproduced the
Cu-induced reversal of cardiac myocyte hypertrophy. Further, Anti-VEGF antibody
blocked the reversal of cardiac myocyte hypertrophy induced by VEGFR-2 knock down.
Finally, siRNA targeting VEGFR-1 ablated Cu-induced reversal of hypertrophy, further
indicating the important role VEGFR-1 plays in the regression of cardiomyocyte
hypertrophy.
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1-4. PKG-l

Before the day is done, the heart will beat over 100,000 times, faithfully fulfilling
its role in delivering oxygen and nutrients to peripheral tissues. With this also comes
the need to adapt rapidly to ever changing demands and stresses, from the stress
induced by physiological or pathological stimuli. Within the heart lies regulators that
can aid in this process, cyclic nucleotides 3' ,5' -monophosphates such as cAMP and
cGMP and their respective effector enzymes, protein kinase A (PKA) and protein
kinase G (PKG). The pathway of cAMPIPKA controls excitation-contraction
coupling associated with the phosphorylation of voltage-gated calcium channels,
phospholamban, ryanodine receptors and sarcomeric proteins, which increase and
drives calcium cycling through the sarcoplasmic reticulum and triggers contraction
and relaxation. Conversely, the pathway of cGMPIPKG acts as a myocardial
decelerator, countering cAMP-dependent-stimulation and signaling different
pathways that act to blunt growth, while increasing relaxation128.
PKG-l is believed to be the primary target of cyclic GMP (cGMP). This
serine/threonine protein kinase is activated by paracrine and autocrine stimuli, which
increase nitric oxide (NO) and cGMP. In mammals, there are three molecular forms
ofPKG: PKG-la,

PKG-l~,

and PKG-II. PKG-la and PKG-l~ result from

alternative mRNA splicing and differ only by about 100 amino acids in the Nterminal dimerization domain I29 ,13o,l3l; and PKGII arises from a different gene locus.
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PKG-1 is the major isoform in cardiac myocytes and will therefore be the focus
of this chapter I32 ,133. The aforementioned N-terminal homodimerization domains of
PKG-1a and

~

consequently determine their isoform-specific interactions with cell

substrates and docking proteins. While PKG-1a and PKG-1~ have indistinguishable
cGMP binding sites, PKG1a binds cGMP with a lO-fold higher affinity than PKG1~134,135. Additionally, PKG-1a dimerization is subject to ROS-regulation, its

dimerization forming a disulfide bond between reactive Cys42 residues that adjoin in
the enzyme homodimer. PKG-1 ~ is neither ROS-sensitive nor does it contain
. C ys at th'IS posItIon
.. 136 .
reactive
In 1986, Murry et al observed the phenomenon that would later become known as

cardioprotection 137 . Since then, a growing body of evidence has shown the complex
signaling pathways involved in the hypertrophic regulation of the heart, and that it is
dependent upon multiple components. One important and well-studied pathway is
cyclic GMP and cGMP-dependent protein kinase (PKG). Studies in mice with
increased cGMP synthesis, which upregulated natriuretic peptide receptor signaling
showed overactivity of cGMP blunted hypertrophy in vitro, and despite abnormal
loading conditions in vivo I38 ,139. Similar observations are made with PKG-1
activation 140, and conversely, PKG-1 inhibition exacerbates hypertrophyl41. A recent
study that also demonstrated the important role that PKG plays in the regulation of
cardiac hypertrophy showed that hyperstimulation of the PKG-1 pathway can prevent
and reverse cardiac hypertrophy98. However, it did not abolish hypertrophy induced
by overexpression of Akt in vivo. Additionally, further studies into the mechanism of
this phenomenon showed that it was VEGF-dependent I42 ,143. However, it has been
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suggested that other signaling pathways may playa role in the observed
antihypertrophic effects, as one study reported that cardiac hypertrophy was not
exacerbated by the deletion of PKG-l in cardiac myocytes 144.
It has been reported that PDE5, a cGMP-specific phosphodiesterase type 5
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right ventricle hypertrophyl47. The preconditioning-like cardioprotective effects of
sildenafil against injury sustained by ischemia-reperfusion were observed in the intact
hearts of animals 148. It was observed in other studies in adult mice that sildenafil had
a direct effect in the heart by protecting against necrosis and apoptosis through
activation of the NO-signaling pathway, and this effect was ablated by gene knock
down of NO synthase l49 . While sildenafil has demonstrated powerful
·
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heart failure l54 and cardiomyopathy induced by doxorubicin l55 , these observations are
not limited to sildenafil as other PDE5 inhibitors, vardenafil 156 and tadalafil 157 limit or
reduce infarct sizes.
As there are activators of cardiac hypertrophy, there are also negative modulators,
and their inactivation may play an important role in cardiac hypertrophy and failure.
One important negative modulator is GSK3B, a serine/threonine kinase that regulates
cardiac development, cell development and cycling, gene transcription, apoptosis and
metabolism l58 . Normally, when GSK3B is active, it inhibits hypertrophy. However,
when it is phosphorylated by Akt or PKA, its activity is suppressed and the inhibition
of hypertrophic pathways is removed, paving the way for hypertrophy to develop.
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Studies have suggested that GSK3~ plays an integral role in regulating VEGF,
which may be critical for cardioprotection 159 and also may be another clue to
understanding the mechanism by which eu can reverse cardiac hypertrophy. Further,
it was observed that Akt phosphorylation was insignificantly abrogated by PKG
inhibitor KT5823 or shRNA-PKG 160 . VEGFR-l plays a critical role in modulating
VEGF/Akt signaling 161 by preventing excessive activation of Akt. This is in

agreement with other studies that showed acute activation of Akt exerted protective
effects against both myocardial infarction and ventricular dysfunction following
ischemia-reperfusion in vivo and in vitro162.163. Sildenafil resulted in PKGindependent increases in Akt phosphorylation, suggesting that perhaps PKG-l and
VEGFR-l act synergistically to switch signaling pathways from hypertrophy to
regression in cell size.
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1-5. VIlVIENTIN
The cytoskeleton is unique to eukaryotic cells. Filling the role of both muscle and
skeleton, it aids in both movement and stability of the cell. The cytoskeleton is
composed of three types of filaments: microfilaments, microtubules and intermediate
filaments 164. Microfilaments, the smallest of the three, are roughly 3-6 nm in
diameter. The most well-known examples of microfilaments are actin and myosin,
which carry out the roles of contraction and cytokinesis in the cell. Microtubules are
cylindrical in appearance, which are 20-25 nm in diameter and are composed of the
protein tubulin, whose subunits are termed alpha and beta. Microtubules are thought
to act as a scaffolding to determine cell shape, and act as a "track" on which
organelles and vesicles within the cell to move. Additionally, during mitosis,
microtubules form spindle fibers that separate the chromosomes during anaphase.
Finally, intermediate filaments, named for their diameter because they fall between
microfilamens and microtubules in size, are roughly 10 nm in diameter, and are
thought to provide the cell with tensile strength l65 .
Intermediate filaments constitute approximately 1% of the total protein of cells.

In humans, there are more than 50 intermediate filaments genes which are expressed
in nearly all cells within the bodyl66. And while microfilaments and microtubules are
highly conserved and similar within cells of a particular species, intermediate
filaments exhibit diversity in their numbers, sequence and abundance l67 . However,
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they do share a common structure: a dimer consisting of two a-helical chains in
parallel and intertwined, making a coiled-coil rod. Though the structure may be
similar, the properties vary and can be quite unique. For example, keratin
intermediate filaments found in hair are highly insoluble, but nuclear lamin
intermediate filaments are dynamic and dissociate and reform in a cell cycledependent manner.
Vimentin is the most abundant intermediate filament protein. It is widely
expressed and once thought to be a static element involved mainly in structural
processes. Initially it was believed to playa main role in providing stability for the
architecture of the cell, yet some studies report that knockout models in which the
animals do not express Vimentin exhibit a normal phenotype, develop and reproduce
normally. Therefore it was concluded that Vimentin is not necessary for the viability
of eukaryotic cells 168. However, under certain circumstances, Vimentin knockout
mice do exhibit phenotypic abnormalities under specific conditions, such as
injuryI69,170. This suggests Vimentin has a specialized biological function that
contributes to specific dynamic cellular processes 171, With respect to the
cardiovascular system, Vimentin is an integral part of the vascular endothelium, and
has been suggested to play an important role in shear stress-induced responses, such
. 1 remo d e I'mg 172 .
as artena

In endothelial cells, Vimentin is phosphorylated at serine and threonine residues,
and its secretion is increased by phosphatase inhibitors, and conversely, blocked by
the inhibitor G06983, which is specific for protein kinase C. This is consistent with
other findings that phosphorylation of Vimentin affects its intracellular localization;
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Vimentin is phosphorylated by numerous protein kinases and is a substrate for protein
kinase C (PKC). Further studies have observed that PKC directly phosphorylates
Vimentin at Ser/Thr residues, possibly marking it for secretory pathways. Also, other
studies have demonstrated that IL-lO, an anti-inflammatory cytokine mediates its
effects by inhibiting the PKC pathway. TNF-a is a well-known cytokine which
functions in opposition to IL-lO in macrophages. It was observed that even at
extremely low doses, TNF-a induced the secretion of Vimentin by as much as 120fold in human monocytes. Yet current models for TNF-a signaling do not transpire
through PKC thus suggesting both PKC and TNF-a activate pathways that mediate
the secretion of Vimentin.
Hypoxia is a physiological stimulus that can occur in various conditions,
including but not limited to ischemia, anemia, high altitude and lung disease. While
these conditions can alter systemic responses, it can also exert direct effects on
individual cells, in particular, endothelial cells. It is interesting to note that Vimentin
is also regulated by hypoxia and undergoes redistribution under hypoxic conditions.
A study investigating the mechanism by which hypoxia precipitated the redistribution
of Vimentin focused on the phosphorylation of Vimentin and its interaction with heat
shock protein 27 (HSP27). The investigators observed that HSP27 overexpression
increased total Vimentin levels in endothelial cells, and both hypoxia and HSP27
overexpression appeared to increase the amount of Vimentin that
coimmunoprecipitated with HSP27. It was thus hypothesized that HSP27 may target
a regulatory subunit of Vimentin. Under hypoxic conditions, cells appear to undergo
changes in biomechanical properties, which would prepare for an adaptive response
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to strengthen tissue and thereby protect it against injury. Some have suggested that
these changes bolster adhesive properties and barrier integrity under hypoxic and
other possible conditions as well.
Coincidently, the mediator of hypoxic responses within cells, the activity of
hypoxia-inducible factor-l activity (HIP-I) is regulated by copper. Previous studies
have shown that pressure overload results in copper decrease in the heart. This is also
associated with the inhibition of angiogenesis, as well as the transition from cardiac
hypertrophy to heart failure in a mouse model 159 • Copper supplementation at
physiologically relevant levels reversed heart hypertrophy in the presence of pressure
overload, and this reversal effect was through CCS-mediated HIF-I activation of
VEGF expression and angiogenesis. Copper chelation decreases transcriptional
activity of HIF-l, and siRNA targeting the a subunit of HIF-l blocked copperinduced stimulation of VEGF. Cu is capable of stabilizing HIF-l a by inhibiting
prolyl hydroxylases, and thereby preventing its degradation. While the role of
Vimentin in cardiac myocytes has yet to be elucidated, we observed that after PE
treatment, Vimentin levels decreased and with Cu treatment, Vimentin levels
increased. We hypothesize that in cardiac myocytes, Vimentin acts as a molecular
switch. Upon the addition of PE, the decrease in Vimentin acts as a molecular switch,
switching signaling pathways to hypertrophic pathways and resulting in an increase in
cardiac myocyte size. Conversely, the Cu treatment causes an increase in VEGFR-l
signaling and Vimentin and thereby switches signaling pathways from hypertrophic,
to regression of hypertrophy.
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1-6. HYPOTHESIS

We hypothesize that Cu supplementation generates a change in VEGF receptor
distribution and the subsequent signaling pathways, leading to the reversal of cardiac
hypertrophy. More specifically, we hypothesize that VEGFR-I is associated with
PKG-I and their association is involved in Cu induced regression of cardiomyocyte
hypertrophy.
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II. MATERIALS, INSTRUMENTS & METHODS

A. MATERIALS AND VENDORS:

The first 1-13 were used for the isolation of neonatal rat cardiac myocytes.
1. Hanks' balanced salt solution (HBSS): Sterile, calcium and magnesium-free HBSS
was purchased from Worthington Biochemical Corporation, Catalog # LKL003210,
pH 7.4, and was stored at 4°C. This solution was used to dissolve trypsin and trypsin
inhibitor as indicated, in addition to incubation of minced neonatal rat hearts on the
first day. For washing purposes, HBSS was purchased from GIBCO, Catalog #
14185. This solution was also calcium, magnesium and magnesium sulphate-free.
The lOX solution was diluted to IX and the pH was adjusted to 7.4.
2. L-15 media powder: This powder was purchased from Worthington Biochemical
Corporation. Catalog # LK003250 and stored at 4°C. To prepare the solution, one

pouch of the L-15 powder was placed into aIL glass beaker. 900 mL of double
distilled water (ddH20) was used to reconstitute the powder, and the pouch was also
rinsed out to remove all traces of the powder. The solution was mixed with a
magnetic stir bar, and the pH adjusted to 7.2. The volume was brought to 1000 mL
with ddH20. After filter sterilization, the solution was stored at 4°C until needed.
3. Trypsin: This was purchased from Worthington Biochemical Corporation. Catalog #
LK003235. The powder was stored at 4°C. 2 mL of sterile HBSS was used to
dissolve the powder. The solution was prepared freshly for each experiment.
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4. Trypsin inhibitor: This was purchased from Worthington Biochemical Corportation.
Catalog # LK003225. The powder was stored at 4°C. 1 mL of sterile HBSS solution
was used to dissolve the powder. This solution was prepared fresh for each
experiment.
5. Collagenase: This was purchased from Worthington Biochemical Corporation.
Catalog # LK003245. The powder was stored at 4°C. 5 mL of sterile L-15 media
was used to reconstitute the powder. The solution was prepared fresh for each
experiment.
6. DMEMlF12: Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (Ham)
(1:1) powder was purchased from GIBCO, Catalog # 12500-062 and was stored at
4°C. One pouch ofDMEMlF12 powder was placed into a 1 L glass beaker. 800 mL
of ddH20 was used to dissolve the powder, as well as rinse out the pouch of any
remaining powder. 2.38 grams of HE PES (4-(2-hydroxyethyl)-1piperazineethanesulfonic acid, Sigma, Catalog # H0891) was added to the solution.
The solution was mixed with a magnetic stir bar, and the pH adjusted to 7.4. The
final volume was brought to 1000 mL with ddH20. After filter sterilization, the
solution was stored at 4°C until needed.
7. DMEM: Dulbecco's Modified Eagle Medium. This powder was purchased from

Sigma-Aldrich, Catalog # D7777 and stored at 4°C. To reconstitute, one pouch of the
DMEM powder was placed into a 1 L glass beaker. The powder and the remaining
contents in the pouch were dissolved with 800 mL of ddH20. 3.7 grams of sodium
bicarbonate (NaHC03) was added to the solution. The solution was mixed with a
magnetic stir bar and the pH was adjusted to 7.2. The final volume was brought to
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1000 mL using ddH20. After filter sterilization, the solution was stored at 4°C until
needed.
8. Cell strainers: These were purchased from Worthington Biochemical Corporation.
Catalog # LK003265 and was used to remove tissue debris during the cell isolation
process. They were stored at room temperature.
9. Antibiotic-antimycotic solution: This solution was purchased from Celigro, Catalog
#30-004-CI. The content includes 10,000 U penicillin, 10,000 /lglmL streptomycin
and 25 /lglmL amphotericin B. 1% of this solution was used in working media (1 mL
of solution per 100 mL of media). This solution was stored at -20°C, and thawed
prior to use.
10. Phosphate Buffered Saline (PBS): IX PBS (1 L) was composed of 8 grams NaCl,
0.2 grams KCI, 1.44 grams Na2HP04, 0.24 grams KH2P04. The pH of the solution
was adjusted to 7.4, filter sterilized and stored at 4°C until needed.

11. Gelatin: Gelatin from porcine skin (type A) was purchased from Sigma-Aldrich,
Catalog # G-2500. Gelatin (2.5%) was prepared by adding 2.5 grams gelatin powder
to 100 mL of PBS. The solution was autoclaved to dissolve and sterilize the solution.
Sterilized gelatin was stored at 4°C until needed. Prior to use, the solution as warmed
up in a 37°C water bath for 15 minutes. 1% of the gelatin solution was used in
working media (1 mL of 2.5% gelatin solution per 24 mL PBS).
12. Fetal Bovine Serum (FBS)-premium select: This was purchased from Atlanta

Biologicals, Catalog # S11550. FBS was ali quoted and stored in -20°e. 10% of FBS
was used in working media (10 mL serum was added per 100 mL media).
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13. Penicillin-Streptomycin: This solution was a 100X dual antibiotic solution. It was
purchased from MP Biomedicals, Catalog # 1670046. It contained 5,000 IU/mL
penicillin and 5 mglmL streptomycin. 1% of this solution was used in working media
(1 mL antibiotic solution per 100 mL media). It was stored at -20°C and thawed in a
37°C water bath prior to use.
14. 5-Bromo-2'-deoxyuridine (BrdU): This powder was purchased from Sigma Aldrich,
Catalog # B5002. BrdU (10 mM) was prepared as a stock solution by adding 307 mg
BrdU powder to 100 mL of ddH20. The solution was filter sterilized, and ali quoted
to 10 mL and stored at -20°C prior to use. The reason for the usage of BrdU is that it
is a thymadine analog, and selectively incorporates into cellular DNA during S-phase.
It was used to inhibit the growth of fibroblasts and other proliferative cells in the

primary cultures of neonatal rat cardiac myocytes.
15. Disposable sterile bottle-top filters: Filters were purchased from Corning, Catalog #
43026. It has a funnel volume of 150 mL and the pore size of the cellulose acetate
membrane is 0.22 11m. They screw onto the mouths of the cell culture bottles and
were used to sterilize all solutions used in cell culture. They were stored at room
temperature.
16. Copper sulfate (CuS04): Copper sulfate was purchased from Sigma-Aldrich,
Catalog # C1297. CuS04 (10 mM) was prepared as a stock solution. 8 mg CuS04
powder was added to 5 mL of ddH20. The solution was filter sterilized, then
ali quoted to 100 ilL and stored at -20°C prior to use.
17. Phenylephrine (PE): Phenylephrine was purchased from Acros Organics, Catalog #
61-76-7. PE (10 mM) was prepared as a stock solution. 10 mg PE powder was added
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to 5 mL ddH20. The solution was filter sterilized, then aliquoted to 100 ilL and
stored at -20°C prior to use.
18.0.25% Trypsin-EDTA·4Na solution (IX): This was purchased from GIBCO,
Catalog # 25200-056. The content containes 2.5 gIL of trypsin and 0.38 gIL
EDTA·4Na in HBSS solution without CaCI2, MgC12·6H20 and MgS04·7H20. It
also contained phenol red as a pH indicator. This solution was used to detach cells in
cultures.
19. Lysis buffer: Two different kinds of lysis buffer were used. In the cultures of
neonatal rat cardiac myocytes, the content of the lysis buffer included 20 mM TrisHCI (pH 7.4), 150 mM NaCl, 1% Triton-X, 10% glycerol. Phenylmethylsulfonyl
fluoride (PMSF) at a final concentration of 1 mM and 1% protease inhibitor cocktail
(Sigma-Aldrich, Catalog # P8340) were freshly added prior to use. In the cultures of

human cardiac myocytes, the lysis buffer included 30 mM MOPS, pH 7, 0.15 M
NaCl, 1 mM NaV04, 5 mM NaF, 1 mM EDTA, 1% NP-40 and 1 mM PMSF and 1%
protease inhibitor cocktail were freshly added prior to use.
20. Human Cardiac Myocytes (HCM), embryonic: Cardiac myocytes were purchased
from ScienCell, Catalog # 6200. These cells were grown in several flasks, collected
and then stored in liquid nitrogen for use in experiments.
21. Cardiac Myocyte Medium (CMM): Medium was purchased from ScienCell,
Catalog # 6201. CMM arrived filter sterilized and incomplete, but with reagents
needed for completion kept separate. Prior to usage, FBS and antibiotic solution
shipped with CMM was added to the medium. Medium was stored at 4°C and
warmed up in a 37°C bath for 30 minutes prior to usage.
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22. Poly-L-Lysine (PLL): PLL (1 mglmL) was purchased from ScienCell, Catalog #
0403. PLL was used to pre-treat cell culture flasks to promote cell adhesion in
cultures. The company recommended 15 J.lL of PLL per 1 J.lL of ddH20, however
some optimization was required depending on the flasks used for cell culture. Flasks
must be treated for at least 1 hour prior to seeding cells, or were treated overnight.
After treatment with PLL, flasks were rinsed with PBS twice, and not allowed to dry
out prior to cell seeding. PLL was stored at -20°C prior to usage, and was warmed in
a 37°C bath briefly when needed.
23. Protein assay kit: This was purchased from BioRad, Catalog # 500-0006 and was
used according to the manufacturer's instructions.
24. Protein G Sepbarose beads: These beads were purchased from Sigma-Aldrich,
Catalog # P3296-5ML. These beads were washed 3X with lysis buffer, centrifuging
between each wash to collect the beads in the bottom of a microcentrifuge tube. After
the last wash, a 50/50 solution of beads/lysis buffer was made. 20-40 J.lL of this
slurry solution was added to sample tubes during co-immunoprecipitation
experiments.
25. Agarose-conjugated cGMP beads: These beads were purchased from Santa Cruz
Biotechnology, Catalog # sc10335ac. 2 J.lg of antibody was added tocelUysates and
incubated overnight for immunoprecipitation. The reason for using agaroseconjugates is to minimize signal disturbance during subsequent LCIMS-MS analysis.
26. Agarose-conjugated Flt-! beads: These beads were purchased from Santa Cruz
Biotechnology, Catalog # sc316ac. 2 J.lg of antibody was added to celllysates and
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incubated overnight for irnmunoprecipitation. The reason for using agaroseconjugates is to minimize signal disturbance during subsequent LCIMS-MS analysis.
27. Vimentin antibody for Western blot: This antibody was purchased from Cell

Signaling, Catalog # 3932S. Vimentin antibody used for Western blot was incubated
with the membrane overnight with diluted antibody (1 :500-1: 1000) in 5% w/v BSA,
IX TBS, 0.1 % Tween-20 at 4°C with gentle shaking.
28. Vimentin antibody for Immunoprecipitation: This antibody was purchased from

Cell Signaling, Catalog # 3390. Vimentin antibody was added to lysate slurry 1:50
and incubated overnight at 4°C under rotation.
29. Fit-! antibody for Western blot: This antibody was purchased from Santa Cruz

Biotechnology, Catalog # sc316. It is critical for this experiment that the membrane
not be blocked with non-fat milk, instead BSA must be used or no band will appear.
Antibody dilution ranged from 1:500-1: 1000.
30. Detergent removal spin columns: These columns were purchased from Thermo

Scientific, Catalog # 87777 and were used according to the manufacturer's
instructions.

B. Methods
1. Primary culture
Primary cultures of neonatal rat cardiac myocytes were established according to a
previously published procedure but with some modifications (Hoffmann, et aI., 1995).
The hearts of 1-3 day old Sprague-Dawley rats were isolated, minced on ice and
incubated overnight at 4°C with 50 /lglmL trypsin (Worthington Biochemical

Corporation, Lakewood, NJ) in 20 mL calcium and magnesium-free Hanks Balanced
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Salt Solution (HBSS, Life Technologies Ltd, Carlsbad, CA). After 16 hours incubation,
soybean trypsin inhibitor was added at a final concentration of 100 mglmL for 30
minutes. During this time, the flask was placed in an incubator, 37°C and the tissue was
digested with collagenase (Worthington Biochemical Corporation) in 5 mL L-15 media

(Worthington Biochemical Corporation) at 3TC for 70 minutes. After pipetting the cells
gently, and filtering through a cell strainer, the solution was centrifuged at 1000 rpm for 5
minutes; this was to remove cells such as endothelial cells and fibroblasts. The
supernatant was removed, and the pellet of cells was resuspended in DMEMIHam's
nutrient mixture F12 (1:1 vol/vol, Life Technologies Ltd) supplemented with antibiotics
(100 U/mL penicillin and 100 JlglmL streptomycin, MP Biomedicals, LLC, Solon, OH),
10% fetal bovine serum (FBS, Life Technologies Ltd) and 0.1 mM 5-bromo-2'deoxyuridine (BrdU, Sigma-Aldrich, St. Louis, MO). Fibroblasts were removed by preincubation for 2 hours at 3TC in the cultures. Cardiac myocytes in suspension were
collected by centrifugation, further purifying the cardiac myocytes. The cardiac
myocytes were seeded in 1% gelatin-coated plates containing DMEMlF12 media
supplemented with FBS, BrdU and antibiotics for 24 hours before subsequent
experiments. Myocytes were seeded at a density of 1.5x106/1O cm culture dish; 6x105/60
5

mm culture dish, 2x 10 /35 mm culture dish. After 4 hours the media was changed to
serum-free Dulbecco's modified Eagle's media (DMEM, Gibco, Gaithersburg, MD)
supplemented with BrdU and antibiotics. Beating cardiac myocytes were observed under
routine microscopy. Unless 90% of the cells were beating, the preparation was not used.
The purity of the cultured cardiac myocytes was examined by staining with anti-asarcomeric actin antibody (Sigma-Aldrich) as described below.
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At the end of each experiment (48 hours PE treatment and 24 hours with Cu), the
purity of the cardiac myocytes was determined using flow cytometry. The purity was
more than 90%. Briefly, cells were trypsinized, washed with PBS and fixed in 75%
ethanol at 4°C for at least 18 hours. Primary anti-a-sarcomeric actin antibody (Sigma-

Aldrich) was diluted in PBS and incubated at room temperature for 1 hour. Secondary
fluorescein-conjugated goat anti-mouse IgM antibody (FITC, Southern Biotech,
Temecula, CA) was used for immunofluorescence and incubated for 30 minutes at room
temperature. The fluorescence distribution from 30,000 cells was captured and recorded
using a Cell Quest Acquisition program (Becton & Dickinson, Franklin Lakes, NJ). Data
were analyzed using FlowJo software (Tree Star, Inc., Ashland, OR) and the perentage of
the a-sarcomeric actin labeled cardiac myocytes in the population was calculated.
2. Experimental procedure
Cell hypertrophy was induced by phenylephrine (Sigma-Aldrich) at a final concentration
of 100 11M for 48 hours in serum-free media, following a previously published
procedure 173. At the end of the 48 hour incubation, Cu in the form of copper sulfate
(CuS04) was added directly to the cultures at a final concentration of 5 11M for an
additional 24 hours. At the end of the treatment, or 72 hours, the media were collected
for VEGF secretion analysis. The cells were collected by trypsinization, suspended in
PBS buffer and counted using a hemocytometer. Protein content was measured using a
Bradford method (Bio-Rad, Hercules, CA) and normalized by the cell number. For flow
cytometry analysis of VEGF receptors, the harvested cells were subjected to fixation and
incubation with different markers before analysis as described below.
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To assess the role of PKG-l in the Cu-induced regression of cell hypertrophy, we
used the PKG-la antagonist, (Rp-8-CPT-cGMPS) (Sigma), at a final concentration of 0.5

/lM in cultures. The antagonist was added to the cultures 1 hour prior to the addition of
Cu in cultures. In VEGFR-2 siRNA-induced regression of cell hypertrophy, the same
concentration of VEGF antibody and PKG antagonist was applied.
3. Protein assay
Protein concentrations were measured by the Bradford method using a commercially
available assay kit according to the manufacturer's instructions (Bio-Rad, Hercules, CA).
The absorbance at 595 nm was measured using a Beckman CU 650 spectrophotometer

(Pegasus Scientific, Frederick, MD). Protein content per cell was determined by dividing
the total amount of protein by the cell number and the final concentration was expressed
as micrograms per 106 cells.
4. Cell size determination
Cell volume was determined using a Lovins microslide field finder (Fisher Scientific,
Pittsburgh, PA) following the procedure described previously174. Briefly, cardiac
myocytes in cultures were trypsinized, suspended in PBS and loaded onto a microslide
field finder. The diameters of approximately 150 cells from each group were assessed
and recorded. The cell volume was calculated using the volume of a sphere: V= (4/3)nr 3
where V = cell volume, 1t = 3.14 and r = radius.
In addition, cell size was also determined by flow cytometry. Briefly, cells were
trypsinized, suspended in PBS and directly passed through the flow cytometer. For each
sample, 30,000 cells were recorded and analyzed through the forward scatter light (FSC),
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which is proportional to cell size. The data were quantitatively analyzed sing the FlowJo
software.
5.. Immunocytochemistry
The examine morphological changes of cardiac myocytes in cultures after treatment
with PE and Cu, cells were cultured in an 8-well chamber slide and treated as described
in experimental procedure. After Cu treatment for 24 hours, cells were fixed in 4%
paraformaldehyde in PBS. After fixation, the culture chamber was incubated with
monoclonal anti-a-sarcoeric-actin antibody (Sigma-Aldrich) followed by incubation with
FITC-conjugated goat anti-mouse IgM. Fluorescence was visualized by a phase contrast
microscope (Nikon Instruments, Melville, NY). Images were acquired by a Nikon digital
camera DXM 1200 (Nikon Instruments) using a Nikon ACT-1 software.
6. Double immunochemistry staining
To examine the alterations of the distribution of VEGF receptors of the membrane of
cardiac myocytes after treatment with PE and/or Cu, cells were cultured in 8-well
chamber slides and treated as described in the experimental procedure. After Cu
treatment for 24 hours, cells were fixed in 100% methanol. After fixation, the culture
chamber was incubated with polyclonal anti-VEGFR-1 antibody (Santa Cruz) followed
by incubation with Alexa Fluor 488 conjugated goat anti-rabbit IgG. After washing the
culture chamber was incubated with monoclonal antiVEGFR-2 antibody (Santa Cruz)
followed by incubation with Alexa Fluor 594 conjugated goat anti-mouse IgG.
Fluorescence was visualized by a phase contrast microscope (Nikon Instruments,
Melville, NY). Images were acquired by a Nikon camera DXM 1200 (Nikon

Instruments) using a Nikon ACT-1 software.
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7. Flow cytometric analysis of VEGF receptors
Quantitative analysis of VEGF receptors in cardiac myocytes under different
treatments was done by flow cytometric assay. Briefly, cells were trypsinized, washed
with PBS and fixed in 75% ethanol at 4°C for at least 18 hours. Immunofluorescence
staining with an Alexa Fluor 488 conjugated antibody to VEGF-l (1 :50, Santa Cruz) and
Alexa Fluor 594 conjugated antibody to VEGFR-2 (1:50, Santa Cruz) were performed on
fixed cardiac myocytes. Receptor expression was determined by the intensity of the
fluorescence using the software FlowJo based on the data collected from 30,000 cells per
sample. The data were plotted in two-dimensional fluorescence intensity versus cell
number.
8. siRNA
siRNA targeting rat VEGFR-2 and negative mismatched control siRNA were
purchased from Ambion, Inc. (Applied Biosystems, Cambridge, MA siRNA ID#:
S130202). The siRNA sequences for VEGFR-2 were (from 5' to 3'):
GGGUAUCACUCAGACGAGAtt (sense); UGUCGUCUGAGUGAUACCCag
(antisense). The siRNA sequences for VEGFR-l were (from 5' to 3'):
GAAGCGGUCUUCUUCCGAAtt (sense); UUCGGAAGAAGACCGCUUCag
(antisense). The optimal transfection efficiency was determined from our preliminary
study testing the range from 5-20 nM, and at the selected level of siRNA with maximum
silencing effect with minimal toxicity. After PE treatment, cardiac myocytes were
transfected for 4 hours with 10 nM annealed siRNA targeting rat VEGFR -1 or VEGFR -2
or neative mismatched siRNA in antibiotic-free media as antibiotics can cause cell death
under these conditions. Lipofectamine 2000 (Invitrogen) was used as the transfection
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reagent according to the manufacturer's instructions. After 4 hours of incubation, cardiac
myocytes were changed to the original serum-free media with antibiotics and PE was
added again for hypertrophic groups. At 48 hours post-transfection, cells were
trypisinzed and collected. The silencing effect of siRNA was examined by flow
cytometry 24 hours after siRNA transfection. From preliminary results, VEGFR-2Ievel
was increased after PE treatment in cardiac myocytes compared with control, and Cu
addition lowered the protein expression. To investigate the effect of siRNA, PE treated
cells were used as a positive control. siRNA-treated cardiac myocytes decreased the
protein expression of VEGFR-2 in PE-treated cells, which is very similar to the effect of
Cu.
9. cGMP-dependent protein kinase activity
cGMP-dependent protein kinase G (PKG)-l activity was assayed by coloimetric
analysis with a non-radioisotopic kit (MBL, Woburn, MA). The assay was performed 30
minutes after treatment with Cu in the experiment of VEGFR-l siRNA-blocked
regression of hypertrophic cardiac myocytes. Each sample was measured in duplicate
carefully following the manufacturer's instructions.
10. Human Cardiac Myocytes Cell Culture Experimental procedure
T-75 flasks were pre-treated with PLL for either 1 hour or overnight, then washed 2
times with PBS prior to cell plating. HCM were obtained, grown and maintained in
CMM. When the cell density is low «50% confluent) media may be changed every
other day, however for higher density cell popUlations, media must be changed daily.
Cardiac myocyte hypertrophy was induced by PE at a final concentration of 100 /lM
for 48 hours. Copper (Cu) in the form of copper sulfate (CUS04) was added directly to
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the cultures at a final concentration of 5 IlM for an additional 24 hours in the concomitant
presence of PE. At the conclusion of Cu treatment, cells were washed with phosphate
buffered saline (PBS), and collected by trypsinization and centrifuged at 2000 RPM for 5
minutes at 4°C. Cells were washed with PBS to remove trypsin and centrifuged again
under the aforementioned conditions and the PBS was removed. If cells were not used
immediately, they were stored in -80°C until needed.
11. Western Blot Procedure
Cells were collected as previously described using trypsinization and centrifugation.
The pellet was washed 2X with ice-cold PBS, after the final wash, remove as much PBS
as possible without disturbing the pellet. Lysis buffer: 30mM MOPS, pH 7.0,0.15 M
NaCI, 1 mM Na3V04, 5 mM NaF, 1 mM EDTA, 1% NP-40 and protease inhibitors were
added to the pellet. The tubes were always kept on ice and handling kept to a minimum
to keep the contents and tube as cool as possible.
Cell lysis was achieved by using a cell sonicator. The sonicator was set to 3-5. The
cells were sonicated for 1 second, and then rest on ice for 10 seconds. This was repeated
2 more times. After, the tubes were placed under constant agitation or in head-over-tail
rotor in 4°C for 30-60 minutes. In order to pellet non-soluble material, the tubes
underwent centrifugation at 12,000 x g for 15 minutes at 4°C. The supernatant was
carefully removed and transfered to a fresh tube on ice.
Protein concentration was determined as previously described using the Bradford
method. Proteins were reduced and denatured by the addition of ~-mercaptoethanol to the
loading buffer, and samples were boiled at 95°C for 10 minutes.
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Samples were carefully loaded into pre-cast gels and the gel was placed on ice or in
4°C. 60 volts was applied to the gel for 30 minutes, then 120 V until the bands are
roughly 1 centimeter from the bottom of the gel.
Following SDS-PAGE, the gel was prepared to undergo electroblotting using a
nitrocellulose membrane (GE Healthcare) at 100 volts for 150 minutes. The membrane
was then washed with 1 X TBST and blocked with 5% w/v BSA, IX TBS, 0.1 % Tween20 for 1 hour at room temperature. The membrane was incubated with diluted antibody.
Vimentin was detected by incubation overnight at 4°C with 1:500-1:1000 of antiVimentin antibody (Cell Signaling Technology, Inc). PKG-1 was detected by incubation
overnight at 4°C with 1:500-1:1000 of anti-PKG-1 antibody (Santa Cruz Biotechnology).
VEGFR-1 was detected by incubation overnight at 4°C with 1:500-1:1000 of antiVEGFR-1 antibody (Santa Cruz Biotechnology).
The following morning, membranes were washed 3X for 5 minutes each with IX
TBST, then incubated with the secondary antibody, horseradish peroxidase (HRP)
conjugated goat anti-rabbit immunoglobulin G antibody, diluted 1:1,000 in TBS
containing 0.5% Tween-20 at room temperature for 1 hour. Proteins were visualized
using enhanced chemiluminescence (ECL) (Amersham, Buckinghamshire, UK),
according to the manufacturer's instructions, to visualize HRP-conjugates.
12. Immunoprecipitation
400-500 Ilg of protein from celllysates were incubated overnight with anti-VEGFR-1

(Santa Cruz Biotechnology), anti-Vimentin (Cell Signaling Technology) or anti-PKG-1
agarose-conjugated beads (Santa Cruz Biotechnology) antibody at a concentration of 2
ug/mL for 16 hours at 4° C under rotation. The following morning, 20-40 ilL of a Protein
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G sepharaose beads slurry to the mixture and incubate under rotation at 4°C for 4 hours.
The samples underwent centrifugation at 1000 X g, and the supernatant was carefully
removed, and the bead pellet 3 times with ice-cold PBS. After the final wash, as much of
the supernatant was removed as possible.
For co-immunoprecipitation, in which IP is followed by Western blot: lysis buffer
was added to the beads and the tube was boiled at 95°C for 10 minutes. Samples were
centrifuged again, and the supernatant underwent SDS-PAGE for Western blot analysis.
For subsequent analysis via LC/MS-MS, after washing the pellet 3X, to elute the immune
complex, capture beads were resuspended in 50 III of 0.1 M gl yeine, pH 2.5 and
incubated with agitation for 10 minutes at 4°C. The supernatant was collected after
centrifugation, run through detergent removal spin columns (Thenno Scientific)
according to the manufacturer's instructions, and analyzed using LC/MS-MS.
13. LC/MS-MS
After immunopreeipitation, samples were sent off to Dr. Jian Cai for MALDI-TOF
analysis. Mass spectrometers contain 3 components: an ionization source, a mass
analyzer, in this case, time-of-flight, and a detector. Typically the ionization source
comes from a UV light. The mass analyzer functions to separate or resolve ions
formed in the ionization source according to the mass/charge (m/z) ratio. Finally, the
detector monitors the ion currents, in the form of mass spectra.
MALDI-TOF, or Matrix Assisted Laser Desorption/Ionization Time of Flight
mass spectrometry is a powerful analytical tool for the identification of unknown
biomolecules which utilizes a UV -light absorbing matrix. This matrix, which
contains the proteins in the sample, is irradiated by a nanosecond laser pulse. The
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majority of the energy is absorbed by the matrix, thereby preventing unwanted
fragmentation of the molecules. At the same time, the molecules become ionized,
leaving it with a positive charge. The purpose of this is because magnetic force only
affects charged particles. The ions then travel through an electric field where they are
accelerated, and enter a flight tube.

In this tube, they are separated according to

their mass/charge ratio, ions with a smaller mass traveling faster than those with a
larger mass. Each biomolecule reach the detector at a different time, yielding a
distinct signal. This method is highly sensitive, with an accuracy of 0.1-0.01 %.
Many things should be taken into consideration for successful experiments when
using this procedure. One big source of problems during LC- MSIMS analysis is
detergents, which can cause large, unknown peaks. Another source is keratin. In
order to minimize potential problems, do as much work as feasible in a laminar flow
hood or biological safety cabinet (BSC).
Assume nothing is free of keratin (it probably isn't). That means assuming your
pipette tips, Eppindorf tubes, reagent containers, skin-everything is a potential
source of keratin. Be mindful of the clothing worn while experimental procedures are
being carried out. Wool sweaters are a terrific source of keratin and probably not the
best choice of clothing to wear while conducting experiments upstream of mass
spectrometry analysis. Even cotton lab coats shed significant amounts of dust, which
may contain keratin. If possible, wear a disposable clean-room type lab coat.
Latex gloves contain a significant amount of keratin as well as proteinaceous
materials. Nitrile or vinyl gloves are the best choice. Rinse gloves under a stream of
water before handling samples. Additionally, working surfaces should be cleaned
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with water and absolute ethanol, and wiped down with clean-room wipes, not dusty,
keratin-rich paper towels. Anything that is placed into the BSC should be wiped
down thoroughly.
All supplies, whether it be pipette tip boxes or bags of microcentrifuge tubes,
should be opened only in the BSC while it is in full operation. Further, detergents are
the enemy. Detergents, while important for solubilizing, stabilizing and
dis aggregating protein complexes will also do nasty things to your sample. It can
form adducts with peptides and proteins, and in MS analysis, this will shift mlz
values, which is bad news. Another big no-no for MS is plasticizers.
Lastly, anything that will come into contact with samples (vials, pipette tips, etc.)
should be rinsed with HPLC grade Acetonitrile or high grade methanol if none is
available, then with HPLC grade water.
14. Statistical analysis
Data were obtained from three separate experiments and are expressed as means ±
S.E.M. A 2X2 factorial design was applied to all experiments and the data were
analyzed according to the experimental design. After a significant interaction was
detected by the analysis of variance (ANOV A) based on the factorial design, the
significance of the main effects was further determined by the F-test. The level of
significance was considered when P <0.05.
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III. RESULTS

A. Previous studies have shown that adding physiologically relevant amounts of Cu
to cardiac myocytes in cell cultures can reverse hypertrophy induced by
phenylephrine. This effect is blocked by adding a VEGF antibody. This recaptures the in vivo observation that Cu-induced regression of hypertrophy is
VEGF-dependent. Additionally, the induction of hypertrophy by phenylephrine
can be blocked by using a VEGF antibody. This led us to the question: does
VEGF have a duel function, acting to stimulate cell growth leading to
hypertrophy as well as reversing hypertrophy?

Cardiac myocyte hypertrophy was induced by PE at a final concentration of 100 11M
in cultures for 48 hours in serum-free media. Cells were then treated with CUS04 by
direct addition into the cultures at a final concentration of 5 11M. As seen below in
Figure 1, and much to our surprise, PE induced VEGF production, but not Cu. Cu did
not affect VEGF, however PE did induce it. This was a rather unexpected
observation.
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Figure 1. Quantitative analysis of VEGF secretion. Hypertrophy was induced by PE at a final
concentration of 100 IlM for 48 hours in serum-free media. CUS04 was added directly to the
cultures at a final concentration of 51lM for 24 hours. VEGF levels in collected media were
determined by a Quantikine VEGF Immunoassay kit. The absorbance of standards and samples
was measured spectrophotometrically at 450 run with a wavelength of 540 nm using a microplate
reader. VEGF concentrations were calculated (in pg/mL) on the basis of the standard curve.
Values are means ±SEM. * denotes statistically significant from Control group. n=3 .

B. The effect of Cll treatment on VEGFRs
The effect of VEGF is mediated through its receptors. VEGF receptors (VEGFRs)
belong to a family of receptors called tyrosine kinases. Upon the binding of VEGF to its
receptor, the receptors undergo dimerization and signal transduction. Since the amount
of VEGF in the media of cell cultures was unchanged by Cu, the next thing we
investigated was the effect that Cu had upon VEGFRs. There are 2 VEGF receptors in
the cardiovascular system, FIt-I, also known as VEGF Receptor 1 (VEGFR-I) and KDR,
also known as VEGF Receptor 2 (VEGFR-2). Activation of VEGFR-2 is associated with
a mitogenic response, and is also involved in angiogenesis and survival signaling. A
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decoy VEGFR-2.receptor blocked Akt-1 signalling pathway, which is associated with
growth and is a critical component in the process of myocardial hypertrophy. VEGFR-1
function was previously enigmatic. Our data suggests it may be associated with the
reversal of hypertrophy. A schematic representation l75 can be seen in Figure 2.
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Figure 2. A schematic representation of VEGF receptor signaling in cardiac myocytes.
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The increase in the ratio of VEGFR-l to VEGFR-2 by Co treatment in hypertrophic
cardiac myocytes
1. We investigated the effect of Cu on the density of VEGFRs. As shown below in

Figure 3, PE increased the density of both VEGFR-l (green) and VEGFR-2 (red).
VEGFR-l was not changed by Cu addition, but markedly reduced that of
VEGFR-2 in hypertrophic cardiac myocytes. The merged images of the two
fluorescent labeling showed more green color (VEGFR-l) than the orange
observed under PE only treatment condition.
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Figure 3. Representative fluorescent microscopic images of cellular density of VEGFR-I
(green) and VEGFR-2 (red) or the combination. Hypertrophy was induced by PE at a
final concentration of 100 flM for 48 hours in serum-free media. CUS04 was added
directly to the cultures at a [mal concentration of 5flM for 24 hours. After fixation, cells
were incubated with polyclonal anti-VEGFR-I antibody, followed by Alexa Fluor 488
conjugated goat anti-rabbit IgG. After washing the slide, the culture chamber was
incubated with monoclonal antiVEGFR-2 antibody and incubated with Alexa Fluor 594
conjugated goat anti-mouse IgG. Fluorescence was visualized by a fluorescent
microscope. Magnification: 400X.
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2. As shown in Figure 4 and 5, we also did quantitative analysis by flow cytometer
to confirm the effect of Cu on the density of VEGFRs. The ratio of VEGFR-l to
VEGFR-2 was significantly increased. Together, with the aforementioned data,
this suggests a role for VEGF outside of angiogenesis due to the lack of blood
vessels in cell cultures. Because Cu did not affect the amount of VEGF in
cultures, this indicates that it has a direct effect that is mediated through VEGF
receptors. And this reversal effect is mediated in part by an increase in the ratio
of VEGFR-l:VEGFR-2.
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Figure 4. Flow cytometric analysis of VEGFR-l and VEGFR-2. Hypertrophy was induced by PE
at a final concentration of 100 ).lM for 48 hours in serum-free media. CUS04 was added directly to
the cultures at a final concentration of 5).lM for 24 hours. Representative histograms show changes
in the density of VEGFR-l and VEGFR-2 under different treatment conditions. The values
presented in the figures are means ±SEM. *Significantly different from Control group (P < 0.05).
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Figure 5. Flow cytometric analysis of VEGFR- l and VEGFR-2 in cultured neonatal rat cardiac
myocytes. Hypertrophy was induced by PE at a final concentration of 100 ~M for 48 hours in
serum-free media. CUS04 was added directly to the cultures at a final concentration of 5~M for 24
hours. At the end of Cu treatment, cells were collected, fixed and incubated with Alexa Fluor488
conjugated antibody of VEGFR-l and Alexa Fluor 594 conjugated antibody to VEGFR-2. Cells
were subjected to flow cytometry analysis and 30,000 cells in each sample were counted.
Receptor density was determined by the intensity of fluorescence using the software FlowJo based
on the data collection from 30,000 cells per sample. Data were plotted in two-dimensional
fluorescence intensity vs. cell number. Each group of data presented were obtained from three
independent experiments and each experiment contains a triplicate sample for each treatment. The
values presented in the figures are means ±SEM. *Significantly different from Control group (P <
0.05). MFI = Median Fluorescence Intensity. n = 3.
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c.

Reversal of PE-induced cardiac myocyte hypertrophy by gene silencing of

VEGFR-2

1. Thus far we have observed that the elevation of VEGFR-1:VEGFR-2 has been

linked to the Cu-induced regression. This led us to the next question: How does
VEGF induce the regression phenomenon? Could it be through VEGFR-l? We
hypothesized that in Cu-treated hypetrophic cardiac myocytes, the distribution of
VEGFRs would be altered, leading to a swich from cell growth stimulation to
regression. To differentiate whether the increase in the ratio of VEGFRIIVEGFR-2 was related to the Cu-induced reversal of cardiomyocyte
hypertrophy, we used siRNA targeting VEGFR-2 to increase the ratio of VEGFRIIVEGFR-2. It should be noted that the amount of siRNA used determines the
efficacy of the knock down; in this case, the goal was not to completely silence
VEGFR-2, but rather mimic the effect of Cu. In figures 6, 7 and 8, we show
preliminary data of experiments targeting siRNA and flow cytometric analysis of
VEGFR-l and 2 density, then the data plotted as a ratio of VEGFR-l:VEGFR-2.
Gene silencing of VEGFR-2 increases the ratio of VEGFR-l to VEGFR-2 the
same as that induced by Cu treatment, which is also associated with a reversal in
cardiac myocyte hypertrophy. The effect is comparable to that induced by Cu
treatment as shown in Figures 9, 10 and 11.
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Figure 6. Quantitative analysis of the density of VEGFR-l based upon flow cytometric analysis.
Hypertrophy was induced by PE at a final concentration of 100 11M for 48 hours in serum-free
media. After PE treatment, cardiac myocytes were transfected with 10 nM annealed siRNA
targeting VEGFR-2. Lipofectamine 2000 was used as the transfecton reagent according to the
manufacturer' s instructions. After 48 hours of transfection, cells were trypsinized, collected, fixed
and incubated with Alexa Fluor488 conjugated antibody ofVEGFR-1 and Alexa Fluor 594
conjugated antibody to VEGFR-2. Cells were subjected to flow cytometry analysis and 30,000
cells in each sample were counted. Receptor density wa$ determined by the intensity of
fluorescence using the software FlowJo based on the data collection from 30,000 cells per sample.
Data were plotted in two-dimensional fluorescence intensity vs. cell number. Each group of data
presented were obtained from three independent experiments and each experiment contains a
triplicate sample for each treatment. The values presented in the figures are means ±SEM.
*Significantly different from Control group (P < 0.05). MFI =Median Fluorescence Intensity. n
= 3.
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Figure 7. Quantitative analysis of the density of VEGFR-2 based upon flow cytometric analysis.
Hypertrophy was induced by PE at a final concentration of 100 ~M for 48 hours in serum-free
media. After PE treatment, cardiac myocytes were transfected with 10 nM annealed siRNA
targeting VEGFR-2. Lipofectamine 2000 was used as the transfecton reagent according to the
manufacturer's instructions. After 48 hours of transfection, cells were trypsinized, collected, fixed
and incubated with Alexa Fluor488 conjugated antibody of VEGFR-l and Alexa Fluor 594
conjugated antibody to VEGFR-2. Cells were subjected to flow cytometry analysis and 30,000
cells in each sample were counted. Receptor density was determined by the intensity of
fluorescence using the software FlowJo based on the data collection from 30,000 cells per sample.
Data were plotted in two-dimensional fluorescence intensity vs. cell number. Each group of data
presented were obtained from three independent experiments and each experiment contains a
triplicate sample for each treatment. The values presented in the figures are means ±SEM.
*Significantly different from Control group (P < 0.05). MFI = Median Fluorescence Intensity. n
=3.
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Figure 8. Ratio ofVEGFR-l:VEGFR-2 after using siRNA targeting VEGFR-2. Hypertrophy
was induced by PE at a final concentration of 100 f!M for 48 hours in serum-free media. After PE
treatment, cardiac myocytes were transfected with 10 nM annealed siRNA targeting VEGFR-2.
Lipofectamine 2000 was used as the transfection reagent according to the manufacturer's
instructions. After 48 hours of transfection, cells were trypsinized, collected, fixed and incubated
with Alexa Fluor488 conjugated antibody of VEGFR-l and Alexa Fluor 594 conjugated antibody
to VEGFR-2. Cells were subjected to flow cytometry analysis and 30,000 cells in each sample
were counted. Receptor density was determined by the intensity of fluorescence using the
software FlowJo based on the data collection from 30,000 cells per sample. Data were plotted in
two-dimensional fluorescence intensity vs. cell number. Each group of data presented were
obtained from three independent experiments and each experiment contains a triplicate sample for
each treatment. The values presented in the figures are means ±SEM. *Significantly different
from Control group (P < 0.05). MFI = Median Fluorescence Intensity. n = 3.
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Figure 9. Regression ofPE-induced cell hypertrophy by siRNA targeting VEGFR-2. Quantitative
analysis of cell size based upon flow cytometric analysis. Hypertrophy was induced by PE at a final
concentration of 100 flM for 48 hours in serum-free media. After PE treatment, cardiac myocytes were
transfected with 10 nM annealed siRNA targeting VEGFR-2. Lipofectamine 2000 was used as the
transfection reagent according to the manufacturer's instructions. After 48 hours of transfection, cells
were trypsinized, collected, fixed and subjected to flow cytometry analysis using forward scatter light,
which is proportional to the cell size. 30,000 cells in each sample were counted. Each group of data
presented were obtained from three independent experiments and each experiment contains a triplicate
sample for each treatment. The values presented in the figures are means ±SEM. *Significantly
different from Control group (P < 0.05). n = 3.
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Figure 10. Regression ofPE-induced cell hypertrophy by siRNA targeting VEGFR-2.
Hypertrophy was induced by PE at a fmal concentration of 100 11M for 48 hours in serum-free
media. After PE treatment, cardiac myocytes were transfected with 10 nM annealed siRNA
targeting VEGFR-2. Lipofectamine 2000 was used as the transfection reagent according to the
manufacturer' s instructions. After 48 hours of transfection, cells were trypsinized, collected. Cell
volume was determined using a Lovins microslide field finder. Briefly, cardiac myocytes in
cultures were trypsinized, suspended in PBS and loaded onto a microslide field finder. The
diameters of approximately 150 cells from each group were assessed and recorded. The cell
volume was calculated using the volume of a sphere: V= (4/3)nr 3 where V = cell volume, n = 3.14
and r = radius. Each group of data presented were obtained from three independent experiments
and each experiment contains a triplicate sample for each treatment. The values presented in the
figures are means ±SEM. *Significantly different from Control group (P < 0.05). n= 3.
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Figure 11. Regression of PE-induced cell hypertrophy by siRNA targeting VEGFR-2. The protein
content in the cells measured by a Bradford method and normalized by cell number. Each group of
data presented were obtained from three independent experiments and each experiment contains a
triplicate sample for each treatment. The values presented in the figures are means ±SEM.
*Significantly different from Control group (P < 0.05).
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D. Regression of PE-induced hypertrophy by siRNA targeting VEGFR-2 and the
requirement of VEGF in the regression of cardiac myocyte hypertrophy.

1. The regression of cardiac myocyte hypertrophy induced by Cu is blocked if a anti-

VEGF antibody is added, further demonstrating that VEGF is required for
angiogenesis and growth, but also plays a role in the regression effect that we
observe. Further, VEGFR-2 gene silencing-induced regression of cardiac
myocyte hypertrophy is VEGF-dependent as we1l 159• We have observed both in

vivo and in vitro that the Cu-effect is VEGF-dependent. When silencing
VEGFR-2, we observed the same phenomenon with Cu. The next question we
asked is: Is this effect also VEGF-dependent?

There are three indices of hypertrophy that we used to measure the effect of Cu on the
reversal of hypertrophy: cell size, cell volume and protein content. Cell size was
determined by flow cytometry, using forward scatter light, which is proportional to
cell size. Cell volume was determined using a microslide field finder, and the diamter
of 150 cells was measured. The equation for the volume of a sphere was used to
determine the volume, V =(4/3)nr 3 . Protein content was measured using the
Bradford method, and was normalized by the cell number.

And as clearly shown in Figures 12, 13 and 14, the regression of PE-induced hypertrophy
by siRNA targeting VEGFR-2 is indeed VEGF-dependent.
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Figure 12. Regression ofPE-induced hypertrophy by siRNA targeting VEGFR-2 and the
requirement of VEGF in the regression of cardiac myocyte hypertrophy induced by siRNA
targeting VEGFR-2. Quantitative analysis of cell size based upon flow cytometric analysis.
Hypertrophy was induced by PE at a final concentration of 100 ~M for 48 hours in serum-free
media. After PE treatment, cardiac myocytes were transfected with 10 nM annealed siRNA
targeting VEGFR-2. Lipofectamine 2000 was used as the transfection reagent according to the
manufacturer's instructions. After 48 hours of transfection, cells were trypsinized, collected, fixed
and subjected to flow cytometry analysis using forward scatter light, which is proportional to the
cell size. 30,000 cells in each sample were counted. Each group of data presented were obtained
from three independent experiments and each experiment contains a triplicate sample for each
treatment. The values presented in the figures are means ±SEM. *Significantly different from
Control group. tsignificantly different from PE-treated group (P < 0.05). n =3.
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Figure 13. Effect of siRNA targeting VEGFR-2 on the regression of PE-induced hypertrophy, and
the requirement of VEGF. Hypertrophy was induced by PE at a final concentration of 100 11M for
48 hours in serum-free media. After PE treatment, cardiac myocytes were transfected with 10 nM
annealed siRNA targeting VEGFR-2. Lipofectamine 2000 was used as the transfection reagent
according to the manufacturer's instructions. After 48 hours of transfection, cells were
trypsinized, collected. Cell volume was determined using a Lovins microslide field finder.
Briefly, cardiac myocytes in cultures were trypsinized, suspended in PBS and loaded onto a
microslide field finder. The diameters of approximately 150 cells from each group were assessed
and recorded. The cell volume was calculated using the volume of a sphere: V= (4/3)m 3 where V
= cell volume, 7t = 3.14 and r = radius. Each group of data presented were obtained from three
independent experiments and each experiment contains a triplicate sample for each treatment. The
values presented in the figures are means ±SEM. *Significantly different from Control group (P <
0.05). n= 3.
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Figure 14, Regression ofPE-induced cell hypertrophy by siRNA targeting VEGFR-2in primary
cultures of neonatal rat cardiomyocytes, and the requirement of VEGF in the regression of
cardiomyocyte hypertrophy induced by siRNA targeting VEGFR-2. The protein content in the cells
measured by a Bradford method and normalized by cell number. Each group of data presented were
obtained from three independent experiments and each experiment contains a triplicate sample for each
treatment. The values presented in the figures are means ±SEM. *Significantly different from Control
group (P < 0.05).
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E. Suppression of eu-induced reversal of cardiomyocyte hypertrophy by gene
silencing of VEGFR-l.
1. Up until this point, all the data points to VEGFR-1. The increase in the ratio of
VEGFR-1NEGFR-2 accompanied with the reversal ofPE-induced cardiac
myocyte hypertrophy indicated the determinant role of VEGFR-1 in Cu
regression of cardiac myocyte hypertrophy. The next question that we asked was:
If you knock out VEGFR-1, what happens? We used siRNA targeting VEGFR-1
to examine the effect of suppressing VEGFR-1 on Cu reversal of cardiac myocyte
hypertrophy. Figures 15, 16 and 17 show quantitative analysis of the effect of
siRNA targeting VEGFR-1 on VEGFR-1, VEGFR-2 and the ratio ofVEGFR1:VEGFR-2 respectively. As shown in Figures 18, 19 and 20, gene silencing of
VEGFR-1 inhibited the response of the cells to PE-induced VEGFR-1 elevation,
and consequently suppressed the increase in the ratio ofVEGFR-lNEGFR-2.
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Figure 15. Effect of siRNA targeting VEGFR-l on the distribution ofVEGFR-l and VEGFR-2
and the antagonistic effect of siRNA targeting VEGFR-l on Cu-induced regression of cell
hypertrophy. Quantitative analysis of the density ofVEGFR-l based on the flow cytometric
analysis. Hypertrophy was induced by PE at a final concentration of 100 11M for 48 hours in
serum-free media. After PE treatment, cardiac myocytes were transfected with 10 nM annealed
siRNA targeting VEGFR-l. Lipofectamine 2000 was used as the transfection reagent according
to the manufacturer's instructions. After 48 hours of transfection, cells were trypsinized,
collected, fixed and incubated with Alexa Fluor488 conjugated antibody of VEGFR-l and Alexa
Fluor 594 conjugated antibody to VEGFR-2. Cells were subjected to flow cytometry analysis and
30,000 cells in each sample were counted. Receptor density was determined by the intensity of
fluorescence using the software FlowJo based on the data collection from 30,000 cells per sample.
Data were plotted in two-dimensional fluorescence intensity vs. cell number. Each group of data
presented were obtained from three independent experiments and each experiment contains a
triplicate sample for each treatment. The values presented in the figures are means ±SEM.
*Significantly different from Control group. tsignificantly different from PE-treated group (P <
0.05). MFI = Median Fluorescence Intensity. n = 3.
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Figure 16. Effect of siRNA targeting VEGFR-l on the distribution of VEGFR-l and VEGFR-2
and the antagonistic effect of siRNA targeting VEGFR-l on Cu-induced regression of cell
hypertrophy. Quantitative analysis of the density ofVEGFR-l based on the flow cytometric
analysis. Hypertrophy was induced by PE at a final concentration of 100 ~M for 48 hours in
serum-free media. After PE treatment, cardiac myocytes were trans fee ted with 10 nM annealed
siRNA targeting VEGFR-l. Lipofectamine 2000 was used as the transfection reagent according
to the manufacturer's instructions. After 48 hours of transfection, cells were trypsinized,
collected, fixed and incubated with Alexa Fluor488 conjugated antibody of VEGFR-l and Alexa
Fluor 594 conjugated antibody to VEGFR-2. Cells were subjected to flow cytometry analysis and
30,000 cells in each sample were counted. R.eceptor density was determined by the intensity of
fluorescence using the software FlowJo based on the data collection from 30,000 cells per sample.
Data were plotted in two-dimensional fluorescence intensity vs. cell number. Each group of data
presented were obtained from three independent experiments and each experiment contains a
triplicate sample for each treatment. The values presented in the figures are means ±SEM.
*Significantly different from Control group (P < 0.05). MFI = Median Fluorescence Intensity. n
=3.

69

C Mismatched siRNA :\<

2
a:• 1.8
u.
0 1.6
w
C'\I

<:.,..,

• VEGFR .. 1 siRNA

1.4

a: 1.2

u.
1
w 0.8

0

-

> 0.6
0

0.4
~
a: 0.2
0
0

Control

PE

Cu

PE+Cu

Figure 17. Quantitative analysis of the density of VEGFR-l based on the flow cytometric analysis.
Ratio of VEGFR-l :VEGFR-2. Effect of siRNA targeting VEGFR-l on the distribution of
VEGFR-l and VEGFR-2 and the antagonistic effect of siRNA targeting VEGFR-l on Cu-induced
regression of cell hypertrophy. Effect of siRNA targeting VEGFR-l on the distribution of
VEGFR-l and VEGFR-2 and the antagonistic effect of siRNA targeting VEGFR-l on Cu-induced
regression of cell hypertrophy. Hypertrophy was induced by PE at a final concentration of 100
/lM for 48 hours in serum-free media. After PE treatment, cardiac myocytes were transfected with
10 nM annealed siRNA targeting VEGFR-l. Lipofectamine 2000 was used as the transfection
reagent according to the manufacturer's instructions. After 48 hours of transfection, cells were
trypsinized, collected, fixed and incubated with Alexa Fluor488 conjugated antibody of VEGFR-l
and Alexa Fluor 594 conjugated aritibody to VEGFR-2. Cells were subjected to flow cytometry
analysis and 30,000 cells in each sample were counted. Receptor density was determined by the
intensity of fluorescence using the software FlowJo based on the data collection from 30,000 cells
per sample. Data were plotted in two-dimensional fluorescence intensity vs. cell number. Each
group of data presented were obtained from three independent experiments and each experiment
contains a triplicate sample for each treatment. The values presented in the figures are means
±SEM. *Significantly different from Control group. tsignificantly different from PE-treated
group (P < 0.05). MFI =Median Fluorescence Intensity. n =3.
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Again, we measured the three indices of hypertrophy: cell size, cell volume and
protein content. Cell size was determined by flow cytometry, using forward scatter
light, which is proportional to cell size. Cell volume was determined using a
microslide field finder, and the diamter of 150 cells was measured. The equation for
the volume of a sphere was used to determine the volume, V =(4/3) nr3. Protein
content was measured using the Bradford method, and was normalized by the cell
number.
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Figure 18. Quantitative analysis of cell size based upon flow cytometric analysis. Hypertrophy
was induced by PE at a final concentration of 100 11M for 48 hours in serum-free media. After PE
treatment, cardiac myocytes were transfected with 10 nM annealed siRNA targeting VEGFR-l.
Lipofectamine 2000 was used as the transfection reagent according to the manufacturer's
instructions. After 48 hours of transfection, cells were trypsinized, collected, fixed and subjected
to flow cytometry analysis using forward scatter light, which is proportional to the cell size.
30,000 cells in each sample were counted. Each group of data presented were obtained from three
independent experiments and each experiment contains a triplicate sample for each treatment. The
values presented in the figures are means ±SEM. *Significantly different from Control group.
tsignificantly different from PE-treated group (P < 0.05). n =3.
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Figure 19. Hypertrophy was induced by PE at a final concentration Of 100 11M for 48 hours in
serum-free media. After PE treatment, cardiac myocytes were transfected with 10 nM annealed
siRNA targeting VEGFR-l. Lipofectamine 2000 was used as the transfection reagent according
to the manufacturer's instructions. After 48 hours of trans feet ion, cells were trypsinized and
collected. Cell volume was determined using a Lovins microslide field finder. Briefly, cardiac
myocytes in cultures were trypsinized, suspended in PBS and loaded onto a microslide field
finder. The diameters of approximately ISO cells from each group were assessed and recorded.
The cell volume was calculatred using the volume of a sphere: V= (4/3)1tr3 where V = cell volume,
1t = 3.14 and r = radius. Each group of data presented were obtained from three independent
experiments and each experiment contains a triplicate sample for each treatment. The values
presented in the figures are means ±SEM. *Significantly different from Control group and
tsignificantly different from PE-treated group (P < 0.05).
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Figure 20. Effect of siRNA targeting VEGFR-l on the distribution ofVEGFR-l and VEGFR-2 and
the antagonistic effect of siRNA targeting VEGFR-l on Cu-induced regression of cell hypertrophy. At
the end of siRNA treatment, cells were collected. The protein content in the cells measured by a
Bradford method and normalized by cell number. Each group of data presented were obtained from
three independent experiments and each experiment contains a triplicate sample for each treatment.
The values presented in the figures are means ±SEM. *Significantly different from Control group and
tsignificantly different from PE-treated group (P < 0.05).

In summary, the data suggests that the regression of hypertrophy is associated
with an increase in the VEGFR-l:VEGFR-2. We also observed that siRNA targeting
VEGFR-2 mimics the Cu-effect. Additionally, we also observed that siRNA targeting
VEGFR-l blocks Cu-induced reversal of cardiac myocyte hypertrophy induced by PE.
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F. Association ofPKG-l with VEGFR-l-mediated reversal of cardiomyocyte
hypertrophy by eu treatment

1. The data thus far suggests that VEGFR-l is a mediator in the reversal effect. The

next question that we asked was: What is the signaling molecule associated with
VEGFR-l? cGMP-dependent protein kinase-l (PKG-l) has been defined to be
involved in the inhibition of myocardial growth. The PKG-l signaling pathway is
a well-studied and important pathway that has also been shown to be involved in
the regression of cardiac hypertrophy176. Additionally, this effect has also been
shown to be VEGF-dependent. The link between VEGFR-l and PKG-l was
examined by the effect of VEGFR-l gene silencing on PKG-l activity.

We hypothesized that the VEGFR-l increase related regression is mediated by
PKG-l and set out to determine the role of PKG-l and VEGFR -1 mediated
regression of cardiac myocyte hypertrophy. The first thing that we examined was
the effect of VEGFR-l gene silencing on PKG-l activity, as seen in Figure 21.
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Figure 21. Inhibitory effect of siRNA targeting VEGFR-} on PKG-l activity on PE-elevated
PKG-l activity. PKG-l activity was assayed by a colormetric analysis procedure. The assay was
performed 30 minutes after treatment with Cu. Each group of data presented were obtained from
three independent experiments and each experiment contains a triplicate sample for each
treatment. The values presented in the figures are means ±SEM. *Significantly different from
Control group and tsignificantly different from PE-treated group (P < 0.05).
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2. We also examined the effect ofPKG-l antagonist on Cu- or VEGFR-2 gene
silencing-induced regression of cardiac myocyte hypertrophy. The results suggest
that PE treatment significantly elevated PKG-l activity and Cu addition did not
change PKG-l activity, but VEGFR-l gene silencing significantly attenuated PEinduced PKG-l activation. Additionally, a PKG-l antagonist, Rp-8-pCPTcGMPS, blocked both VEGFR-2 gene silencing- and Cu-induced reversal of
cardiac myocyte hypertrophy, as shown in Figures 22-24 and 25-27 respectively.
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Figure 22. Antagonistic effect PKG-I inhibitor, Rp-8-pCPT -cGl\1PS, on regression of cell
hypertrophy by siRNA targeting VEGFR-2. PKG-l inhibitor was added 1 hour prior to siRNA at
a concentration of 0.5 11M. Hypertrophy was induced by PE at a final concentration of 100 11M for
48 hours in serum-free media. After PE treatment, cardiac myocytes were trans fee ted with 10 nM
annealed siRNA targeting VEGFR-2. Lipofectamine 2000 was used as the transfection reagent
according to the manufacturer's instructions. After 48 hours of trans feet ion, cells were trypsinized
and collected. Quantitative analysis of cell size based upon flow cytometric analysis. Each group
of data presented were obtained from three independent experiments and each experiment contains
a triplicate sample for each treatment. The values presented in the figures are means ±SEM.
*Significantly different from Control group and tsignificantly different from PE-treated group (P
< 0.05).
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Figure 23. Antagonistic effect PKG-l inhibitor, Rp-8-pCPT -cGMPS, on regression of cell
hypertrophy by siRNA targeting VEGFR-2. PKG-l inhibitor was added 1 hour prior to siRNA at
a concentration of 0.5 11M. Hypertrophy was induced by PE at a final concentration of 100 11M for
48 hours in serum-free media. After PE treatment, cardiac myocytes were transfected with 10 nM
annealed siRNA targeting VEGFR-2. Lipofectamine 2000 was used as the transfection reagent
according to the manufacturer's instructions. After 48 hours oftransfection, cells were trypsinized
and collected. Cell volume was determined using a Lovins microslide field finder. Briefly,
cardiac myocytes in cultures were trypsinized, suspended in PBS and loaded onto a microslide
field finder. The diameters of approximately 150 cells from each group were assessed and
recorded. The cell volume was calculated using the volume of a sphere: V= (4/3)rrr 3 where V =
cell volume, 1t = 3.14 and r = radius. Each group of data presented were obtained from three
independent experiments and each experiment contains a triplicate sample for each treatment. The
values presented in the figures are means ±SEM. *Significantly different from Control group (P <
0.05).
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Figure 24. Antagonistic effect of PKG-I inhibitor, Rp-8-pCPT -cGMPS, on regression of cell
hypertrophy induced by siRNA targeting VEGFR-2. PKG-I inhibitor was added I hour prior to
siRNA at a concentration of 0.5 IlM. Hypertrophy was induced by PE at a final concentration of
100 IlM for 48 hours in serum-free media. After PE treatment, cardiac myocytes were transfected
with 10 nM annealed siRNA targeting VEGFR-2. Lipofectamine 2000 was used as the
transfection reagent according to the manufacturer's instructions. After 48 hours of transfection,
cells were trypsinized and collected. The protein content in the cells measured by a Bradford
method and normalized by cell number. Each group of data presented were obtained from three
independent experiments and each experiment contains a triplicate sample for each treatment. The
values presented in the figures are means ±SEM. *Significantly different from Control group and
tsignificantly different from PE-treated group (P < 0.05).
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Figure 25. Antagonistic effect PKG-l inhibitor, Rp-8-pCPT -cGMPS, on regression of cell
hypertrophy by Cu supplementation. PKG-l inhibitor was added 1 hour prior to Cu at a
concentration of 0.5 /!M, Hypertrophy was induced by PE at a final concentration of 100 I!M for
48 hours in serum-free media. After PE treatment, cardiac myocytes were treated with 5 /!M Cu
by direct addition to the cultures. Quantitative analysis of cell size based upon flow cytometric
analysis. Each group of data presented were obtained from three independent experiments and
each experiment contains a triplicate sample for each treatment. The values presented in the
figures are means ±SEM. *Significantly different from Control group and tsignificantly different
from PE-treated group (P < 0.05).
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Figure 26. Antagonistic effect PKG-l inhibitor, Rp-8-pCPT-cGMPS, on regression of cell hypertrophy
by Cu supplementation. PKG-l inhibitor was added 1 hour prior to Cu at a concentration of 0.5 11M.
Hypertrophy was induced by PE at a final concentration of 100 11M for 48 hours in serum-free media.
After PE treatment, cardiac myocytes were treated with 5 11M Cu by direct addition to the cultures.
Cell volume was determined using a Lovins microslide field finder. Briefly, cardiac myocytes in
cultures were trypsinized, suspended in PBS and loaded onto a microslide field finder. The diameters
of approximately 150 cells from each group were assessed and recorded. The cell volume was
calculatred using the volume of a sphere: V= (4/3)m 3 where V = cell volume, 1t = 3.14 and r = radius.
Each group of data presented were obtained from three independent experiments and each experiment
contains a triplicate sample for each treatment. The values presented in the figures are means ±SEM.
*Significantly different from Control group and tsignificantly different from PE-treated group (P <
0.05).
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Figure 27. Antagonistic effect PKG-I inhibitor, Rp-8-pCPT -cGMPS, on regression of cell
hypertrophy by Cu supplementation. PKG-I inhibitor was added I hour prior to Cu at a
concentration of 0.5 ~M. Hypertrophy was induced by PE at a final concentration of I 00 ~M for
48 hours in serum-free media. After PE treatment, cardiac myocytes were treated with 5 ~M Cu
by direct addition to the cultures. The protein content in the cells measured by a Bradford method
and normalized by cell number. Each group of data presented were obtained from three
independent experiments and each experiment contains a triplicate sample for each treatment. The
values presented in the figures are means ±SEM. *Significantly different from Control group and
tsignificantly different from PE-treated group (P < 0.05).
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In summary, these data suggest that PKG-l antagonist blocks the regression of

cardiac myocyte hypertrophy induced by siRNA targeting VEGFR-2, as well as
eu-induced regression of cardiac myocyte hypertrophy.

As a whole, this body of data suggests that the VEGFR-l pathway is somehow
linked to the PKG-l signaling pathway. It appears that both are involved in the
regression of cardiac hypertrophy and are somehow linked.

Regression of cardiac hypertrophy

Induction of cardiac hypertrophy

Figure 28. A complete schematic representation of VEGF receptor signaling in cardiac
myocytes.
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G. The involvement of Vimentin in the regression of cardiac myocyte
hypertrophy
1. The next question we asked was if there was a correlation between VEGFR-1 and
PKG-l? Was it direct, or indirect? How? We then hypothesized that VEGFR-l and
PKG-l are members of the same signaling cluster.

Copper-induced regression of cardiac myocyte hypertrophy is associated with
enhanced VEGFR-l signaling, as well as an increase in PKG-l activity. In order to
investigate the mechanisms by which this phenomena occurs, we used functional
proteomics to identify proteins associated with PKG-l(Tables 1,2 and 3) and
VEGFR-l (Table 4). There is one caviat: neither VEGFR-l nor.PKG-l are copperbinding proteins, yet the phenomenon we have observed is related to Cu
supplementation.

We used immunoprecipitation to pull down the immune complexes associated with
VEGFR-l as well as PKG-l. These immune complexes were sent off for LC-MS/MS
analysis. Hundreds of proteins were identified in both complexes, however we were
most interested in a copper-binding protein. For this reason, we chose Vimentin. Our
preliminary Western blot analysis, in Figure 29 showed that PE treatment caused a
decrease in the amount of Vimentin.

To further validate this interaction, we used co-immunoprecipitation, pulling down
Vimentin and then subjecting the immunopreciptate to Western blot analysis. These
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experiments further validated the protein-protein interaction between Vimentin and
PKG-1 (Figure 30), and Vimentin and VEGFR-1(Figures 31 and 32). We
hypothesize that PE causes a decrease in Vimentin, and this tips the scale, favoring
hypertrophic signaling and growth in cardiac myocytes.
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Table 1: PKG-1 pull-down
Control
60 kDa heat shock protein,
mitochondrial
ATP synthase subunit alpha,
mitochondrial

00
U\

Cu

PE

60 kDa heat shock protein,
mitochondrial
ATP synthase subunit alpha,
mitochondrial
ATP synthase subunit beta,
mitochondrial

60 kDa heat shock protein,
mitochondrial

Malate dehydrogenase,
mitocho ndrial

Malate dehydrogenase,
mitochondrial

Malate dehydrogenase,
mitochondrial

14-3-3 protein beta/alpha
14-3-3 protein gamma
14-3-3 protein epsilon

14-3-3 protein beta/alpha
14-3-3 protein gamma
14-3-3 protein epsilon
14-3-3 protein eta
14-3-3 protein zeta/delta
14-3-3 protein theta

14-3-3 protein beta/alpha
14-3-3 protein gamma
14-3-3 protein epsilon
14-3-3 protein eta
14-3-3 protein zeta/delta
14-3-3 protein theta

40S ribosomal protein SA
40S ribosomal protein S2
40S ribosomal protein S3
40S ribosomal protein S5
40S ribosomal protein S6
40S ribosomal protein S12
40S ribosomal protein S 18

40S ribosomal protein SA
40S ribosomal protein S2
40S ribosomal protein S3

14-3-3 protein zeta/delta
14-3-3 protein theta

40S ribosomal protein S3

40S ribosomal protein S12
40S ribosomal protein S 18
40S ribosomal protein S20

ATP synthase subunit beta,
mitochondrial

40S ribosomal protein S12
40S ribosomal protein S 18
40S ribosomal protein S20

PE+Cu
60 kDa heat shock protein,
mitochondrial
ATP synthase subunit alpha,
mitochondrial
ATP synthase subunit beta,
mitochondrial
ATP synthase subunit 0,
mitochondrial
Malate dehydrogenase,
mitochondrial
Serine hydroxymethyltransferase,
mitochondrial
14-3-3 protein beta/alpha
14-3-3 protein gamma
14-3-3 protein epsilon
14-3-3 protein eta
14-3-3 protein zeta/delta
14-3-3 protein theta
26S proteasome non-ATPase
regulatory subunit
40S ribosomal protein SA
40S ribosomal protein S2
40S ribosomal protein S3
40S ribosomal protein S5
40S ribosomal protein S6
40S ribosomal protein S12 .
40S ribosomal protein S 18
40S ribosomal protein S 19

40S ribosomal protein S24
40S ribosomal protein S28

40S ribosomal protein S28
60S ribosomal protein L4
60S ribosomal protein L6

40S ribosomal protein S28
60S ribosomal protein L4
60S ribosomal protein L 7

40S ribosomal protein S26
40S ribosomal protein S28
60S ribosomal protein L4
60S ribosomal protein L 7
60S ribosomal protein LII
60S ribosomal protein LI2

60S ribosomal protein LI7
60S ribosomal protein L23
60S ribosomal protein L23a
60S ribosomal protein L24
60S ribosomal protein L27a

00
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78 kDa glucose-regulated protein
Protein SIOO-A6
Protein SIOO-A7
Protein SlOO-A7A
Protein SIOO-A8
Protein SIOO-A9
Protein SIOO-AII

60S ribosomal protein L23a
60S ribosomal protein L24
60S acidic ribosomal protein POlike
60S acidic ribosomal protein PO

60S ribosomal protein L27a
60S acidic ribosomal protein
PO-like
60S acidic ribosomal protein PO

60S acidic ribosomal protein P2
78 kDa glucose-regulated
protein

60S acidic ribosomal protein P2
78 kDa glucose-regulated
protein

Protein SIOO-AII

Protein S IOO-All
SH3 domain-binding glutamic
acid-rich-like protein
UPF0568 protein C14orfl66
UPF0027 protein C22orf28
Alpha-actinin-l

UPF0568 protein C 14orfl66

UPF0568 protein C14orfl66

Alpha-actinin-l

Alpha-actinin-l

60S acidic ribosomal protein PO
60S acidic ribosomal protein PI
60S acidic ribosomal protein P2
78 kDa glucose-regulated protein

Protein SIOO-AII
SH3 domain-binding glutamic acidrich-like protein
UPF0568 protein C14orfl66
UPF0027 protein C22orf28
Alpha-actinin-l
Alpha-actinin-2

Alpha-actinin-4
Adenylyl cyclase-associated
protein I
Annexin Al
AnnexinA2

Alpha-actinin-4
Adenylyl cyclase-associated
protein I
AnnexinAI
AnnexinA2

Putative annexin A2-like protein
AnnexinA5

Putative annexin A2-like protein
AnnexinA5
AnnexinA6
Actin, cytoplasmic I
Actin, cytoplasmic 2
Actin-related protein 3
Actin, aortic smooth muscle
Actin, alpha cardiac muscle I
Actin, gamma-enteric smooth
muscle
Actin, alpha skeletal muscle
ADP-ribosylation factor I
ADP-ribosylation factor 3
ADP-ribosylation factor 4
ADP-ribosylation factor 5

Actin, cytoplasmic I
Actin, cytoplasmic 2

00

-....l

Actin, aortic smooth muscle
Actin, alpha cardiac muscle I
Actin, gamma-enteric smooth
muscle
Actin, alpha skeletal muscle
ADP-ribosylation factor I
ADP-ribosylation factor 3
ADP-ribosylation factor 4
ADP-ribosylation factor 5

Alpha-actinin-4
Adenylyl cyclase-associated
protein I
AnnexinAI
AnnexinA2
Putative annexin A2-like
protein
AnnexinA5
AnnexinA6
Actin, cytoplasmic I
Actin, cytoplasmic 2
Actin-related protein 3
Actin, aortic smooth muscle
Actin, alpha cardiac muscle I
Actin, gamma-enteric smooth
muscle
Actin, alpha skeletal muscle
ADP-ribosylation factor I
ADP-ribosylation factor 3
ADP-ribosylation factor 4
ADP-ribosylation factor 5

Alpha-actinin-4
Adenylyl cyclase-associated protein
1
AnnexinAl
AnnexinA2

Beta-actin-like protein 2
Beta-actin-like protein 3
Brain acid soluble protein 1
Calmodulin
Calpain small subunit 1

Beta-actin-like protein 2
Beta-actin-like protein 3
Brain acid soluble protein 1
Calmodulin
Calpain small subunit 1

ADP/ATP translocase 2
ADPI ATP translocase 3

Apolipoprotein D
ATP-dependent RNA helicase
DDX3X
Beta-actin-like protein 2
Beta-actin-like protein 3
Brain acid soluble protein 1
Calmodulin

ADP/ATP translocase 3

Beta-actin-like protein 2
Beta-actin-like protein 3
Brain acid soluble protein I
Calmodulin
Cal pain small subunit 1

Putative annex in A2-like protein
AnnexinA5
Annexin A6
Actin, cytoplasmic 1
Actin, cytoplasmic 2
Actin-related protein 3
Actin, aortic smooth muscle
Actin, alpha cardiac muscle 1
Actin, gamma-enteric smooth muscle
Actin, alpha skeletal muscle
ADP-ribosylation factor 1
ADP-ribosylation factor 3
ADP-ribosylation factor 4
ADP-ribosylation factor 5
ADPIATP translocase I
ADP/ATP translocase 2
ADPIATP translocase 3

Calponin-2
Calponin-3

Calponin-2

Calponin-2
Calponin-3
Calumenin
Cathepsin B

Chloride intracellular channel
protein I
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Cofilin-I
Cofilin-2
Complement C3
Complement C4-A
Complement C4-B
Cullin-associated NEDDSdissociated protein I
Elongation factor I-alpha 1
Putative elongation factor 1alpha-like 3
Elongation factor 2
Elongation factor I-alpha 2
Elongation factor I-delta
Endoplasmin
Alpha-enolase
Beta-enolase
Gamma-enolase

CathepsinD
Chloride intracellular channel
protein I
Chloride intracellular channel
protein 4
Clathrin heavy chain I
Coatomer subunit beta
Cofilin-I

Chloride intracellular channel
protein I

Clathrin heavy chain I
Cofilin-I
Cofilin-2

Cofilin-I

Cullin-associated NEDDSdissociated protein I

Cullin-associated NEDDSdissociated protein I
Elongation factor I-alpha I
Putative elongation factor 1alpha-like 3
Elongation factor I-beta
Elongation factor 2
Elongation factor I-alpha 2
Elongation factor I-delta
Elongation factor I-gamma
Endoplasmin
Alpha-enolase
Beta-enolase
Gamma-enolase

Calponin-2
Calponin-3
Calreticulin
Calumenin
CathepsinB
CathepsinD
Chloride intracellular channel protein
I
Chloride intracellular channel protein
4
Clathrin heavy chain I

Cytochrome c
Elongation factor I-alpha I
Putative elongation factor 1alpha-like 3
Elongation factor I-beta
Elongation factor 2
Elongation factor I-alpha 2
Elongation factor I-delta
Elongation factor I-gamma
Endoplasmin
Alpha-enolase
Beta-enolase
Gamma-enolase

Elongation factor I-alpha I
Putative elongation factor l-alphalike 3
Elongation factor I-beta
Elongation factor 2
Elongation factor I-alpha 2
Elongation factor I-delta
Elongation factor I-gamma
Endoplasmin
Alpha-enolase
Beta-enolase
Gamma-enolase

Eukaryotic initiation factor 4A-I
Eukaryotic initiation factor 4A-II
Eukaryotic translation initiation
factor 5A-I
Eukaryotic translation initiation
factor 5A-l-Iike
Eukaryotic translation initiation
factor 5A-2
Exportin-2

Eukaryotic initiation factor 4A-I
Eukaryotic initiation factor 4AII
Eukaryotic translation initiation
factor 5A-I
Eukaryotic translation initiation
factor 5A-l-Iike
Eukaryotic translation initiation
factor 5A-2
Exportin-2

Eukaryotic initiation factor 4A-I
Eukaryotic initiation factor 4AII
Eukaryotic translation initiation
factor 5A-I
Eukaryotic translation initiation
factor 5A-I-like
Eukaryotic translation initiation
factor 5A-2
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Fructose-bisphosphate aldolase A
Galectin-I
Glucose-6-phosphate isomerase

Fructose-bisphosphate aldolase
A
Galectin-I
Glucose-6-phosphate isomerase

Glutathione S-transferase P
Glyceraldehyde-3-phosphate
dehydrogenase

Glutathione S-transferase P
Glyceraldehyde-3-phosphate
dehydrogenase

GTP-binding nuclear protein Ran
Heat shock protein HSP 90-alpha
Heat shock protein HSP 90-beta
Heat shock-related 70 kDa protein
2

GTP-binding nuclear protein
Ran
Heat shock protein HSP 90alpha
Heat shock protein HSP 90-beta
Heat shock protein beta-I
Heat shock-related 70 kDa
protein 2

Eukaryotic initiation factor 4A-I1
Eukaryotic translation initiation
factor 5A-I
Eukaryotic translation initiation
factor 5A-I-like
Eukaryotic translation initiation
factor 5A-2
Ezrin
F-actin-capping protein subunit
alpha-I
Filamin-A
Filamin-B
Filamin-C

F-actin-capping protein subunit
alpha-I
Filamin-A

CXl

Eukaryotic initiation factor 4A-I

Fructose-bisphosphate aldolase
A
Galectin-I
Glucose-6-phosphate isomerase
Glutathione S-transferase
omega-I
Glutathione S-transferase P
Glyceraldehyde-3-phosphate
dehydrogenase
Guanine nucleotide-binding
protein subunit beta-2-l
GTP-binding nuclear protein
Ran
Heat shock protein HSP 90alpha
Heat shock protein HSP 90-beta
Heat shock protein beta-I
Heat shock-related 70 kDa
protein 2

Fructose-bisphosphate aldolase A
Galectin-I
Glucose-6-phosphate isomerase

Glutathione S-transferase P
Glyceraldehyde-3-phosphate
dehydrogenase

GTP-binding nuclear protein Ran
Heat shock protein HSP 90-alpha
Heat shock protein HSP 90-beta

Heat shock-related 70 kDa protein 2

Heat shock 70 kDa protein 6

Heat shock 70 kDa protein 6

Heat shock cognate 71 kDa
protein
Putative heat shock protein HSP
90-alpha A2
Putative heat shock protein HSP
90-beta 2
Putative heat shock protein HSP
90-beta-3

Heat shock cognate 71 kDa
protein
Putative heat shock protein HSP
90-alpha A2
Putative heat shock protein HSP
90-beta 2
Putative heat shock protein HSP
90-beta-3

Heterogeneous nuclear
ribonucleoproteins A21B I

Heterogeneous nuclear
ribonucleoprotein Al
Putative heterogeneous nuclear
ribonucleoprotein A
Heterogeneous nuclear
ribonucleoprotein AI-like
Heterogeneous nuclear
ribonucleoprotein AlB
Heterogeneous nuclear
ribonucleoproteins A21B I

Heat shock cognate 71 kDa
protein
Putative heat shock protein HSP
90-alpha A2
Putative heat shock protein HSP
90-beta 2
Putative heat shock protein HSP
90-beta-3
Putative heat shock protein HSP
90-beta 4
Heterogeneous nuclear
ribonucleoprotein Al
Putative heterogeneous nuclear
ribonucleoprotein A
Heterogeneous nuclear
ribonucleoprotein AI-like
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Heterogeneous nuclear
ribonucleoproteins C l/C2

Heterogeneous nuclear
ribonucleoproteins C l/C2
Heterogeneous nuclear
ribonucleoprotein DO

Heterogeneous nuclear
ribonucleoprotein K

Heterogeneous nuclear
ribonucleoprotein K

Heterogeneous nuclear
ribonucleoproteins A21B I
Heterogeneous nuclear
ribonucleoprotein C-like I
Heterogeneous nuclear
ribonucleoproteins C l/C2
Heterogeneous nuclear
ribonucleoprotein DO

Heterogeneous nuclear
ribonucleoprotein K
Heterogeneous nuclear
ribonucleoprotein M

Heat shock 70 kDa protein 1
Heat shock 70 kDa protein 6
Putative heat shock 70 kDa protein 7
Heat shock 70 kDa protein lL
Heat shock cognate 71 kDa protein
Putative heat shock protein HSP 90alpha A2
Putative heat shock protein HSP 90beta 2
Putative heat shock protein HSP 90beta-3
Putative heat shock protein HSP 90beta 4
Heterogeneous nuclear
ribonucleoprotein Al
Putative heterogeneous nuclear
ribonucleoprotein A
Heterogeneous nuclear
ribonucleoprotein A I-like

Heterogeneous nuclear
ribonucleoproteins A21B 1
Heterogeneous nuclear
ribonucleoprotein C-like I
Heterogeneous nuclear
ribonucleoproteins ClIC2
Heterogeneous nuclear
ribonucleoprotein DO
Heterogeneous nuclear
ribonucleoprotein D-like
Heterogeneous nuclear
ribonucleoprotein K

Importin subunit beta-I

-

Histone H2A type I
Histone H2A type I-BIE
Histone H2A type I-C
Histone H2A type 1-D
Histone H2A type 1-H
Histone H2A type I-J
Histone H2A type 2-A
Histone H2A type 2-C
Histone H2A type 3
Histone H2A.J
Importin-5
Importin subunit alpha-2
Importin subunit beta-I

Histone H2A type I
Histone H2A type I-BIE
Histone H2A type l-C
Histone H2A type I-D
Histone H2A type I-H
Histone H2A type I-J
Histone H2A type 2-A
Histone H2A type 2-C
Histone H2A type 3
Histone H2A.J

Latexin

Latexin
L-Iactate dehydrogenase A
chain
L-Iactate dehydrogenase B
chain
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L-Iactate dehydrogenase A chain

L-Iactate dehydrogenase A chain

L-Iactate dehydrogenase B chain
Lysosome-associated membrane
glycoprotein 2

L-Iactate dehydrogenase B chain
Lysosome-associated membrane
glycoprotein 2

Myosin-9
Myosin-IO
Myosin-II
Myosin-14
Myosin light polypeptide 6
Myosin light chain 6B
Myosin regulatory light chain
12A
Myosin regulatory light chain
12B

Moesin
Myosin-9
Myosin-IO
Myosin-ll
Myosin-14
Myosin light polypeptide 6
Myosin light chain 6B
Myosin regulatory light chain
12A
Myosin regulatory light chain
12B

Importin-5
Importin subunit beta-I

Moesin
Myosin-9
Myosin-ll
Myosin-14
Myosin light polypeptide 6
Myosin light chain 6B
Myosin regulatory light chain
12A
Myosin regulatory light chain
12B

Importin subunit beta-l
Integrin beta-l
Latexin
L-Iactate dehydrogenase A chain
L-Iactate dehydrogenase B chain

Malate dehydrogenase, cytoplasmic
Moesin
Myosin-9
Myosin-IO
Myosin-ll
Myosin-14
Myosin light polypeptide 6
Myosin light chain 6B
Myosin regulatory light chain 12A
Myosin regulatory light chain 12B
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Myosin regulatory light
polypeptide 9
Myristoylated alanine-rich Ckinase substrate

Myosin regulatory light
polypeptide 9
Myristoylated alanine-rich Ckinase substrate

Myosin regulatory light
polypeptide 9
Myristoylated alanine-rich Ckinase substrate

Nicotinamide Nmethyl transferase
Neuroblast differentiationassociated protein AHNAK

Nicotinamide Nmethyltransferase
Neuroblast differentiationassociated protein AHNAK
Nucleophosmin

Nicotinamide Nmethyl transferase
Neuroblast differentiationassociated protein AHNAK
Nucleophosmin

POTE ankyrin domain family
memberE
POTE ankyrin domain family
memberF
Peptidyl-prolyl cis-trans
isomerase A
Peptidyl-prolyl cis-trans
isomerase B
Peroxiredoxin-l
Peroxiredoxin-6
Phosphoglycerate kinase 1

POTE ankyrin domain family
memberE
POTE ankyrin domain family
memberF
Peptidyl-prolyl cis-trans
isomerase A
Peptidyl-prolyl cis-trans
isomerase B
Peroxiredoxin-l
Peroxiredoxin-6
Peripherin
Phosphoglycerate kinase 1
Phosphoglycerate mutase 1

Putative nucleoside diphosphate
kinase
Nucleoside diphosphate kinase
B
POTE ankyrin domain family
memberE
POTE ankyrin domain family
memberF
Peptidyl-prolyl cis-trans
isomerase A
Peptidyl-prolyl cis-trans
isomerase B
Peroxiredoxin-l
Peroxiredoxin-6
Peripherin
Phosphoglycerate kinase 1
Phosphoglycerate mutase 1
Phosphoglycerate mutase 2
Probable phosphoglycerate
mutase 4

Myosin regulatory light polypeptide
9
Myristoylated alanine-rich C-kinase
substrate
Multifunctional protein ADE2
NAD(P)H dehydrogenase [quinone]
1
Nicotinamide N-methyltransferase
Neuroblast differentiation-associated
protein AHNAK
Nucleophosmin
Nuclease-sensitive element-binding
protein 1

POTE ankyrin domain family
memberE
POTE ankyrin domain family
memberF
Peptidyl-prolyl cis-trans isomerase A
Peptidyl-prolyl cis-trans isomerase B
Peroxiredoxin-l
Peripherin
Phosphoglycerate kinase 1
Phosphoglycerate mutase 1
Phosphoglycerate mutase 2
Probable phosphoglycerate mutase 4
Proteasome subunit beta type-3

Plastin-3
Proactivator polypeptide
Profilin-l
Prolactin-inducible protein
Proteasome activator complex
subunit 2
Protein disulfide-isomerase
Protein disulfide-isomerase A3

Pyruvate kinase isozymes MIIM2
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Plastin-3
Polyadenylate-binding protein I
Pro activator polypeptide
Profilin-l

Plastin-3
Pro activator polypeptide
Profilin-l

Proactivator polypeptide
Profilin-l

Protein disulfide-isomerase
Protein disulfide-isomerase A3

Protein disulfide-isomerase
Protein disulfide-isomerase A3
Protein disulfide-isomerase A4
Protein disulfide-isomerase A6
Pyruvate kinase isozymes
MIIM2
Poly(rC)-binding protein 1
Poly(rC)-binding protein 2
Poly(rC)-binding protein 3

Protein disulfide-isomerase
Protein disulfide-isomerase A3

Protein disulfide-isomerase A6
Pyruvate kinase isozymes
MIIM2
Poly(rC)-binding protein I
Poly(rC)-binding protein 2
Rab GOP dissociation inhibitor
alpha
Rab GOP dissociation inhibitor
beta

~

Ras-related protein Rab-l 0

Reticulon-4

Protein disulfide-isomerase A6
Pyruvate kinase isozymes MIIM2
Poly(rC)-binding protein I
Poly(rC)-binding protein 2

Rab GOP dissociation inhibitor alpha

Ras-related protein Rab-l 0
Ras-related protein Rab-IA
Ras-related protein Rab-lB
Ras-related protein Rab-15
Putative Ras-related protein
Rab-lC

Ras-related protein Rab-lO
Ras-related protein Rab-lB
Ras-related protein Rab-15

Rab GOP dissociation inhibitor beta
Radixin
Ras-related protein Rab-5C
Ras-related protein Rab-l 0
Ras-related protein Rab-IA
Ras-related protein Rab-lB
Ras-related protein Rab-15

Reticulon-4

Reticulon-4

Putative Ras-related protein Rab-IC
Ras-related C3 botulinum toxin
substrate
Ras-related C3 botulinum toxin
substrate 3
Reticulon-4

Rho GDP-dissociation inhibitor
I
Ribonuclease inhibitor
RNA-binding protein EWS
RNA-binding protein PUS
Sacsin
Serpin HI

T-complex protein I subunit beta
T -complex protein I subunit
gamma
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Thioredoxin
Thioredoxin domain-containing
protein 5
Transgelin
Transgelin-2

Triosephosphate isomerase
Tubulin alpha-IA chain
Tubulin alpha-IB chain
Tubulin alpha-l C chain

RNA-binding protein FUS
Serpin HI
Serine/threonine-protein
phosphatase 2A 65 kDa

Serpin HI

T-complex protein I subunit
beta
T-complex protein I subunit
gamma

T -complex protein I subunit
beta
T-complex protein I subunit
gamma

T-complex protein 1 subunit
theta
T -complex protein I subunit eta

T -complex protein I subunit
theta

Thioredoxin
Thioredoxin domain-containing
protein 5
Transgelin
Transgelin-2
Transitional endoplasmic
reticulum ATPase

Thioredoxin

Transketo lase
Triosephosphate isomerase
Tropomyosin alpha-4 chain
Tubulin alpha-I A chain
Tubulin alpha-IB chain
Tubulin alpha-IC chain

Transgelin
Transgelin-2

Transketolase
Triosephosphate isomerase
Tropomyosin alpha-4 chain
Tubulin alpha-IA chain
Tubulin alpha-lB chain
Tubulin alpha-IC chain

Serpin HI
Serine/threonine-protein phosphatase
2A65 kDa
Sorcin
T-complex protein I subunit beta
T -complex protein I subunit gamma
T-complex protein 1 subunit delta
T-complex protein I subunit theta
T -complex protein 1 subunit eta
T -complex protein I subunit epsilon

Transgelin
Transgelin-2

Translationally-controlled tumor
protein
Transketolase
Triosephosphate isomerase
Tubulin alpha-IA chain
Tubulin alpha-lB chain
Tubulin alpha-IC chain

Tubulin alpha chain-like 3
Tubulin alpha-3CID chain
Tubulin alpha-3E chain
Tubulin alpha-4A chain
Tubulin alpha-8 chain
Tubulin beta chain
Tubulin beta-2C chain
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Tubulin beta-8 chain
Tubulin beta-8 chain B
Putative tubulin beta-4q chain
Tubulin beta-2A chain
Tubulin beta-2B chain
Tubulin beta-3 chain
Tubulin beta-6 chain
Putative tubulin-like protein
alpha-4B
Tubulin alpha chain-like 3
Ubiquitin
Ubiquitin carboxyl-terminal
hydrolase isozyme L1

Ubiquitin-conjugating enzyme E2
N
Vimentin
Zinc-alpha-2-glycoprotein

Tubulin alpha chain-like 3
Tubulin alpha-3CID chain
Tubulin alpha-3E chain
Tubulin alpha-4A chain
Tubulin alpha-8 chain
Tubulin beta chain
Tubulin beta-l chain
Tubulin beta-2C chain
Tubulin beta-4 chain
Tubulin beta-8 chain
Tubulin beta-8 chain B
Putative tubulin beta-4q chain
Tubulin beta-2A chain
Tubulin beta-2B chain
Tubulin beta-3 chain
Tubulin beta-6 chain
Putative tubulin-like protein
alpha-4B

Tubulin alpha chain-like 3
Tubulin alpha-3CID chain
Tubulin alpha-3E chain
Tubulin alpha-4A chain
Tubulin alpha-8 chain
Tubulin beta chain
Tubulin beta-l chain
Tubulin beta-2C chain
Tubulin beta-4 chain
Tubulin beta-8 chain
Tubulin beta-8 chain B
Putative tubulin beta-4q chain
Tubulin beta-2A chain
Tubulin beta-2B chain
Tubulin beta-3 chain
Tubulin beta-6 chain
Putative tubulin-like protein
alpha-4B

Tubulin alpha chain-like 3
Tubulin alpha-3CID chain
Tubulin alpha-3E chain
Tubulin alpha-4A chain
Tubulin alpha-8 chain
Tubulin beta chain

Ubiquitin
Ubiquitin carboxyl-terminal
hydrolase isozyme L1

Ubiquitin carboxyl-terminal
hydrolase isozyme L1

Ubiquitin carboxyl-terminal
hydrolase isozyme L1
Ubiquitin-conjugating enzyme E2
variant 1
Ubiquitin-conjugating enzyme E2
variant 2

Vimentin

Vimentin

Vimentin

Tubulin beta-2C chain
Tubulin beta-4 chain
Tubulin beta-8 chain
Tubulin beta-8 chain B
Putative tubulin beta-4q chain
Tubulin beta-2A chain
Tubulin beta-2B chain
Tubulin beta-3 chain
Tubulin beta-6 chain
Putative tubulin-like protein alpha4B

Table 2: PKG-l pull-down
Control
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PE

10 kDa heat shock protein,
mitochondrial
60 kDa heat shock protein,
mitochondrial

10 kDa heat shock protein,
mitochondrial
60 kDa heat shock protein,
mitochondrial

Stress-70 protein, mitochondrial
ATP synthase subunit alpha,
mitochondrial
ATP synthase subunit beta,
mitochondrial
Malate dehydrogenase,
mitochondrial

ATP synthase subunit alpha,
mitochondrial
ATP synthase subunit beta,
mitochondrial
Malate dehydrogenase,
mitochondrial

14-3-3 protein beta/alpha
14-3-3 protein zeta/delta
14-3-3 protein gamma
14-3-3 protein theta
14-3-3 protein eta
14-3-3 protein epsilon
14-3-3 protein sigma
40S ribosomal protein SA
40S ribosomal protein S2
40S ribosomal protein S3
40S ribosomal protein S4, X
isoform
40S ribosomal protein S6
40S ribosomal protein S8
40S ribosomal protein S9
40S ribosomal protein S 12
40S ribosomal protein S 15a
40S ribosomal protein S 18

Thioredoxin-dependent peroxide
reductase, mitochon
14-3-3 protein beta/alpha
14-3-3 protein zeta/delta
14-3-3 protein gamma
14-3-3 protein theta
14-3-3 protein eta
14-3-3 protein epsilon
14-3-3 protein sigma
40S ribosomal protein SA
40S ribosomal protein S2
40S ribosomal protein S3
40S ribosomal protein S4, X
isoform
40S ribosomal protein S8
40S ribosomal protein S9
40S ribosomal protein S12

Cu

10 kDa heat shock protein, mitochondrial
60 kDa heat shock protein,
mitochondrial
Stress-70 protein,
mitochondrial
ATP synthase subunit alpha,
mitochondrial

60 kDa heat shock protein, mitochondrial
Stress-70 protein, mitochondrial
ATP synthase subunit alpha, mitochondrial
ATP synthase subunit beta, mitochondrial

Malate dehydrogenase,
mitochondrial
Thioredoxin-dependent
peroxide reductase,
mitochon
14-3-3 protein beta/alpha
14-3-3 protein zeta/delta
14-3-3 protein gamma
14-3-3 protein theta
14-3-3 protein eta
14-3-3 protein epsilon
14-3-3 protein sigma
40S ribosomal protein SA
40S ribosomal protein S3
40S ribosomal protein S4, X
isoform

Malate dehydrogenase, mitochondrial

14-3-3 protein beta/alpha
14-3-3 protein zeta/delta
14-3-3 protein gamma
14-3-3 protein theta
14-3-3 protein eta
14-3-3 protein epsilon
14-3-3 protein sigma
40S ribosomal protein SA
40S ribosomal protein S2
40S ribosomal protein S3
40S ribosomal protein S4, X isoform

40S ribosomal protein S8
40S ribosomal protein S9
40S ribosomal protein S12

40S ribosomal protein S9
40S ribosomal protein S 12

40S ribosomal protein S 19
40S ribosomal protein S20

40S ribosomal protein S 18
40S ribosomal protein S 19
40S ribosomal protein S20

40S ribosomal protein S 18
40S ribosomal protein S20

PE+Cu

40S ribosomal protein S25
60S ribosomal protein L6
60S ribosomal protein L 7
60S ribosomal protein LI2
60S ribosomal protein LI3

40S ribosomal protein S25
60S ribosomal protein L6
60S ribosomal protein L 7
60S ribosomal protein LI2
60S ribosomal protein LI3
60S ribosomal protein LI4

60S
60S
60S
60S
60S

ribosomal protein L7
ribosomal protein LI Oa
ribosomal protein LI2
ribosomal protein LI3
ribosomal protein LI4

60S ribosomal protein L 15
60S
60S
60S
60S

ribosomal protein L22
ribosomal protein L30
ribosomal protein L36
acidic ribosomal protein PO

60S acidic ribosomal protein P2
78 kDa glucose-regulated protein
A-kinase anchor protein 12
1.0
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ADPIATP translocase 2
ADP/ATP translocase 3

ADP-ribosylation factor I
ADP-ribosylation factor 3

60S ribosomal protein LI8
60S ribosomal protein L22
60S ribosomal protein L30

60S ribosomal protein L22
60S ribosomal protein L30

60S ribosomal protein L 7
60S ribosomal protein L 12

60S ribosomal protein LI5
60S ribosomal protein LI8
60S ribosomal protein L22

60S acidic ribosomal protein PO
60S acidic ribosomal protein P2
78 kDa glucose-regulated
protein
ADP/ATP translocase 1
ADPIATP translocase 2
ADP/ATP translocase 3

ADP-ribosylation factor I
ADP-ribosylation factor 3
ADP-ribosylation factor 4
ADP-ribosylation factor 5

60S acidic ribosomal protein
P2
78 kDa glucose-regulated
protein

ADP/ATP translocase 3
ADP-ribosylation factor 1
ADP-ribosylation factor 3
ADP-ribosylation factor 4

60S acidic ribosomal protein P2
78 kDa glucose-regulated protein
A-kinase anchor protein 12

ADP-ribosylation factor 1
ADP-ribosylation factor 3
ADP-ribosylation factor 4
ADP-ribosylation factor 5

ATP-citrate synthase

ATP-dependent RNA helicase
DDX39
ATP-dependent RNA helicase
DDX3X
ATP-dependent RNA helicase
DDX3Y
Actin, alpha cardiac muscle 1

Probable ATP-dependent RNA
helicase DDX 17
Probable ATP-dependent RNA
helicase DDX5
ATP-dependent RNA helicase
DDX39
ATP-dependent RNA helicase
DDX3X

Actin, alpha cardiac muscle 1

Probable ATP-dependent
RNA helicase DDX17
Probable ATP-dependent
RNA helicase DDX5

Probable ATP-dependent RNA helicase
DDX5

ATP-dependent RNA
helicase DDX3X
ATP-dependent RNA
helicase DDX3Y
Actin, alpha cardiac muscle

Actin, alpha cardiac muscle 1
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Actin, aortic smooth muscle
Actin, alpha skeletal muscle
Actin, gamma-enteric smooth
muscle
Actin, cytoplasmic I
Actin, cytoplasmic 2
Adenylyl cyclase-associated
protein I
Adenosylhomocysteinase
Alpha-actinin-I
Alpha-actinin-2
Alpha-actinin-3
Alpha-actinin-4
AnnexinAI
AnnexinA2
Annexin AS
AnnexinA6

Actin, aortic smooth muscle
Actin, alpha skeletal muscle
Actin, gamma-enteric smooth
muscle
Actin, cytoplasmic I
Actin, cytoplasmic 2
Adenylyl cyclase-associated
protein 1
Adenosylhomocysteinase
Alpha-actinin-l

Actin, aortic smooth muscle
Actin, alpha skeletal muscle
Actin, gamma-enteric
smooth muscle
Actin, cytoplasmic I
Actin, cytoplasmic 2
Adenylyl cyclase-associated
protein I

Alpha-actinin-4
Annexin Al
Annexin A2
AnnexinA5
AnnexinA6

Alpha-actinin-4
Annexin Al
AnnexinA2
AnnexinAS
AnnexinA6

Calmodulin
Calnexin
Calponin-2
Calreticulin

Calmodulin

Calmodulin

Alpha-actinin-4
AnnexinAI
AnnexinA2
AnnexinA5
AnnexinA6
AnnexinA7
Calmodulin

Calreticulin

Calponin-2
Calreticulin

Chloride intracellular channel
protein I
Chloride intracellular channel
protein 4
Clathrin heavy chain 1
Clathrin heavy chain 2
Coatomer subunit gamma
Cofilin-l
Cofilin-2
Complement component 1 Q
subcomponent-binding prot
Cytoskeleton-associated protein 4

Calponin-2
Calreticulin
CathepsinD
Chloride intracellular channel
protein I
Chloride intracellular channel
protein 4
Clathrin heavy chain 1
Clathrin heavy chain 2
Cofilin-l
Cofilin-2
Complement component 1 Q
subcomponent-binding prot
Cytoskeleton-associated protein

Alpha-actinin-l
Alpha-actinin-2

Actin, aortic smooth muscle
Actin, alpha skeletal muscle
Actin, gamma-enteric smooth muscle
Actin, cytoplasmic I
Actin, cytoplasmic 2
Adenylyl cyclase-associated protein I
Adenosylhomocysteinase
Alpha-actinin-l

Chloride intracellular channel protein I
Chloride intracellular
channel protein 4
Clathrin heavy chain I
Clathrin heavy chain 2
Cofilin-l
Complement component 1
Q subcomponent-binding
prot
Cytoskeleton-associated

Clathrin heavy chain 1
Clathrin heavy chain 2
Cofilin-l
Cofilin-2

Cytoskeleton-associated protein 4

4

Cystatin-B

Cystatin-B

Desmin
Dolichyldiphosphooligosaccharide--protein
glycosyl
Elongation factor I-alpha I
Elongation factor I-alpha 2

Desmin

Elongation factor I-gamma
Elongation factor I-delta
Elongation factor 2
Endoplasmin
Alpha-enolase
Beta-enolase

\0
\0

Eukaryotic initiation factor 4A-I
Eukaryotic initiation factor 4A-II
Eukaryotic translation initiation
factor 5A-I
Eukaryotic translation initiation
factor 5A-2
Ezrin
F-actin-capping protein subunit
alpha-l
Fascin
Filamin-A
Filamin-B
Filamin-C
Fructose-bisphosphate aldolase A
Galectin-l
Glucose-6-phosphate 1dehydrogenase

Elongation factor
Elongation factor
Elongation factor
Elongation factor

protein 4
Cystatin-B
Cytochrome c
Desmin

I-alpha I
I-alpha 2
I-beta
I-gamma

Elongation factor 2
Endoplasmin
Alpha-enolase
Beta-enolase
Gamma-enolase
Eukaryotic initiation factor 4A-I
Eukaryotic initiation factor 4AII
Eukaryotic translation initiation
factor 5A-I
Eukaryotic translation initiation
factor 5A-2
Ezrin

Fascin
Filamin-A
Filamin-B
Filamin-C
Fructose-bisphosphate aldolase
A

Galectin-I
Glucose-6-phosphate 1dehydrogenase

Elongation factor
Elongation factor
Elongation factor
Elongation factor

Cystatin-B
Desmin

I-alpha I
I-alpha 2
I-beta
I-gamma

Elongation factor 2
Endoplasmin
Alpha-enolase
Beta-enolase
Gamma-enolase
Eukaryotic initiation factor
4A-I
Eukaryotic initiation factor
4A-II
Eukaryotic translation
initiation factor 5A-I
Eukaryotic translation
initiation factor 5A-2
Ezrin

Filamin-A

Fructose-bisphosphate
aldolase A

Elongation factor
Elongation factor
Elongation factor
Elongation factor
Elongation factor
Elongation factor
Endoplasmin
Alpha-enolase
Beta-enolase

I-alpha 1
I-alpha 2
I-beta
I-gamma
I-delta
2

Eukaryotic initiation factor 4A-I
Eukaryotic initiation factor 4A-II
Eukaryotic translation initiation factor 5A-I

Ezrin

Filamin-A
Filamin-B
Filamin-C
Fructose-bisphosphate aldolase A
Galectin-I

Glucose-6-phosphate isomerase
Glucosidase 2 subunit beta
Glutathione S-transferase P
Glutathione S-transferase omega-l
Glyceraldehyde-3-phosphate
dehydrogenase
Guanine nucleotide-binding protein
subunit beta-2-1

Heat shock cognate 71 kDa protein
Heat shock 70 kDa protein lA1lB

0
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Heat shock 70 kDa protein 4
Heat shock 70 kDa protein 6

Glucose-6-phosphate isomerase
Glucosidase 2 subunit beta
Glutathione S-transferase P
Glutathione S-transferase
omega-l
Glyceraldehyde-3-phosphate
dehydrogenase
Guanine nucleotide-binding
protein subunit beta-2-l
GTP-binding nuclear protein
Ran
Heat shock cognate 71 kDa
protein
Heat shock 70 kDa protein
lA11B

Glucose-6-phosphate
isomerase
Glucosidase 2 subunit beta
Glutathione S-transferase P
Glutathione S-transferase
omega-l
GI yceraldehyde-3-phosphate
dehydro genase
Guanine nucleotide-binding
protein subunit beta-2-1
GTP-binding nuclear protein
Ran
Heat shock cognate 71 kDa
protein
Heat shock 70 kDa protein
IAlIB
Heat shock-related 70 kDa
protein 2

Heat shock 70 kDa protein 6

Heat shock 70 kDa protein 6

Heat shock protein HSP 90alpha

Heat shock protein HSP 90alpha
Heat shock protein HSP 90beta
Heat shock protein beta-I

Glucose-6-phosphate isomerase
Glucosidase 2 subunit beta
Glutathione S-transferase P
Glutathione S-transferase omega-l
Glyceraldehyde-3-phosphate dehydrogenase
Guanine nucleotide-binding protein subunit
beta-2-l
GTP-binding nuclear protein Ran
Heat shock cognate 71 kDa protein
Heat shock 70 kDa protein IAlIB
Heat shock-related 70 kDa protein 2
Heat shock 70 kDa protein 6
Putative heat shock 70 kDa protein 7

Hsp90 co-chaperone Cdc37
Heat shock protein HSP 90-alpha
Heat shock protein HSP 90-beta
Heat shock-related 70 kDa protein
2
Heterogeneous nuclear
ribonucleoprotein Ai
Heterogeneous nuclear
ribonucleoprotein AlB
Heterogeneous nuclear
ribonucleoproteins A21B I
Heterogeneous nuclear
ribonucleoprotein A3

Heat shock protein HSP 90-beta
Heat shock protein beta-I
Heat shock-related 70 kDa
protein 2
Heterogeneous nuclear
ribonucleoprotein Al
Heterogeneous nuclear
ribonucleoprotein AlB
Heterogeneous nuclear
ribonucleoproteins A21B 1

Heterogeneous nuclear
ribonucleoprotein Al
Heterogeneous nuclear
ribonucleoprotein AlB
Heterogeneous nuclear
ribonucleoproteins A21B I
Heterogeneous nuclear
ribonucleoprotein A3

Heat shock protein HSP 90-alpha
Heat shock protein HSP 90-beta
Heat shock protein beta-l

Heterogeneous nuclear ribonucleoprotein
Al

Heterogeneous nuclear ribonucleoproteins
A2IBI
Heterogeneous nuclear ribonucleoprotein
A3

----0

Heterogeneous nuclear
ribonucleoproteins ClfC2
Heterogeneous nuclear
ribonucleoprotein DO
Heterogeneous nuclear
ribonucleoprotein F
Heterogeneous nuclear
ribonucleoprotein G
Heterogeneous nuclear
ribonucleoprotein H
Heterogeneous nuclear
ribonucleoprotein H2
Heterogeneous nuclear
ribonucleoprotein K
Heterogeneous nuclear
ribonucleoprotein Q
Heterogeneous nuclear
ribonucleoprotein R
Heterogeneous nuclear
ribonucleoprotein U
Histone H2A type I-BIE
Histone H2A type l-C
Histone H2A type 1-D
Histone H2A type I-H
Histone H2A type I-J
Histone H4

Heterogeneous nuclear
ribonucleoproteins Cl/C2
Heterogeneous nuclear
ribonucleoprotein DO
Heterogeneous nuclear
ribonucleoprotein F
Heterogeneous nuclear
ribonucleoprotein G
Heterogeneous nuclear
ribonucleoprotein H
Heterogeneous nuclear
ribonucleoprotein H2
Heterogeneous nuclear
ribonucleoprotein K
Heterogeneous nuclear
ribonucleoprotein Q
Heterogeneous nuclear
ribonucleoprotein R

HistoneH4

Histone H2A type
Histone H2A type
Histone H2A type
Histone H2A type
Histone H2A type
HistoneH4

Importin subunit beta-l
Integrin beta-l
Interleukin enhancer-binding factor
2

Importin subunit beta-l
Integrin beta-l

Importin subunit beta-l
Integrin beta-l

L-lactate dehydrogenase A chain

L-lactate dehydrogenase A
chain

L-lactate dehydrogenase B chain
Lamin-AiC
Latexin

L-lactate dehydrogenase B chain
Lamin-AiC
Latexin

L-lactate dehydrogenase A
chain
L-lactate dehydrogenase B
chain
Lamin-AiC
Latexin

Heterogeneous nuclear
ribonucleoproteins C l/C2
Heterogeneous nuclear
ribonucleoprotein DO
Heterogeneous nuclear
ribonucleoprotein F

Heterogeneous nuclear
ribonucleoprotein H
Heterogeneous nuclear
ribonucleoprotein H2
Heterogeneous nuclear
ribonucleoprotein K
Heterogeneous nuclear
ribonucleoprotein Q
Heterogeneous nuclear
ribonucleoprotein R

1-BIE
l-C
I-D
I-H
I-J

Heterogeneous nuclear ribonucleoproteins
Cl/C2
Heterogeneous nuclear ribonucleoprotein
DO
Heterogeneous nuclear ribonucleoprotein F

Heterogeneous nuclear ribonucleoprotein H
Heterogeneous nuclear ribonucleoprotein
H2
Heterogeneous nuclear ribonucleoprotein K
Heterogeneous nuclear ribonucleoprotein Q
Heterogeneous nuclear ribonucleoprotein R

Histone H2A type I-BIE
Histone H2A type l-C
Histone H2A type 1-D
Histone H2A type 1-H
Histone H2A type I-J
HistoneH4
Hypoxia up-regulated protein 1
Importin subunit beta-l

L-lactate dehydrogenase A chain
L-Iactate dehydrogenase B chain
Lamin-AiC
Latexin

Leucine-rich repeatcontaining protein 59
Lysosome-associated membrane
glycoprotein
Microtubule-associated protein

4
Moesin
Myosin light polypeptide 6

Myosin regulatory light chain 12A

o
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Myosin regulatory light chain 12B
Myosin regulatory light
polypeptide 9
Myristoylated alanine-rich Ckinase substrate
Nascent polypeptide-associated
complex subunit alph
Nestin
Neuroblast differentiationassociated protein AHNAK
Nuclease-sensitive element-binding
protein I
Nucleolin
Nucleophosmin
Nucleoside diphosphate kinase A
Nucleoside diphosphate kinase B

POTE ankyrin domain family
memberE
Peripherin
Peroxiredoxin-l

Moesin
Myosin-9
Myosin light polypeptide 6
Myosin light chain 6B
Myosin regulatory light chain
12A
Myosin regulatory light chain
12B
Myosin regulatory light
polypeptide 9

Nascent polypeptide-associated
complex subunit alph
Nestin
Neuroblast differentiationassociated protein AHNAK
Nuclease-sensitive elementbinding protein I
Nucleolin
Nucleophosmin
Nucleoside diphosphate kinase
A
Nucleoside diphosphate kinase
B
Nucleosome assembly protein
I-like I
POTE ankyrin domain family
memberE
Peripherin
Peroxiredoxin-l

Moesin
Myosin light polypeptide 6
Myosin light chain 6B
Myosin regulatory light
chain 12A
Myosin regulatory light
chain 12B
Myosin regulatory light
polypeptide 9

Nestin
Neuroblast differentiationassociated protein AHNAK

Nucleolin
Nucleophosmin
Nucleoside diphosphate
kinase A
Nucleoside diphosphate
kinase B

POTE ankyrin domain
family member E
Peripherin
Peroxiredoxin-l

Microtubule-associated protein 4
Moesin
Myosin light polypeptide 6
Myosin light chain 6B
Myosin regulatory light chain 12A
Myosin regulatory light chain 12B
Myosin regulatory light polypeptide 9

Nascent polypeptide-associated complex
subunit alph
Nestin
Neuroblast differentiation-associated
protein AHNAK
Nuclease-sensitive element-binding protein
1
Nucleolin
Nucleophosmin
Nucleoside diphosphate kinase A
Nucleoside diphosphate kinase B

POTE ankyrin domain family member E
Peroxiredoxin-l

Peroxiredoxin-2
Peroxiredoxin-6
Peptidyl-prolyl cis-trans isomerase
A
Peptidyl-prolyl cis-trans isomerase
B
Phosphoglycerate kinase I
Phosphoglycerate mutase 1

0
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Plastin-3

Peroxiredoxin-2
Peroxiredoxin-6
Peptidyl-prolyl cis-trans
isomerase A
Peptidyl-prolyl cis-trans
isomerase B
Phosphoglycerate kinase 1
Phosphoglycerate mutase 1
Plasminogen activator inhibitor
1 RNA-binding prot
Plastin-3

Poly(rC)-binding protein 1
Poly(rC)-binding protein 2
Poly(rC)-binding protein 3

Poly(rC)-binding protein I
Poly(rC)-binding protein 2
Poly(rC)-binding protein 3

Polyadenylate-binding protein I

Polyadenylate-binding protein 1

Polyadenylate-binding protein 3
Polyadenylate-binding protein 4
Polypyrimidine tract-binding
protein I
Proactivator polypeptide
Profilin-l
Proliferation-associated protein
2G4
Prolyl 3-hydroxylase I

Peroxiredoxin-2
Peroxiredoxin-6
Peptidyl-prolyl cis-trans
isomerase A
Peptidyl-prolyl cis-trans
isomerase B
Phosphoglycerate kinase I
Phosphoglycerate mutase 1

Peroxiredoxin-2
Peroxiredoxin-6
Peptidyl-prolyl cis-trans isomerase A
Peptidyl-prolyl cis-trans isomerase B
Phosphoglycerate mutase 1

Polyadenylate-binding protein 3

Plastin-3
Plectin-l
Poly(rC)-binding protein I
Poly(rC)-binding protein 2
Poly(rC)-binding protein 3
Polyadenylate-binding
protein 1
Polyadenylate-binding
protein 3

Polyadenylate-binding protein 3

Polypyrimidine tract-binding
protein 1
Proactivator polypeptide
Profilin-l

Proactivator polypeptide
Profilin-l

Proactivator polypeptide
Profilin-l

Poly(rC)-binding protein I

Polyadenylate-binding protein I

Prostaglandin E synthase 3
Protein SET
Protein S lOO-AII
Protein disulfide-isomerase

Protein SlOO-All
Protein disulfide-isomerase

Protein disulfide-isomerase A3
Protein disulfide-isomerase A4

Protein disulfide-isomerase A3
Protein disulfide-isomerase A4

Protein disulfide-isomerase A6
Pyruvate kinase isozymes MIIM2

Protein disulfide-isomerase A6
Pyruvate kinase isozymes

Protein disulfide-isomerase
Protein disulfide-isomerase
A3
Protein disulfide-isomerase
A6
Pyruvate kinase isozymes

Protein SIOO-AII
Protein disulfide-isomerase
Protein disulfide-isomerase A3
Protein disulfide-isomerase A4
Protein disulfide-isomerase A6
Pyruvate kinase isozymes MIIM2

MIIM2

Rab GDP dissociation inhibitor
alpha
Rab GDP dissociation inhibitor
beta
Ras GTPase-activating-like protein
IQGAPI
Ras-related protein Rab-IA
Ras-related protein Rab-lB
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Ras-related protein Rab-lO
Ras-related protein Rab-15
Rho GDP-dissociation inhibitor
RNA-binding protein EWS
RNA-binding protein FUS
Radixin

Reticulon-4

Rab GDP dissociation inhibitor
alpha
Rab GDP dissociation inhibitor
beta

Ras-related protein Rab-IA
Ras-related protein Rab-lB
Putative Ras-related protein
Rab-IC
Ras-related protein Rab-l 0
Ras-related protein Rab-15

MIIM2
Rho GDP-dissociation
inhibitor I

Rab GDP dissociation
inhibitor beta
Ras GTPase-activating-like
protein IQGAPI
Ras-related protein Rab-IA
Ras-related protein Rab-lB

Ras-related protein Rab-l 0
Ras-related protein Rab-I5

RNA-binding protein EWS
RNA-binding protein FUS
Radixin

RNA-binding protein EWS
RNA-binding protein FUS
Radixin

Reticulon-4

Reticulon-4

Rab GDP dissociation inhibitor beta

Ras-related protein Rab-IA
Ras-related protein Rab-l B
Putative Ras-related protein Rab-l C
Ras-related protein Rab-l 0
Ras-related protein Rab-15
RNA-binding protein EWS
Radixin
Reticuiocalbin-l
Reticulocalbin-3
Ribosome-binding protein 1
SH3 domain-binding glutamic acid-richlike protein

Serine/threonine-protein
phosphatase PP I-alpha
Serine/threonine-protein
phosphatase PPI-beta
Serine/threonine-protein
phosphatase PP I-gamma
Serpin HI
Small nuclear ribonucleoprotein
SmD3
Spectrin alpha chain, brain
Spliceosome RNA helicase BATl

Serine/threonine-protein
phosphatase PP I-alpha
Serine/threonine-protein
phosphatase PP I-beta
Serine/threonine-protein
phosphatase PP I-gamma
Serpin HI

Spectrin alpha chain, brain
Spliceosome RNA helicase
BATl

Serpin HI

Serpin HI

Spectrin alpha chain, brain

Splicing factor 3B subunit 2
Splicing factor U2AF 65 kDa
subunit
TATA-binding protein-associated
factor 2N

T -complex protein 1 subunit beta
T-complex protein 1 subunit
gamma
T-complex protein 1 subunit delta
T -complex protein I subunit
epsilon

.....
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T -complex protein 1 subunit theta
T-complex protein 1 subunit zeta
T -complex protein 1 subunit eta
Talin-l
Thioredoxin domain-containing
protein 5

Transgelin
Transgelin-2
Transitional endoplasmic reticulum
ATPase
Transketolase

Triosephosphate isomerase
Tropomyosin alpha-3 chain
Tropomyosin alpha-4 chain

Splicing factor 3B subunit 2
Splicing factor U2AF 65 kDa
subunit
TATA-binding proteinassociated factor 2N

T -complex protein
gamma
T -complex protein
delta
T -complex protein
epsilon
T -complex protein
theta

I subunit
I subunit
1 subunit
1 subunit

Talin-I
Thioredoxin
Thioredoxin domain-containing
protein 5
Transaldolase
Transcription intermediary
factor I-beta
Transgelin
Transgelin-2
Transitional endoplasmic
reticulum ATPase
Transketolase
Translationally-controlled tumor
protein
Triosephosphate isomerase
Tropomyosin alpha-I chain
Tropomyosin alpha-3 chain
Tropomyosin alpha-4 chain

TATA-binding proteinassociated factor 2N
T -complex protein I subunit
alpha
T -complex protein I subunit
beta
T -complex protein I subunit
gamma
T -complex protein I subunit
delta
T -complex protein 1 subunit
epsilon
T-complex protein 1 subunit
theta

Splicing factor 3B subunit 2

T -complex protein 1 subunit alpha
T -complex protein I subunit beta
T -complex protein I subunit gamma
T -complex protein I subunit delta
T-complex protein 1 subunit epsilon
T-complex protein 1 subunit theta

Talin-l

T -complex protein I subunit eta
Talin-I

Thioredoxin domaincontaining protein 5

Thioredoxin domain-containing protein 5

Transgelin
Transgelin-2
Transitional endoplasmic
reticulum ATPase
Transketolase
Translationally-controlled
tumor protein
Triosephosphate isomerase
Tropomyosin alpha-3 chain
Tropomyosin alpha-4 chain

Transgelin
Transgelin-2
Transitional endoplasmic reticulum ATPase
Transketolase

Triosephosphate isomerase

Tropomyosin alpha-4 chain

Tropomyosin beta chain
Tubulin alpha-lA chain
Tubulin alpha-lB chain
Tubulin alpha-l C chain
Tubulin alpha-3CID chain
Tubulin alpha-3E chain
Tubulin alpha-4A chain
Tubulin beta chain
Tubulin beta-l chain
Tubulin beta-2A chain
Tubulin beta-2B chain
Tubulin beta-2C chain
Tubulin beta-3 chain
Tubulin beta-4 chain
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UPF0568 protein C14orfl66
Ubiquitin
Ubiquitin carboxyl-terminal
hydrolase isozyme Ll
Ubiquitin-conjugating enzyme E2
variant 1
Ubiquitin-conjugating enzyme E2
variant 2

Vimentin
Vinculin
Voltage-dependent anion-selective
channel protein

Tropomyosin beta chain
Tubulin alpha-lA chain
Tubulin alpha-lB chain
Tubulin alpha-l C chain
Tubulin alpha-3CID chain
Tubulin alpha-3E chain
Tubulin alpha-4A chain
Tubulin alpha-8 chain
Tubulin beta chain
Tubulin beta-l chain
Tubulin beta-2A chain
Tubulin beta-2B chain
Tubulin beta-2C chain
Tubulin beta-3 chain
Tubulin beta-4 chain
Tubulin beta-6 chain
UPF0568 protein C14orfl66
Ubiquitin
Ubiquitin carboxyl-terminal
hydrolase isozyme Ll
Ubiquitin-conj ugating enzyme
E2 variant 1
Ubiquitin-conjugating enzyme
E2 variant 2
uv excision repair protein
RAD23 homolog B
Vimentin
Vinculin

Tropomyosin beta chain
Tubulin alpha-lA chain
Tubulin alpha-lB chain
Tubulin alpha-l C chain
Tubulin alpha-3CID chain
Tubulin alpha-3E chain
Tubulin alpha-4A chain
Tubulin beta chain
Tubulin beta-l chain
Tubulin beta-2A chain
Tubulin beta-2B chain
Tubulin beta-2C chain
Tubulin beta-3 chain
Tubulin beta-4 chain
Tubulin beta-6 chain
UPF0556 protein C190rflO
UPF0568 protein C14orfl66
Ubiquitin

Ubiquitin-conjugating
enzyme E2 variant 1
Ubiquitin-conjugating
enzyme E2 variant 2
UV excision repair protein
RAD23 homolog B
Vimentin

Tropomyosin beta chain
Tubulin alpha-lA chain
Tubulin alpha-lB chain
Tubulin alpha-IC chain
Tubulin alpha-3CID chain
Tubulin alpha-3E chain
Tubulin alpha-4A chain
Tubulin alpha-8 chain
Tubulin beta chain
Tubulin beta-2A chain
Tubulin beta-2B chain
Tubulin beta-2C chain
Tubulin beta-3 chain
Tubulin beta-4 chain
Tubulin beta-6 chain
UPF0568 protein C14orfl66
Ubiquitin

Ubiquitin-conjugating enzyme E2 variant 1

Vimentin

Table 3: PK!!.J!ull-down
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Control
60 kDa heat shock protein,
mitochondrial
14-3-3 protein beta/alpha
14-3-3 protein gamma
14-3-3 protein zeta/delta
14-3-3 protein epsilon
14-3-3 protein eta
14-3-3 protein sigma
14-3-3 protein theta
40S ribosomal protein SA
40S ribosomal protein S3
40S ribosomal protein S5
40S ribosomal protein S9
40S ribosomal protein S 18
60S ribosomal protein LII
60S ribosomal protein LI4

PE
60 kDa heat shock protein,
mitochondrial
14-3-3 protein beta/alpha
14-3-3 protein gamma
14-3-3 protein zeta/delta
14-3-3 protein epsilon
14-3-3 protein eta

Cu
60 kDa heat shock protein,
mitochondrial
14-3-3 protein beta/alpha
14-3-3 protein gamma
14-3-3 protein zeta/delta
14-3-3 protein epsilon

14-3-3 protein theta
40S ribosomal protein S3
40S ribosomal protein S5
40S ribosomal protein S9
40S ribosomal protein S 18

PE+Cu

14-3-3 protein beta/alpha
14-3-3 protein gamma
14-3-3 protein zeta/delta
14-3-3 protein epsilon
14-3-3 protein eta
14-3-3 protein sigma
14-3-3 protein theta

40S ribosomal protein S3
40S ribosomal protein S5
40S ribosomal protein S 18
60S ribosomal protein LII
60S ribosomal protein L22

60S acidic ribosomal protein PO
60S acidic ribosomal protein P2
78 kDa glucose-regulated protein
Acyl-CoA-binding protein
Actin, alpha cardiac muscle 1
Actin, alpha skeletal muscle
Actin, aortic smooth muscle
Actin, cytoplasmic 1
Actin, cytoplasmic 2
Actin, gamma-enteric smooth
muscle
Alpha-actinin-l
Alpha-actininA
AnnexinAI
AnnexinA2
Annexin A5

78 kDa glucose-regulated protein
Acyl-CoA-binding protein
Actin, alpha cardiac muscle 1
Actin, alpha skeletal muscle
Actin, aortic smooth muscle
Actin, cytoplasmic 1
Actin, cytoplasmic 2
Actin, gamma-enteric smooth
muscle

78 kDa glucose-regulated protein

78 kDa glucose-regulated protein

Actin, alpha cardiac muscle 1
Actin, alpha skeletal muscle
Actin, aortic smooth muscle
Actin, cytoplasmic 1
Actin, cytoplasmic 2
Actin, gamma-enteric smooth
muscle

Actin, alpha cardiac muscle 1
Actin, alpha skeletal muscle
Actin, aortic smooth muscle
Actin, cytoplasmic 1
Actin, cytoplasmic 2
Actin, gamma-enteric smooth
muscle

AnnexinAI
AnnexinA2
Annexin A5

Annexin Al
AnnexinA2
AnnexinA5

Annexin Al
Annexin A2
Annexin A5

Calmodulin
Calumenin

Calmodulin

Calmodulin

CathepsinB

Cathepsin B

CathepsinB

Cofilin-I
Complement component 1 Q
subcomponent-binding prot
Cystatin-B

Cofilin-l

Elongation factor I-alpha 1
Elongation factor I-alpha 2
Elongation factor 2
Endoplasmin
Alpha-enolase
Beta-enolase

Elongation factor I-alpha 1
Elongation factor I-alpha 2
Elongation factor 2

Elongation factor I-alpha 1
Elongation factor I-alpha 2
Elongation factor 2
Endoplasmin
Alpha-enolase
Beta-enolase
Gamma-enolase

Galectin-I
Glucose-6-phosphate isomerase
Glutathione S-transferase P
Glyceraldehyde-3-phosphate
dehydrogenase
GTP-binding nuclear protein Ran
Heat shock 70 kDa protein IAlIB
Heat shock 70 kDa protein 6
Heat shock cognate 71 kDa
protein

Galectin-l

Chloride intracellular channel
protein 1
Cofilin-l
Complement component I Q
subcomponent-binding prot
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Cytochrome c
Elongation factor I-alpha 1
Elongation factor I-alpha 2
Elongation factor 2
Endoplasmin
Alpha-enolase
Beta-enolase
Gamma-enolase
Eukaryotic initiation factor 4A-I
Eukaryotic initiation factor 4A-II

Clathrin heavy chain 1
Cofilin-I
Complement component 1 Q
subcomponent-binding prot

Alpha-enolase
Beta-enolase
Gamma-enolase
Eukaryotic initiation factor 4A-I
Eukaryotic initiation factor 4A-II
Eukaryotic translation initiation
factor 5A-I
Eukaryotic translation initiation
factor 5A-2

Filamin-A
Fructose-bisphosphate aldolase A
Glucose-6-phosphate isomerase
Gl yceraldehyde-3-phosphate
dehydrogenase
GTP-binding nuclear protein Ran

Heat shock cognate 71 kDa
protein
Heat shock protein beta-l

Glucose-6-phosphate isomerase
Glyceraldehyde-3-phosphate
dehydrogenase
GTP-binding nuclear protein Ran

Glyceraldehyde-3-phosphate
dehydrogenase
GTP-binding nuclear protein Ran

Heat shock cognate 71 kDa protein
Heat shock protein beta-I

Heat shock cognate 71 kDa protein

Heat shock protein HSP 90-alpha
Heat shock protein HSP 90-beta
Hepatoma-derived growth factor

Heat shock protein HSP 90-alpha
Heat shock protein HSP 90-beta

Heterogeneous nuclear ribonucleoprotein Al
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Heterogeneous nuclear ribonucleoprotein AlB
Heterogeneous nuclear
Heterogeneous nuclear
ribonucleoproteins A21B I
ribonucleoproteins A21B I
Heterogeneous nuclear
Heterogeneous nuclear
ribonucleoproteins C lIC2
ribonucleoproteins C l/C2
Heterogeneous nuclear
Heterogeneous nuclear
ribonucleoprotein DO
ribonucleoprotein DO
Heterogeneous nuclear ribonucleoprotein H
Heterogeneous nuclear
Heterogeneous nuclear
ribonucleoprotein K
ribonucleoprotein K
Histone H4
Lamin-A/C
L-Iactate dehydrogenase A
L-Iactate dehydrogenase A chain
chain
L-lactate dehydrogenase B
L-Iactate dehydrogenase B chain
chain
Moesin
Myosin light chain 6B
Myosin light chain 6B
Myosin light polypeptide 6
Myosin light polypeptide 6
Myristoylated alanine-rich C-kinase Myristoylated alanine-rich Csubstrate
kinase substrate
N-acetylglucosamine-6sulfatase
Nucleolar RNA helicase 2
Nucleolin
Nucleolin
POTE ankyrin domain family
POTE ankyrin domain family
memberE
memberE
Peptidyl-prolyl cis-trans isomerase
Peptidyl-prolyl cis-trans
isomerase A
A
Peptidyl-prolyl cis-trans
Peptidyl-prolyl cis-trans isomerase
isomerase B
B

Heat shock protein HSP 90-alpha
Heat shock protein HSP 90-beta

Heat shock protein HSP 90-alpha
Heat shock protein HSP 90-beta

Heterogeneous nuclear
ribonucleoprotein Al
Heterogeneous nuclear
ribonucleoprotein AlB
Heterogeneous nuclear
ribonucleoproteins A21B I
Heterogeneous nuclear
ribonucleoproteins C lIC2
Heterogeneous nuclear
ribonucleoprotein DO

Heterogeneous nuclear
ribonucleoproteins A21B I

Heterogeneous nuclear
ribonucleoprotein DO

HistoneH4
Lamin-A/C
L-Iactate dehydrogenase A chain

L-Iactate dehydrogenase A chain

L-lactate dehydrogenase B chain

L-lactate dehydrogenase B chain

Myosin light chain 6B
Myosin light polypeptide 6
Myristoylated alanine-rich C-kinase
substrate

Myristoylated alanine-rich Ckinase substrate

Nucleolin
POTE ankyrin domain family
memberE
Peptidyl-prolyl cis-trans isomerase
A
Peptidyl-prolyl cis-trans isomerase
B

Nucleolin

Peptidyl-prolyl cis-trans isomerase
A

Peroxiredoxin-l
Peroxiredoxin-l
Peroxiredoxin-2
Peroxiredoxin-2
Phosphatidylethanolamine-binding
protein
Plasminogen activator inhibitor I RNA-binding prot
Poly(rC)-binding protein I
Proactivator polypeptide
Profilin-l
Profilin-l
Protein disulfide-isomerase
Protein disulfide-isomerase
Protein disulfide-isomerase A3
Protein disulfide-isomerase A3
Protein disulfide-isomerase A6
Protein disulfide-isomerase A6
Pyruvate kinase isozymes
Pyruvate kinase isozymes MIIM2
MIIM2
Reticulocalbin-l
RNA-binding protein EWS
RNA-binding protein EWS
RNA-binding protein FUS
RNA-binding protein FUS

o

Serpin HI
Splicing factor, arginine/serine-rich
3
TATA-binding protein-associated
factor 2N
T -complex protein I subunit beta

Peroxiredoxin-I

Proactivator polypeptide
Profilin-I

Peroxiredoxin-l

Protein disulfide-isomerase A3
Protein disulfide-isomerase A6

Profilin-l
Protein disulfide-isomerase
Protein disulfide-isomerase A3
Protein disulfide-isomerase A6

Pyruvate kinase isozymes MlIM2

Pyruvate kinase isozymes MIIM2
RNA-binding protein EWS

Serpin HI

RNA-binding protein FUS
SH3 domain-binding glutamic acidrich-like protein
Serpin HI

T ATA-binding proteinassociated factor 2N

TATA-binding protein-associated
factor 2N

Serpin HI

Thioredoxin
Transgelin-2

Triosephosphate isomerase
Tubulin alpha-IA chain
Tubulin alpha-IB chain
Tubulin alpha-IC chain
Tubulin alpha-3CID
Tubulin alpha-3E chain
Tubulin alpha-4A chain
Tubulin beta chain

Transgelin
Transgelin-2

Triosephosphate isomerase
Tubulin alpha-IA chain
Tubulin alpha-lB chain
Tubulin alpha-IC chain
Tubulin alpha-3CID
Tubulin alpha-3E chain
Tubulin beta chain

Transgelin-2

Triosephosphate isomerase
Tubulin alpha-IA chain
Tubulin alpha-lB chain
Tubulin alpha-IC chain
Tubulin alpha-3CID
Tubulin alpha-3E chain
Tubulin alpha-4A chain
Tubulin beta chain

Transgelin-2
Transitional endoplasmic reticulum
ATPase
Tubulin alpha-l A chain
Tubulin alpha-IB chain
Tubulin alpha-IC chain
Tubulin alpha-3CID
Tubulin alpha-3E chain
Tubulin alpha-4A chain
Tubulin beta chain

Tubulin beta-2A chain
Tubulin beta-2B chain
Tubulin beta-2C chain
Tubulin beta-3 chain
Tubulin beta-4 chain
Tubulin-specific chaperone A
Transgelin
Transketolase
Ubiquitin
Ubiquitin carboxyl-terminal
hydrolase isozyme Ll
Vimentin

--

Tubulin beta-2A chain
Tubulin beta-2B chain
Tubulin beta-2C chain

Tubulin beta-2A chain
Tubulin beta-2B chain
Tubulin beta-2C chain
Tubulin beta-3 chain
Tubulin beta-4 chain
Transgelin

Transketolase
Ubiquitin
Ubiquitin carboxyl-terminal
hydrolase isozyme Ll
Vimentin

Ubiquitin
Ubiquitin carboxyl-terminal
hydrolase isozyme Ll
Vimentin

Tubulin beta-l chain
Tubulin beta-2A chain
Tubulin beta-2B chain
Tubulin beta-2C chain
Tubulin beta-3 chain

Transgelin
Transketolase

Vimentin

Table 4: VEGFR-l pull-down

Control

PE

Cu
10 kDa heat shock protein,
mitochondrial

60 kDa heat shock protein,
mitochondrial

14-3-3 protein beta/alpha

14-3-3 protein beta/alpha

14-3-3 protein beta/alpha

14-3-3 protein beta/alpha

14-3-3 protein gamma

14-3-3 protein gamma

14-3-3 protein gamma

14-3-3 protein gamma

14-3-3 protein zeta/delta

14-3-3 protein zeta/delta

14-3-3 protein zeta/delta

14-3-3 protein zeta/delta

60 kDa heat shock protein,
mitochondrial
ATP synthase subunit alpha,
mitochondrial

14-3-3 protein eta

14-3-3 protein eta

-

PE+Cu

10 kDa heat shock protein,
mitochondrial
60 kDa heat shock protein,
mitochondrial

14-3-3 protein theta

14-3-3 protein theta

14-3-3 protein theta

14-3-3 protein theta

14-3-3 protein epsilon

14-3-3 protein epsilon

14-3-3 protein epsilon

14-3-3 protein epsilon

N

14-3-3 protein sigma
40S ribosomal protein SA

40S ribosomal protein SA

40S ribosomal protein SA

40S ribosomal protein SA

40S ribosomal protein S3

40S ribosomal protein S3

40S ribosomal protein S3

40S ribosomal protein S3
40S ribosomal protein S6

40S ribosomal protein S 12
40S ribosomal protein S 18
60S acidic ribosomal
proteinP2

40S ribosomal protein S 18
60S acidic ribosomal protein
P2

40S ribosomal protein S 18

40S ribosomal protein S18
60S acidic ribosomal protein P2

60S ribosomal protein L 7
60S ribosomal protein LII
60S ribosomal protein LI4
78 kDa glucose-regulated
protein

78 kDa glucose-regulated
protein

60S ribosomal protein LI8
78 kDa glucose-regulated
protein

78 kDa glucose-regulated protein

Acyl-CoA-binding protein

w

Actin, alpha cardiac muscle
1
Actin, alpha skeletal
muscle
Actin, aortic smooth
muscle
Actin, gamma-enteric
smooth muscle

Acyl-CoA-binding protein

Acyl-CoA-binding protein

ADP-ribosylation factor 1

ADP-ribosylation factor 1

ADP-ribosylation factor 3

ADP-ribosylation factor 3

ADP-ribosylation factor 4

ADP-ribosylation factor 4

ADP-ribosylation factor 5

ADP-ribosylation factor 5
ATP-dependent RNA helicase
DDX39

Actin, alpha cardiac muscle 1

Actin, alpha cardiac muscle 1

Actin, alpha cardiac muscle 1

Actin, alpha skeletal muscle

Actin, alpha skeletal muscle

Actin, alpha skeletal muscle

Actin, aortic smooth muscle
Actin, gamma-enteric smooth
muscle

Actin, aortic smooth muscle
Actin, gamma-enteric
smooth muscle

Actin, aortic smooth muscle
Actin, gamma-enteric smooth
muscle

Actin, cytoplasmic 1

Actin, cytoplasmic 1

Actin, cytoplasmic 1

Actin, cytoplasmic 1

Actin, cytoplasmic 2
Adenylyl cyclaseassociated protein 1

Actin, cytoplasmic 2

Actin, cytoplasmic 2

Actin, cytoplasmic 2
Adenylyl cyclase-associated
protein I

Alpha-actinin-l

Alpha-actinin-l

Alpha-actinin-l

Alpha-actinin-4

Alpha-actinin-4

Alpha-actinin-4

Annexin Al

AnnexinAl

AnnexinAI

AnnexinAl

AnnexinA2

AnnexinA2

Annexin A2

AnnexinA2

AnnexinA5

AnnexinA5

AnnexinA5
Astrocytic phosphoprotein
PEA-15

AnnexinA5

Calmodulin

Calmodulin

Calmodulin

Calmodulin

Calponin-2

Calponin-2

Brain acid soluble protein 1

Calponin-2

Calreticulin
Calumenin

Calumenin

Cathepsin B

Cathepsin B

Clathrin heavy chain 1

Clathrin heavy chain 1

Calumenin
Cathepsin B

Cathepsin B
Chloride intracellular channel
protein 1
Clathrin heavy chain 1

Coactosin-like protein

......

......
.j:::..

Cofilin-l

Cofilin-l

Cofilin-l

Cofilin-l

Cofilin-2
Complement component 1
Q subcomponent-binding
prot
Cu-Zn Superoxide
dismutase

Cofilin-2

Cofilin-2

Cofilin-2

Complement component 1 Q
subcomponent-binding prot

Complement component I Q
subcomponent-binding prot

Complement component 1 Q
subcomponent-binding prot

Cytochrome c

Cytochrome c

Cytochrome c

Cytochrome c

Cystatin-B

Cystatin-B

Cystatin-B

Cystatin-B

Cu-Zn Superoxide dismutase

DNA-binding protein A
Desmo glein-I
Alpha-enolase

Alpha-enolase

Alpha-enolase

Alpha-enolase

Beta-enolase

Beta-enolase

Beta-enolase

Beta-enolase

ELAV-like protein I

ELAV -like protein I

Elongation factor I-alpha I

Elongation factor I-alpha I

Elongation factor I-alpha I

Elongation factor I-alpha I

Elongation factor I-alpha 2

Elongation factor I-alpha 2

Elongation factor I-alpha 2

Elongation factor I-alpha 2
Elongation factor I-gamma

Elongation factor 2
Endoplasmin

Elongation factor 2

Elongation factor 2

Elongation factor 2

Endoplasmin

Endoplasmin
Epididymal secretory protein EI

Eukaryotic initiation factor
4A-I
Eukaryotic initiation factor
4A-II
Eukaryotic translation
initiation factor 5A-I
Eukaryotic translation
initiation factor 5A-2

Eukaryotic initiation factor 4AI
Eukaryotic initiation factor 4AII
Eukaryotic translation
initiation factor 5A-I
Eukaryotic translation
initiation factor 5A-2

Eukaryotic initiation factor
4A-I
Eukaryotic initiation factor
4A-II
Eukaryotic translation
initiation factor 5A-I
Eukaryotic translation
initiation factor 5A-2

Ezrin
Far upstream elementbinding protein I

VI

Filamin-A

Filamin-A

Filamin-B

Filamin-B

Filamin-C
Fructose-bisphosphate
aldolase A
GTP-binding nuclear
protein Ran

Filamin-C

Galectin-l
Gamma-glutamyl
hydrolase

Galectin-l

Eukaryotic initiation factor 4A-I
Eukaryotic initiation factor 4A-II
Eukaryotic translation initiation
factor 5A-I
Eukaryotic translation initiation
factor 5A-2

Far upstream elementbinding protein I

Ezrin
Far upstream element-binding
protein I

Filamin-A

Filamin-A

Fructose-bisphosphate
aldolase A

Fructose-bisphosphate aldolase
A

GTP-binding nuclear protein
Ran

GTP-binding nuclear protein Ran
Galectin-l
Gammaglutamylcyclotransferase
Glucosidase 2 subunit beta

Glucosidase 2 subunit beta
Gl yceraldeh yde-3-phosphate
dehydrogenase

Glutathione S-transferase P
Glyceraldehyde-3-phosphate
dehydrogenase

Guanine nucleotide-binding
protein subunit beta-2

Guanine nucleotide-binding
protein subunit beta-2

Heat shock protein beta-l
Heat shock 70 kDa protein
IAilB

Heat shock protein beta-l
Heat shock 70 kDa protein
IAlIB

Heat shock protein beta-l
Heat shock 70 kDa protein
IAilB

Heat shock 70 kDa protein 6

Heat shock 70 kDa protein 6

Heat shock 70 kDa protein 6

Glyceraldehyde-3phosphate dehydrogenase
Guanine nucleotidebinding protein subunit
beta-2-l

Glyceraldehyde-3-phosphate
dehydrogenase

Heat shock protein beta-l
Heat shock 70 kDa protein
IAilB
Heat shock 70 kDa protein
6

i-'
i-'
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Heat shock cognate 71 kDa
protein
Heat shock protein HSP
90-alpha
Heat shock protein HSP
90-beta
Hepatoma-derived growth
factor
Heterogeneous nuclear
ribonucleoprotein AlB
Heterogeneous nuclear
ribonucleoprotein Al
Heterogeneous nuclear
ribonucleoproteins A21B I
Heterogeneous nuclear
ribonucleoproteins C l/C2
Heterogeneous nuclear
ribonucleoprotein DO
Heterogeneous nuclear
ribonucleoprotein F
Heterogeneous nuclear
ribonucleoprotein G
Heterogeneous nuclear
ribonucleoprotein H

Heterogeneous nuclear
ribonucleoprotein H3
Heterogeneous nuclear
ribonucleoprotein K
High mobility group
protein Bl
Histone H2A type I-BIE
Histone H2A type I-C
Histone H2A type I-D

Heat shock cognate 71 kDa
protein
Heat shock protein HSP 90alpha
Heat shock protein HSP 90beta
Hepatoma-derived growth
factor
Heterogeneous nuclear
ribonucleoprotein AlB
Heterogeneous nuclear
ribonucleoprotein Al
Heterogeneous nuclear
ribonucleoproteins A21B 1
Heterogeneous nuclear
ribonucleoproteins C l/C2
Heterogeneous nuclear
ribonucleoprotein DO
Heterogeneous nuclear
ribonucleoprotein F
Heterogeneous nuclear
ribonucleoprotein G
Heterogeneous nuclear
ribonucleoprotein H
Heterogeneous nuclear
ribonucleoprotein H2

Heterogeneous nuclear
ribonucleoprotein K
High mobility group protein
BI

Heat shock cognate 71 kDa
protein
Heat shock protein HSP 90alpha
Heat shock protein HSP 90beta

Heterogeneous nuclear
ribonucleoprotein AlB
Heterogeneous nuclear
ribonucleoprotein Al
Heterogeneous nuclear
ribonucleoproteins A21B 1
Heterogeneous nuclear
ribonucleoproteins ClfC2
Heterogeneous nuclear
ribonucleoprotein DO
Heterogeneous nuclear
ribonucleoprotein F
Heterogeneous nuclear
ribonucleoprotein G
Heterogeneous nuclear
ribonucleoprotein H
Heterogeneous nuclear
ribonucleoprotein H2
Heterogeneous nuclear
ribonucleoprotein H3
Heterogeneous nuclear
ribonucleoprotein K
High mobility group protein
BI

Heat shock cognate 71 kDa
protein
Heat shock protein HSP 90-alpha
Heat shock protein HSP 90-beta
Hepatoma-derived growth factor
Heterogeneous nuclear
ribonucleoprotein AlB
Heterogeneous nuclear
ribonucleoprotein Al
Heterogeneous nuclear
ribonucleoproteins A21B I
Heterogeneous nuclear
ribonucleoproteins ClIC2
Heterogeneous nuclear
ribonucleoprotein DO
Heterogeneous nuclear
ribonucleoprotein F
Heterogeneous nuclear
ribonucleoprotein G
Heterogeneous nuclear
ribonucleoprotein H
Heterogeneous nuclear
ribonucleoprotein H2
Heterogeneous nuclear
ribonucleoprotein H3
Heterogeneous nuclear
ribonucleoprotein K
High mobility group protein B I

Histone H2A type l-H
Histone H2A type l-J
Histone H4

HistoneH4

Integrin beta-l
L-lactate dehydrogenase A
chain
L-Iactate dehydrogenase B
chain

-l

Lamin-A/C
Lamina-associated
polypeptide 2, isoform
alpha
Lamina-associated
polypeptide 2, isoforms
beta/gam
Lysosome-associated
membrane glycoprotein 2

Importin subunit beta-l

Importin subunit beta-l
L-Iactate dehydrogenase A
chain
L-Iactate dehydrogenase B
chain

L-Iactate dehydrogenase A
chain
L-Iactate dehydrogenase B
chain

L-Iactate dehydrogenase B chain

Lamin-A/C

Lamin-A/C

Lamin-A/C

Lamina-associated
polypeptide 2, isoform alpha

Lamina-associated polypeptide 2,
isoform alpha

Lysosome-associated
membrane glycoprotein 2
Microtubule-associated protein
1B

Microtubule-associated
protein 4

L-Iactate dehydrogenase A chain

Lamina-associated polypeptide 2, isoforms beta/gam
Lysosome-associated membrane
glycoprotein 2
Microtubule-associated protein
IB
Microtubule-associated protein
4
Microtubule-associated protein 4

Moesin

Moesin

Moesin

Moesin

Myosin light polypeptide 6

Myosin light polypeptide 6

Myosin light polypeptide 6

Myosin light polypeptide 6

Myosin light chain 6B
Myosin regulatory light
polypeptide 9
Myosin regulatory light
chain 12A
Myosin regulatory light
chain l2B
Myristoylated alanine-rich
C-kinase substrate

Myosin light chain 6B

Myosin light chain 6B

Myosin light chain 6B

Myosin regulatory light chain
l2A
Myosin regulatory light chain
l2B
Myristoylated alanine-rich Ckinase substrate

Myosin regulatory light chain
12A
Myosin regulatory light chain
12B
Myristoylated alanine-rich Ckinase substrate

Myosin regulatory light polypeptide 9
Myosin regulatory light chain 12A
Myosin regulatory light chain 12B
Myristoylated alanine-rich C-kinase
substrate

N-acetylglucosamine-6sulfatase
Nascent polypeptideassociated complex subunit
alph

Nascent polypeptide-associated
complex subunit alph

N-acetylglucosamine-6-sulfatase
Nascent polypeptide-associated
complex subunit alph

Nascent polypeptide-associated complex
subunit alph

Nestin
Nuclease-sensitive elementbinding protein 1
Nucleolar RNA helicase 2

00

Nucleolin

Nucleolin

Nucleolin

Nucleolin

N ucleophosmin
Nucleoside diphosphate
kinase A
Nucleoside diphosphate
kinase B
Neuroblast differentiationassociated protein AHNAK
POTE ankyrin domain
family member E
Peptidyl-prolyl cis-trans
isomerase A
Peptidyl-prolyl cis-trans
isomerase B

Nucleophosmin
Nucleoside diphosphate kinase
A
Nucleoside diphosphate kinase
B
Neuroblast differentiationassociated protein AHNAK
POTE ankyrin domain family
memberE
Peptidyl-prolyl cis-trans
isomerase A
Peptidyl-prolyl cis-trans
isomerase B

Nucleophosmin
Nucleoside diphosphate kinase
A
Nucleoside diphosphate kinase
B
Neuroblast differentiationassociated protein AHNAK
POTE ankyrin domain family
memberE
Peptidyl-prolyl cis-trans
isomerase A
Peptidyl-prolyl cis-trans
isomerase B

Nucleophosmin

Peroxiredoxin-l

Peroxiredoxin-l

Peroxiredoxin-l

Peroxiredoxin-l

Peroxiredoxin-2

Peroxiredoxin-2

Peroxiredoxin-2

Peroxiredoxin-2

Peroxiredoxin-6
Phosphatidylethanolaminebinding protein 1

Peroxiredoxin-6
Phosphatidylethanolaminebinding protein 1

Peroxiredoxin-6
Phosphatidylethanolaminebinding protein 1

Peroxiredoxin-6

Nucleoside diphosphate kinase A
Nucleoside diphosphate kinase B
Neuroblast differentiation-associated
protein AHNAK
POTE ankyrin domain family member E
Peptidyl-prolyl cis-trans isomerase A
Peptidyl-prolyl cis-trans isomerase B

Phosphoglycerate mutase 1
Plasminogen activator
inhibitor 1 RNA-binding
prot
Poly(rC)-binding protein 1

Plasminogen activator inhibitor 1 RNAbinding prot
Poly(rC)-binding protein 1

Poly(rC)-binding protein 1

Poly(rC)-binding protein 1

Poly(rC)-binding protein 2

Poly(rC)-binding protein 2

Poly(rC)-binding protein 3
Polyadenylate-binding
protein I
Polyadenylate-binding
protein 3

Poly(rC)-binding protein 3
Polyadenylate-binding protein
1
Polyadenylate-binding protein
3

Polyadenylate-binding protein
1
Polyadenylate-binding protein
3

Proactivator polypeptide

Proactivator polypeptide

Proactivator polypeptide

Pro activator polypeptide

Profilin-l

Profilin-l

Profilin-l

Profilin-l

Poly(rC)-binding protein 2
Poly(rC)-binding protein 3

Protein CDV3 homolog

Protein CDV3 homolog

Protein SET

Protein SET

Protein SIOO-All

\0

Protein disulfide-isomerase
Protein disulfide-isomerase
A3
Protein disulfide-isomerase
A6
Pyruvate kinase isozymes
MIIM2

Polyadenylate-binding protein 1
Polyadenylate-binding protein 3

Protein SET
Protein S IOO-All

Protein disulfide-isomerase

Protein disulfide-isomerase

Protein disulfide-isomerase

Protein disulfide-isomerase A3

Protein disulfide-isomerase A3

Protein disulfide-isomerase A3

Protein disulfide-isomerase A6
Pyruvate kinase isozymes
MIIM2

Protein disulfide-isomerase A6
Pyruvate kinase isozymes
MIIM2

Protein disulfide-isomerase A6

Radixin

Pyruvate kinase isozymes MIIM2
Radixin
Ras-related protein Rab-lB
Ras-related protein Rab-l 0
Ras-related protein Rab-15
Rab GDP dissociation inhibitor beta

RNA-binding protein EWS

RNA-binding protein EWS

RNA-binding protein EWS

RNA-binding protein EWS

RNA-binding protein FUS
RNA-binding motif
protein, X-linked-like-2

RNA-binding protein FUS
RNA-binding motif protein, Xlinked-like-2

RNA-binding protein FUS

RNA-binding protein FUS
RNA-binding motif protein, X-linkedlike-2

Reticulocalbin-l

Reticulocalbin-l

Reticulon-4

Reticulon-4

SH3 domain-binding
glutamic acid-rich-like
protein

SH3 domain-binding glutamic
acid-rich-like protein

SerpinHl

Serpin HI

Splicing factor 3B subunit
2
Splicing factor,
arginine/serine-rich 3

Serpin HI

Serum albumin
Splicing factor,
arginine/serine-rich 3

Serpin HI

Splicing factor, arginine/serine-rich 3

Spliceosome RNA helicase BAT!

......

N
0

Stathmin
Stress-inducedphosphoprotein 1
T -complex protein 1
subunit gamma
TATA-binding proteinassociated factor 2N

Stress-induced-phosphoprotein
Stress-induced-phosphoprotein 1

1

T-complex protein 1 subunit
gamma
TATA-binding proteinassociated factor 2N

TATA-binding proteinassociated factor 2N

T-complex protein 1 subunit beta
T ATA-binding protein-associated factor
2N

Thioredoxin reductase 1,
cytoplasmic
Thioredoxin domaincontaining protein 5
Thioredoxin domaincontaining protein 17

Thioredoxin reductase 1,
cytoplasmic

Thioredoxin reductase 1, cytoplasmic

Thioredoxin domaincontaining protein 17

Thioredoxin domain-containing protein
17

Transgelin

Transgelin

Transgelin

Transgelin

Transgelin-2

Transgelin-2

Transgelin-2

Transgelin-2

Transketolase

Transketolase

Transketolase

Transketolase

Triosephosphate isomerase

Triosephosphate isomerase
Transitional endoplasmic
reticulum ATPase

Triosephosphate isomerase

Triosephosphate isomerase
Transitional endoplasmic reticulum
ATPase

Thioredoxin
Thioredoxin reductase 1,
cytoplasmic

Tropomyosin alpha-1 chain
Tropomyosin alpha-3 chain

Tropomyosin alpha-3 chain

Tropomyosin alpha-4 chain

Tropomyosin alpha-4 chain

Tropomyosin beta chain

Tropomyosin alpha-4 chain
Tropomyosin beta chain

Tubulin alpha-lA chain
Tubulin alpha-lB chain

Tubulin alpha-lA chain

Tubulin alpha-lA chain

Tubulin alpha-IA chain

Tubulin alpha-IC chain

Tubulin alpha-IB chain

Tubulin alpha-lB chain

Tubulin alpha-IB chain

Tubulin alpha-IC chain

Tubulin alpha-IC chain

Tubulin alpha-IC chain

Tubulin alpha-3CID chain

Tubulin alpha-3CID chain

Tubulin alpha-3CID chain

Tubulin alpha-3CID chain

Tubulin alpha-3E chain

Tubulin alpha-3E chain

Tubulin alpha-3E chain

Tubulin alpha-3E chain

Tubulin alpha-4A chain

Tubulin alpha-4A chain

Tubulin alpha-4A chain

Tubulin alpha-4A chain
Tubulin alpha-8 chain

Tubulin alpha-8 chain
Tubulin beta chain

-N

Tubulin beta chain

Tubulin beta chain

Tubulin beta chain
Tubulin beta-l chain

Tubulin beta-l chain
Tubulin beta-2A chain

Tubulin beta-2A chain

Tubulin beta-2A chain

Tubulin beta-2A chain

Tubulin beta-2B chain

Tubulin beta-2B chain

Tubulin beta-2B chain

Tubulin beta-2B chain

Tubulin beta-2C chain

Tubulin beta-2C chain

Tubulin beta-2C chain

Tubulin beta-2C chain

Tubulin beta-3 chain

Tubulin beta-3 chain

Tubulin beta-3 chain

Tubulin beta-3 chain

Tubulin beta-4 chain

Tubulin beta-4 chain

Tubulin beta-4 chain

Tubulin beta-4 chain

Tubulin beta-6 chain
Tubulin-specific chaperone
A
Ubiquitin
Ubiquitin carboxylterminal hydrolase isozyme
Ll
Ubiquitin-conjugating
enzyme E2 variant 1

Tubulin beta-6 chain
Tubulin-specific chaperone A

Tubulin-specific chaperone A

Tubulin-specific chaperone A

Ubiquitin

Ubiquitin

Ubiquitin

Ubiquitin carboxyl-terminal
hydrolase isozyme Ll
Ubiquitin-conjugating enzyme
E2 variant 1

Ubiquitin carboxyl-terminal
hydrolase isozyme Ll

Ubiquitin carboxyl-terminal hydrolase
isozyme Ll
Ubiquitin-conjugating enzyme E2
variant 1
Ubiquitin-conjugating enzyme E2
variant 2
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1. Vimentin Western Blot
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Figure 29. Representative Western blot of Vimentin under different treatment groups
and densitometric analysis of Western blot. Imrnunoblotting was performed with
anti- Vimentin antibody. This blot is representative of two independent experiments,
and densitometric analysis is the mean of both blots.
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2. Interaction between Vimentin and PKG-1
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Figure 30. Co-immunoprecipitation of Vimentin and PKG-1. PKG-1 was coimmunoprecipitated after a Vimentin pull down. Semi-quantitative analysis
of Western blot detecting PKG-1, bars are means for each group. One-way
ANOVA, followed by Bonferroni's Multiple Comparison Test. No
significant difference among groups. n=3.
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3. Interaction between Vimentin and VEGFR-1
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Figure 31. Co-immunoprecipitation of Vimentin and VEGFR-1.
Semi-quantitative analysis of Western blot detecting VEGFR-1, bars are means
from each group. n=2.
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IV. DISCUSSION

It has been observed that Cu supplementation reverses cardiac myocyte

hypertrophy of neonatal rat cardiac myocytes as well as embryonic cardiac
myocytes derived from human embryos, and that this effect is VEGFdependent l77 • This study was undertaken to provide mechanistic insights into the
action of Cu. We have demonstrated that Cu at physiologically relevant levels
which were used in this study does not increase VEGF production in primary
cultures, yet anti-VEGF antibody blocked the reversal effect. This VEGFdependent action of Cu suggests that while Cu did not result in an increase in
VEGF production, it did result in downstream events that are VEGF-dependent,
and such downstream events would include VEGFRs. We observed that Cu
increased the ratio ofVEGFR-l :VEGFR-2, and that this increase was highly
responsible for the reversal of cardiac myocyte hypertrophy (Figures 4 and 5).
This cause-effect relationship between the increase in the ratio ofVEGFR-l to
VEGFR-2 and the reversal of cardiac myocyte hypertrophy was obtained from the
experiment using siRNA targeting VEGFR-2 to elevate the ratio ofVEGFR1:VEGFR-2. By using siRNA targeting VEGFR-2, we were able to increase the
ratio of VEGFR-l :VEGFR-2 and thereby differentiate the regression phenomenon
from the action of Cu. However, it reproduced the same effect as Cu-induced
reversal of cardiac myocyte hypertrophy (Figures 9, 10 and 11). Further evidence
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from the experiment demonstrating that anti-VEGF antibody blocked the reversal of
cardiac myocyte hypertrophy induced by VEGFR-2 gene silencing (Figures 12, 13
and 14), which is indicative of the importance of the interaction between VEGFR-l
and VEGF. siRNA targeting VEGFR-l blocked Cu-induced reversal of cardiac
myocyte hypertrophy, further indicating the role of VEGFR-l in mediating Cuinduced reversal of cardiac myocyte hypertrophy (Figures 18, 19 and 20).
Numerous studies have established the differing functions of VEGFR-1 and
VEGFR-2. VEGFR-2 is associated with cell growth stimulation by VEGF in
endothelial cells. In cells with VEGFR-2 that are devoid ofVEGFR-l, activation of
VEGFR-2 by VEGF culminates in a mitogenic response l78 , 179. Additionally,
VEGFR-2 is more predominant in many of the known cellular responses elicited by
VEGF such as embryonic vasculogenesis and tumor angiogenesis 180. VEGFR-2 and
its downstream pathways are more related to growth stimulation via MAPK signaling
pathways. Aktl, which plays a critical role in the hypertrophic process has been
linked to VEGFR-2, which was demonstrated in a study where a decoy VEGFR-2
inhibited cardiac growth induced by Aktl activation I8I ,182.
While previous studies have not given a clear, comprehensive understanding of
the role of VEGFR-l in cellular function, several studies have shown a counter action
ofVEGF-l relative to VEGFR-2, and it was suggested that VEGFR-l acted to
negatively regulate VEGFR-2 183, 184, 185,

186.

This study demonstrates that VEGFR-l

is associated with PKG-l activation. The link between VEGFR-l to this well-known
and well-studied pathway in the regression of heart hypertrophy provides an
explanation of the VEGFR-l-dependent regression of cardiac myocyte hypertrophy.
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It is likely that many pathways are triggered by VEGFR-1 activation. Yet, PKG-1

signaling is the most studied and arguably the most important with respect to the
regression of heart hypertrophy. We observed that siRNA targeting VEGFR-1
reduced PKG-1 activity (Figure 21), suggesting that the activation of PKG-1 is at
least in part VEGFR-1-dependent. Conversely, the PKG-1 antagonist, Rp-8-pCPTcGMPS blocked both Cu and VEGFR-2 knockdown-induced reversal of cardiac
myocyte hypertrophy (Figures 22-27). Taken together, these results demonstrate that
VEGFR-1 is likely involved in Cu-induced regression of cardiac myocyte
hypertrophy, and that this pathway is likely associated with PKG-1 activation.
PKG-1 is activated in hypertrophic myocardium induced by pressure overload 187 •
In mouse models of cardiac pressure overload induced by transverse aortic
constriction (TAC), heart hypertrophy was observed 3 weeks after TAC, and PKG-1
activity was significantly elevated in the hypertrophic myocardium. Although PKG-1
activation alone was not sufficient to stop the development of heart hypertrophy,
treatment with the oral phosphidiesterase-5A inhibitor, sildenafil, blocks the intrinsic
catabolism of cGMP, leading to further activation ofPKG-1 and resulted in the
regression of heart hypertrophy. In our study, we observed that PE treatment
enhanced PKG-1 activity, but Cu did not have any effect on PE-induced activation of
PKG-l. But, Cu abrogated VEGFR-2, which is associated with Akt-1 signaling. In
addition to this, inhibition was associated with the increase in the ratio of VEGF1:VEGFR-2, thus providing a molecular switch from growth via the VEGFR-2
pathway, to regression of cardiac myocyte hypertrophy via the VEGFR-1 pathway.
While Cu did not increase PKG-1 activity, the switch in signaling pathways from
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VEGFR-2 to VEGFR-l would make the activity ofPKG-l become dominant, leading
to activation of hypertrophic reversal signaling cascades.
Initially, we hypothesized that the link between VEGFR-l and PKG-l was direct.
However, after numerous VEGFR-l and PKG-l co-immunoprecipitations, we
discovered that this was more than likely not the case. In order to elucidate the
mechanism by which eu increased VEGFR-l signaling and thereby reversed cardiac
myocyte hypertrophy, we turned to functional proteomics. Immune complex
associated with VEGFR -lor PKG-l were sent off for analysis by liquid
chromatography tandem mass spectrometry. Hundreds of proteins were identified.
Upon further analysis of the data collected, we looked for proteins present in both the
immune complexes of both VEGFR-l and PKG-l. A literature search revealed very
little knowledge regarding the role of Vimentin in the heart. Of the hundreds of
proteins identified, we chose to further investigate the role of a protein interacting
with both VEGFR-l and PKG-l, Vimentin.
Preliminary results showed that PE decreases Vimentin in human cardiac
myocytes. To validate the interaction between Vimentin and VEGFR-l and Vimentin
and PKG-l, co-immunoprecipitation was performed: pulling down Vimentin and
analyzing the immunoprecipitate by Western blot to detect VEGFR-l, and then the
reverse, pulling down VEGFR-l and subjecting the immunoprecipiate to Western
blot to detect Vimentin. The same experiment was performed to validate the proteinprotein interaction between PKG-l and Vimentin.
Vimentin is the most abundant intermediate filament protein and is widely
expressed. It is thought to have a primary role in biological structural processes, such
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as wound healing l88 and is secreted by activated macrophages. Because of its
abundance, it was assumed to play an important role in the stabilization of the
cytoplasm, but knockout animals who do not express Vimentin have remarkably
nonnal phenotypes I89 ,190. However, Vimentin knockout mice exhibited phenotypic
abnonnalities under specific conditions, such as injuryl91. Therefore, Vimentin may
playa specialized role that contributes to distinct dynamic cellular processes 192.
Previously thought to be an exclusively intracellular protein, recent studies have
shown that Vimentin is also secreted by human macrophages into the extracellular
space in a process that is regulated by pro- and anti-inflammatory cytokines l93 .
Vimentin is phosphorylated at serine and threonine residues, and is phosphorylated by
numerous protein kinases and is a substrate for protein kinase C (PKC). Additionally,
the secretion of Vimentin is blocked by G06983, a specific PKC inhibitor. These
findings are consistent with previous research that phosphorylation of Vimentin
impacts its intracellular localization 194 ,195. Interestingly, PKC is also an essential
mediator of heart hypertroph y I96,197,198,199. Thus providing a possible link and further
clue to the mechanism by which Cu can reverse cardiac hypertrophy. While the exact
implications have yet to be understood, it is also interesting to note that Vimentin is
also a known copper binding protein. It may also playa role in tissue repair I57 • We
hypothesize that Vimentin acts as a molecular switch, somehow switching pathways
from growth to regression upon the addition of Cu.
Recently, a lot of attention has been given to the role of VEGF and it's receptors
in cancer. In 2004, the FDA approved bevacizumab (A vastinTM), the first approved
biological therapy for the prevention of angiogenesis in tumors. It is one of many
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inhibitors developed on the idea of inhibiting angiogenesis in tumors and thereby
delaying or completely halting the progression of cancer. Additionally, they have the
benefit of fewer side effects than chemotherapy. However, results of these inhibitors
may be dependent upon the type of cancer being treated. The investigators in a recent
study that involved 2385 glioblastoma patients treated with small molecule kinase
inhibitors suggested that the efficacy did not warrant their use in clinical practice2OO •
Other studies have shown that the prognostic value of VEGF and FIt-1 expression in
tumors has yet to be determined, and in patients with stage IIIIII non-small cell lung
cancer, tumor expression did not appear to have a significant impact on overall
survival, locoregional control or metastases-free survivat2° 1• While there is great
potential for drugs targeting VEGF and its receptors, there is clearly also a need to
proceed with caution and take into careful consideration if the potential
cardiovascular side effects outweigh the risk.
There were several limits to this study. We did not examine how eu regulates the
expression or differentialdistribution of VEGFRs. This is an important question and
the answer to this question will help further understand the role of eu in regression of
heart hypertrophy. From our observation that eu suppressed PE-elevated VEGFR-2
levels, it would suggest that eu would not cause overexpression of VEGFR -1. Then
the question needs to be addressed is how eu reduces VEGFR-2, suppressing its
expression or enhancing its degradation? Our future studies will address this question.
Another limitation of this study is that the mechanism by which VEGFR-1 regulates
PKG-1 activation has not been defined. While it is clear that Vimentin plays a role,
the mechanistic insight is important for further understanding the signalling pathway
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leading to regression of cardiomyocyte hypertrophy, which will be an important focus
in our future studies.
In conclusion, the present study demonstrates that Cu-induced regression of
cardiomyocyte hypertrophy is related to a switch of signaling pathways from
VEGFR-2 to VEGFR-l. Although both pathways are VEGF-dependent, the data
suggest that VEGFR-l is associated with signaling pathways linked to PKG-l, which
has been demonstrated both in vivo and in vitro to be associated with cardiomyocyte
growth inhibition and regression of cardiomyocyte hypertrophy. It remains to be
elucidative how Cu regulates the differential distribution between VEGFR-l and
VEGFR-2 in hypertrophic cardiomyocytes and how VEGFR-l interacts with PKG-l
leading to the activation of hypertrophic reversal signalling pathways, however, we
have observed that Vimentin is associated with both VEGFR-l and PKG-l
suggesting it may act as a link between the two, or perhaps acts as a molecular switch
between hypertrophic and reversal of regression signaling. Further studies using
siRNA targeting Vimentin will be instrumental in testing the hypothesis that it is a
critical component in the reversal effect.
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APPENDIX
List of Abbreviations

Atrial Natriuretic Peptide

ANP

Anal ysis of Variance

ANOVA
BrdU

5' -Bromo-2' -DeoxyUridine

CaCh

Calcium Chloride

CCO

Cytochrome C Oxidase

cGMP

Guanosine 3' ,5' -cyclic monophosphate

Cu

Copper

CUS0 4

Copper Sulfate

C02

Carbon Dioxide

ddH20

Double Distilled Water

FACS

Fluorescence-Activated Cell Sorting

FBS

Fetal Bovine Serum

Flk

Fetal Liver Kinase 1

Fit

fins-Like Tyrosine Kinase 1

FSC

Forward Scatter Light

HBSS
HEPES

Hanks' Balanced Salt Solution
4-(2-HydroxyEthyl)-I-PiperazineEthaneSulfonic Acid
Hydrogen Peroxide

H 202
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Hydrochloric Acid

HCI

HRP

Horseradish Peroxidase

KDR

Kinase insert Domain-containing Receptor
Magnesium Chloride

MgClz
NaCl

Sodium Chloride
Sodium Bicarbonate
Sodium Hydroxide

NaOH
PBS

Phosphate Buffered Saline

PDE

Phosphodiesterase

PE

Phenylephrine

PKC

Protein Kinase C

PKG

Protein Kinase G

PMSF
Rp-8-CPT -cGMPS

Phenylmethanesulfonyl Fluoride
8-(4-Chlorophenylthio)-guanosine 3' ,5' -cyclic
monophosphorothioate, Rp Isomer triethylammonium salt

RTK

Tryosine Kinase Receptor
Standard Deviation

SD
SOD

Superoxide Dismutase

SSC

Side Scatter Light

siRNA

Small Interfering RNA

TNF-a

Tumor Nectrosis Factor-a

VEGF

Vascular Endothelial Growth Factor

VEGFR

VEGF Receptor
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